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Abstract 
Janus kinase 2 (JAK2) is a critical activator of signalling associated with many 
different receptors, particularly those associated with haematopoiesis and the 
inflammatory response. Classically JAK2 has been thought of as a cytoplasmic 
protein, but more recently there is evidence that JAK2 is able to enter the nucleus 
leading to alteration of epigenetic modifiers and enhancement of JAK2 
transcriptional targets. This role in haematopoiesis means that alteration of JAK2 
signalling, such as in malignant haematopoiesis, can be a critical factor in the 
development and maintenance of disease. 
The myeloproliferative neoplasms (MPN) are a group of conditions characterised 
by over-production of myeloid cells as a result of acquired mutations in 
haematopoietic stem cells. Two well-known MPNs are chronic myeloid leukaemia 
(CML), driven by the novel oncoprotein BCR-ABL, and polycythaemia vera (PV), 
driven by the JAK2 V617F activating mutation. JAK2 is critical for normal 
haematopoiesis through its role in initiating signalling following activation of a 
receptor by its ligand. In this study we looked several aspects of JAK2 activity, 
including its effect on gene expression, its activity within the nucleus, and the 
effect of overactivity on aspects of inflammation. 
Here we show that gene expression in both CML and PV patient samples is 
deregulated compared to normal controls with both previously confirmed 
alterations such as BCL2 and MCL1 in CML and STAT1 and MPL in PV, and 
novel alterations such as Rex1 and SUMO2 in CML and EGR1 in PV. These 
alterations at the level of mRNA transcription are validated by significant 
alterations in cell cycle and apoptosis in cell lines following treatment with JAK2 
inhibitors. 
As part of the investigation of the activity of JAK2 in the nucleus we hypothesised 
that JAK2 may interact directly with PML nuclear bodies, a subnuclear structure 
with numerous regulatory roles in apoptosis, cell cycle, DNA repair and response 
to infection. Using immunofluorescence based techniques in cell lines and patient 
samples we showed that JAK2 does interact directly with PML nuclear bodies. 
This interaction was affected by JAK2 inhibitors in cell lines and increased in PV 
patient monocytes compared to normal controls. Treatment of cell lines with the 
14 
 
JAK2 inhibitor ruxolitinib and arsenic trioxide, which degrades PML, led to an 
increase in apoptosis compared to either compound alone, suggesting a 
meaningful functional interaction in both normal and malignant haematopoiesis. 
The role of the JAK2 V617F in cellular function has been extensively investigated 
particularly in neutrophils and platelets. However the effect of the JAK2 V617F 
mutation on monocytes and monocyte derived macrophages has not previously 
been investigated. Here we show that patients with PV have an alteration in 
monocyte subsets with an increase in the inflammatory intermediate monocytes at 
the expense of classical monocytes. We also showed that macrophages derived 
from peripheral blood monocytes obtained from patients with JAK2 V617F positive 
PV behaved differently from those derived from normal controls. There were 
alterations both at rest and in response to stimulation in terms of the morphology, 
with a more inflammatory phenotype seen, and in cytokine release with blunting of 
some responses and heightening of other. These alterations were seen both in M1 
and M2 macrophages. 
Overall the work presented in this thesis shows wide ranging alterations in many 
aspects of cellular behaviour as a result of overactivity of JAK2. Some of these 
findings have been previously identified and discussed, but there are several key 
novel findings which progress out understanding of JAK2 function both in normal 
and malignant haematopoiesis, and the effects of malignant JAK2 activation on 
cellular behaviour.   
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1 Introduction 
1.1 Normal haematopoiesis 
Haematopoiesis is the process that leads to production of all mature blood cells 
and is sustained by the multipotent haematopoietic stem cell (HSC). This cell 
resides in the bone marrow (BM) and has the ability to differentiate into all different 
blood cell types5. The presence of a multipotent cell capable of supporting 
haematopoiesis was first suggested in 1963 following experiments in mice where 
BM transplanted into lethally irradiated mice was capable of generating myeloid 
and erythroid colonies in the spleen6,7. It was proposed that these cells contained 
the HSC after it was shown they were capable of regenerating all peripheral blood 
cell types confirming both the self-renewal and differentiation potential6,7. 
The classical model of haematopoiesis places long term HSCs, short term HSCs 
and multipotent progenitors (MPP) at the top of a hierarchy which differentiate 
through progressively more mature cells under the control of a wide range of 
cytokines. Underlying this hierarchy is the ability of HSCs to undergo asymmetrical 
replication leading to the main properties of HSCs, multipotency and self-renewal 
capability. This asymmetric division results in the production of one daughter cell 
which is identical to the original stem cell and one daughter cell which is more 
differentiated than the stem cell (Figure 1.1). This process allows the maintenance 
of the stem cell pool, while still providing differentiating cells and differs from 
symmetrical division where 2 identical daughter cells are produced8. As the cells 
differentiate and mature they lose these properties, becoming lineage committed 
and losing their self-renewal capability, ultimately leading to the generation of a 
wide range of functionally distinct, terminally differentiated cells which are unable 
to undergo any further cell divisions. During this differentiation cells will develop 
towards either a lymphoid or myeloid potential, with the common myeloid 
progenitor able to produce all myeloid cells9, and the common lymphoid progenitor  
producing B cells, T cells and NK cells10. More recently other models have been 
proposed where the cells are more able to switch between lineages to support the 
production of myeloid cells in response to infection, with the myeloid-based model 
proposing that all progenitors retain the ability to convert to myelopoiesis allowing 
a rapid increase in mature myeloid cells in response to infection11 and a two-tier 
model where the adult bone marrow produces differentiated cells directly from 
multipotent cells with no intervening committed oligopotent cells12. These varying 
17 
 
models highlight the complexity of the haematopoietic system and the difficulty 
faced in trying to tease out the mechanisms of blood production in laboratory 
based models. 
Figure 1.1 Classical model of the haematopoietic system   
 
Mature blood cells are produced in a hierarchical manner starting with 
haematopoietic stem cells which have the ability to differentiate into any mature 
cell. Under the influence of cytokines these cells replicate and mature as required 
to produce the mature cells seen in the blood. LT – long term, ST – short term, MPP 
– multipotent progenitor, CMP – common myeloid progenitor, LMPP – lymphoid 
primed multipotent progenitor, MEP – megakaryocytic-erythroid progenitor, GMP – 
granulocyte-monocyte progenitor, CLP – common lymphoid progenitor.  
An important regulator of haematopoiesis is the stroma in which the cells develop, 
where cytokines and chemokines that support cell maintenance and development 
are produced. Haematopoietic stem cells reside in the relatively hypoxic 
osteoblastic niche, which supports self-renewal and quiescence through 
interactions of the HSCs with the ligands N-cadherin expressed on the HCSs and 
Jagged 1 expressed on the osteoblasts13. N-cadherin helps to anchor these 
quiescent stem cells in the osteoblastic niche which keeps them in the 
18 
 
environment to maintain their stem cell properties, while Jagged 1 interferes with 
the Notch signalling pathway and regulates HSC quiescence and self-renewal 
capacity. Deletion of Jagged 1 from endothelial cells leads to expansion of HSCs 
confirming its role in maintaining the HSC pool. Using in vivo imaging it is possible 
to identify a population of HSCs in a more vascular area away from the 
osteoblastic niche. In this peri-sinusoidal niche the cells are exposed to growth 
factors which stimulate proliferation and differentiation.  
1.2 Myelopoiesis 
Myelopoiesis refers to production of cells of the myeloid lineage including 
neutrophils, monocytes, red cells and platelets. Once HSCs have entered a 
proliferation phase they will lose their self-renewal capacity as they differentiate 
into mature blood cells, with terminally differentiated myeloid cells having no 
renewal capacity. The mechanisms underlying normal myelopoiesis have been 
investigated thoroughly for many years and yet there are still new insights being 
made in the populations of cells capable of driving myelopoiesis, with the 
discovery in recent years of a lymphoid primed multipotent progenitor (LMPP) 
capable of producing lymphocytes and granulocytes, but not erythroid or 
megakaryocytic cells14. This progenitor appears to be separate from the common 
myeloid progenitor, capable of differentiating into all myeloid cells, and the 
common lymphoid progenitor, which appears to be the next step for cells 
differentiating down the lymphoid path (Figure 1.1).  
Cytokines control all of haematopoiesis with different cytokines at different stages 
exerting specific effects. To initiate myelopoiesis primitive cells are exposed to IL-3 
and stem cell factor which drives them towards the myeloid lineage. Interleukin 
(IL)-3 and granulocyte macrophage-colony stimulating factor (GM-CSF) have 
overlapping activities explained by the shared signalling receptor subunit, the β 
chain, which is required for high affinity binding of these cytokines to the receptor. 
The α chain creates the specificity of the receptor by only allowing binding of either 
IL-3 or GM-CSF. The common β chain leads to a significant degree of functional 
overlap for IL-3 and GM-CSF in myelopoiesis. Following ligand binding 
downstream signal transduction events are initiated (Section 1.3), which lead to 
transcription of genes involved in cell proliferation, differentiation and survival.  
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1.2.1 Granulopoiesis 
Granulopoiesis refers to the production of granulocytes which can develop either 
from the CMP or the LMPP. Both of these can differentiate into granulocyte 
macrophage progenitors (GMPs) which then develop into granulocyte specific 
precursors. This ability of two separate precursors involved in granulocyte 
production increases the number of cells which can respond to severe infection, 
thus maximising the first line of defence against disseminated pathogens15.  
Production of granulocytes is regulated by the interaction of growth factors, 
signalling pathways and transcription factors. Part of the regulation involves the 
effects of different factors on cells at different stages of maturation. Once cells 
have developed into the myeloid lineage the action of granulocyte colony 
stimulating factor (G-CSF) is the key to driving granulocytic development. G-CSF 
exists as a 20kDa protein which is produced mainly by cells of the 
monocyte/macrophage lineage. In addition to this fibrobalsts, T-lymphocytes and 
endothelial cells will produce G-CSF in response to stimulation by inflammatory 
cytokines, such as TNF-αm IFN-γ and IL-116. G-CSF interacts with its receptor, 
which leads to activation of the JAK2/STAT5 pathway leading to transcription of 
factors which drive granulocytic maturation17.  
Interestingly it appears that expression of transcription factors associated with 
granulocytic development have a profound effect on lineage commitment. CCAAT-
enhancer binding protein α (C/EBPα) and Purine box factor 1 (PU.1) regulate the 
expression of both G-CSFR and GM-CSFR; with mice lacking these two 
transcription factors have a more profound reduction in granulocyte production 
than those with G-CSF and G-CSFR deleted18,19. 
1.2.2 Erythropoiesis 
Erythropoiesis specifically refers to the production of mature red cells the site of 
which changes from fetal development, with liver and spleen being the main sites, 
through to adult life, where the bone marrow produced mature cells. The earliest 
stage of erythropoiesis is the burst-forming unit-erythroid (BFU-E) followed by 
colony-forming unit-erythroid (CFU-E)20. BFU-E and CFU-E are identifiable 
following colony formation assay of BM cells, but are morphologically indistinct 
from early precursors of other lineages. Morphologically the earliest identifiable 
stage is the proerythroblast which progresses through early and late normoblasts, 
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reticulocytes and finally mature erythrocytes (Figure 1.2). Prior to release from the 
bone marrow the cells extrude their nucleus with the final stage of maturation 
being the loss of RNA from the cytoplasm and development of the classic 
biconcave disc of the mature erythrocyte. Red cells circulate for 100-120 days 
before being destroyed by splenic macrophages20. 
Figure 1.2 Erythropoiesis 
 
Progression of erythropoiesis from highly proliferative EPO-dependent erythroid 
precursors with progressive maturation to enucleated and haemoglobinised mature 
red cells which are released into the peripheral circulation. BFU-E – burst forming 
unit – erythroid, CFU-E – colony forming unit – erythroid, proEB – proerythroblast, 
NB – normoblast, Retic – reticulocyte, RBC – red blood cell. 
The main cytokine controlling the production of red cells is erythropoietin (EPO) 
which is produced by interstitial cells in the peritubular capillary bed of the kidneys 
in response to hypoxic conditions. EPO receptors are initially expressed on BFU-E 
cells and maximally expressed on CFU-E cells. CFU-E cells require the presence 
of EPO to prevent apoptosis and to stimulate maturation. Although EPO is the 
main driver of erythropoiesis there are multiple other cytokines involved which help 
to maintain early precursors and stimulate differentiation. Some of these are 
similar to those needed for early myelopoiesis including IL-316.  
EPO was the first cytokine to be purified, following a long process using large 
volumes of urine from anaemic patients21. Sequencing of the protein and cloning 
of the EPO gene22,23 followed, allowing production of recombinant EPO for 
laboratory investigation of its actions and subsequently treatment of EPO deficient 
anaemias24. EPO is a 34kDa protein produced in response to hypoxia by 
interstitial fibroblasts in the kidney. EPO has a short half-life of around 5 hours and 
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has a low plasma concentration in the absence of anaemia, but can increase by a 
factor of 1000 in response to hypoxic stress. The best known action of EPO is on 
erythroid precursors in the bone marrow, however, since the identification of the 
EPO receptor on the surface of non-erythroid cells the activity of this cytokine has 
been shown to be much more diverse. As a result it is clear that EPO has direct 
effects on immune cells, endothelial cells and BM stroma cells in the 
haematopoetic system, as well as cells of the nervous system25 and heart26 
among others.  
1.2.3 Thrombopoiesis 
Platelets in the peripheral blood are derived from megakaryocytes in the BM. 
Megakaryocytes are large multinucleate cells that tend to exist individually beside 
blood vessels in the marrow where they release platelets directly into the blood 
stream by extending cytoplasmic processes between the endothelial cells of the 
blood vessels and shedding this projection27. The primary regulator of the 
maturation of megakaryocytes is thrombopoietin (TPO)28, which is released by 
stromal cells in the marrow. In addition to this the stromal cells also release 
chemokine (C-X-C motif) ligand 12 (CXCL12), which attracts megakaryocytes to 
the marrow microenvironment, and express SCF which acts in synergy with TPO 
to stimulate growth of megakaryocytes29. TPO is also produced from the liver and 
released into the blood stream, where platelets absorb and destroy it30. 
Traditionally it has been thought that this leads to an alteration in the amount of 
TPO reaching the bone marrow dependent on the number of platelets in the 
peripheral blood. Recent evidence has shown that aging platelets become 
desialylated and bind to the Ashwell-Morell receptor (AMR) in the liver31, which 
signals through JAK2/STAT3. This study showed that mice lacking AMR had 
reduced platelet production, while those that lacked sialyltransferase activity had 
increased platelet production. This mechanism is thought to partly explain the 
thrombocytopenia seen with JAK2 inhibitors31. 
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1.2.4 Monocyte and macrophage development 
Monocytes and macrophages are part of the mononuclear phagocyte system, 
which develop from the myeloid lineage. Monocyte precursors derive from the 
GMP, which differentiate into macrophage and dendritic cell precursors (MDP). 
MDPs are able to produce monocytes, classical dendritic cells and plasmacytoid 
dendritic cells32. Once they have reached their differentiated state, monocytes 
circulate in the peripheral blood and BM for 1 to 3 days before entering the tissues 
and differentiating into macrophages. There is a large pool of monocytes in the 
spleen which can rapidly mobilise during infection or inflammation to provide 
macrophages to the affected tissues33. Monocytes can be categorised according 
to the cell surface expression of CD14 and CD16 as classical, non-classical and 
intermediate monocytes34. Classical monocytes make up the majority found in the 
peripheral blood and are involved in phagocytosis and production of inflammatory 
cytokines. Non-classical monocytes comprise approximately 5-10% of monocytes 
and tend to have a more anti-inflammatory and immunoregulatory role through the 
production of IL-1 receptor antagonist (IL-1 RA). The intermediate population 
makes up less than 5% of the total monocyte pool and are actively pro-
inflammatory, producing IL-6, IL-1β and in response to LPS, TNF-α35. There is 
evidence to show that monocytes play a key role in autoimmune disorders36, 
atherosclerosis37 and cancer biology38 both directly and through differentiation into 
macrophages.  
Once monocytes leave the circulation and enter the tissues they begin to undergo 
further differentiation to macrophages39. Tissue macrophages associate closely 
with T helper cells, that act as regulators of the type of response and therefore the 
type of macrophages that develop. In the context of inflammation and direct 
damage to organisms the TH1 mediated response predominates, while tissue 
remodelling and immune regulation generates a TH2 mediated response
40 (Figure 
1.3). Macrophages have been a source of interest in solid malignancy as 
macrophages are known to associate with tumours and promote angiogenesis, 
support metastasis and decrease the local pro-inflammatory anti-tumour 
response41,42.   
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Figure 1.3 Macrophage interactions with T cells 
 
1.3 Cytokine signalling in haematopoiesis 
Cytokines are soluble regulators required to maintain the fine balance required for 
normal haematopoiesis and can stimulate the whole system to respond to a 
physiological stress such as infection or bleeding. Cytokines bind to receptors 
expressed on target cells and trigger signalling pathways which result in a 
receptor-specific gene transcriptional programme being triggered43. Numerous 
pathways are involved in cytokine signalling and control of the associated 
transcriptional programme triggered by activation of receptors. Key cytokines in 
haematopoiesis include EPO which drives red cell development20, TPO which is 
critical in the production of platelets30, and GM-CSF and G-CSF which are 
involved in granulopoiesis44,45. All of these cytokines signal through receptors 
which are associated only with JAK2 in a homodimeric configuration46. Many other 
receptors, including IFNγ, are associated with two different JAK proteins in a 
heterodimeric fashion and this is particularly common in inflammatory cytokine 
receptors47,48. The binding of ligand to their receptor leads to activation of the JAK 
proteins (Table 1.1) which in turn activates other cellular pathways either directly 
or indirectly, which have complementary activity to the canonical JAK-STAT 
pathway (Figure 1.6). These include the PI3K-Akt-mTOR pathway, the Ras-Raf- 
MEK-ERK pathway, and indirectly the NFκB pathway.  
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1.3.1 PI3K-Akt signalling 
Phosphoinositide-3-kinase (PI3K) plays a critical role in the differentiation of 
haematopoietic cells. PI3K consists of a family of proteins which exist in three 
subclasses (class I, II, III) with class I being of most importance in the 
haematopoietic system. Following activation of a cytokine receptor PI3K is 
activated by tyrosine kinases, including JAK249, with the active PI3K going on to 
transform phosphatidylinositol 4,5 bisphosphate to phosphatidylinositol 3,4,5 
triphosphate (PIP3). PIP3 then goes on to activate Akt, a protein kinase, which acts 
as the main effector of the pathway by activating mTOR signalling and inhibiting 
FoxO activity. This leads to a reduction in transcriptional targets of FoxO, which 
results in a reduction in cell cycle inhibition and apoptosis. In addition to this 
mTOR signalling is activated which drives cell cycle progression and proliferation50 
(Figure 1.4). This pathway has been found to be significantly upregulated in a 
number of haematological malignancies, including acute and chronic 
leukaemias51,52, lymphoma49 and myeloproliferative neoplasms (MPN)53. Most of 
these abnormalities are as a result of increased signalling through a normal 
pathway52. It is also overactive in solid tumours, such as breast cancer54, 
colorectal cancers55 and prostate cancers56, where there are often activating 
mutations present57. 
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Figure 1.4 PI3K-Akt signalling 
 
Activation of PI3K leads to the activation of Akt which in turns co-ordinates signals 
to reduce apoptosis and drive cell cycle progression. This is achieved primarily 
through inhibiting FoxO activity and promoting mTOR signalling. 
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1.3.2 RAS-RAF-MEK-ERK pathway 
This pathway plays a key role in proliferation and preventing the apoptosis of cells 
and is commonly over-active in malignant cells of several types52,58. The initiation 
of signalling in this pathway is by activation of cytokine receptor, with common 
ligands including IL-3, GM-CSF, EPO and G-CSF. The active receptor leads to the 
formation of an activating complex consisting of SHC (Scr homology 2 domain 
containing) transforming protein 1 (SHC1), growth factor receptor bound protein 2 
(GRB2) and son of sevenless (SOS) which in turn leads to farnesylation of Ras 
and its attachment to the cell membrane59. Ras exists in several isoforms which 
vary according to tissue and developmental stage. Once Ras has translocated to 
the cell membrane its GTPase activity is triggered, and in combination with Src 
kinases activates Raf, which in turn activates MAPK/ERK kinase (MEK). MEK 
exists in seven forms and activates four effector proteins; MEK1/2 activating 
ERK1/2, MEK3/6 activating p38, MEK4/7 activating Jun N-terminal kinase (JNK) 
and MEK5 activating ERK5. The effector proteins ERK1/2 interacts with and 
regulates over 100 proteins including transcription factors involved in cell 
proliferation and differentiation. The JNK and p38 pathways are activated by 
cellular stress and mediate a wider range of responses from inflammation, cell 
survival and cell migration60,61 As with other signalling pathways the Ras-Raf-
MEK-ERK pathway has been found to play a role in solid tumours, with activating 
mutations of Ras isoforms in lung62 and colon cancer63, and mutations of B Raf in 
malignant melanoma64. In haematological malignancy there can be other 
mutations which can directly stimulate the pathway to drive increased signalling, 
such as that seen in CML as a result of BCR-ABL directly activating the pathway52.  
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Figure 1.5 RAS-RAF-MEK-ERK signalling pathway 
 
RAS-RAF-MEK-ERK signalling starts with the formation of an activating complex 
consisting of SHC1, GRB2 and SOS. This activated the pathway through 
farnesylation of RAS. This then goes on to phosphorylate RAF, which in turn 
activates MEK, then ERK, which enters the nucleus activating cell survival and 
proliferation genes. 
 
 
 
 
 
 
 
 
 
 
28 
 
1.3.3 NFκB signalling 
Nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) is a 
transcriptionally active complex which exists in the cytoplasm bound to an 
inhibitory protein (IκB) which keeps it inactive65. The canonical NFκB pathway is 
activated as part of the innate immune system in response to physical, 
physiological or oxidative stress leading to degradation of the inhibitory protein, 
which allows the complex to enter the nucleus and effect transcriptional 
alterations. There are five proteins in the NFκB family which contain a Rel domain 
in the N-terminus (p50, p52, RelA (p65), RelB, c-Rel). The proteins exist in a 
dimerised state and will have different transcriptional effects depending on the 
combination of subunits. Both p50 and p52, when bound homodimerically, will act 
as transcriptional repressors, but will become activators when bound with any of 
RelA, RelB or c-Rel66. These latter three proteins will always act as transcriptional 
activators. The canonical pathway is activated directly by several receptors, 
including Toll-like receptors (TLRs), TNF-α and IL-1. In addition to receptor 
mediated activation, the NFκB pathway can be activated by other cell signalling 
pathways and transcriptional regulators, including Akt and STAT367. The role of 
JAK2 in NFκB signalling is less direct than in the previously discussed pathways. 
Both the NFκB pathway and JAK2 are activated by TLR468, and JAK2 activates 
STAT3 directly and Akt through PI3K. The biggest role JAK2 plays however is in 
the potentiation of inflammatory signalling that leads to the release, by immune 
cells, of further inflammatory ligands which then go on to activate NFκB69,70. 
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1.3.4 JAK/STAT pathway 
The Janus kinase/signal transducers and activators of transcription (JAK/STAT) 
pathway is probably the most investigated pathway in cellular biology. The JAKs 
and STATs were initially identified separately in association with interferon (IFN) 
signalling in the late 1980’s and early 1990’s71–73 with all JAKs and STATs 
identified by 199573. The connection between JAKs and STATs in IFN signalling 
was clarified in 199374, and by 1994 it was clear the pathway was utilised by many 
other cytokine receptors. Four JAK proteins have been identified (JAK1, JAK2, 
JAK3 and TYK2) which attach in different combinations to transmembrane 
cytokine receptors75. Activation of the receptor leads to a conformational change 
which allows the JAK proteins to cross-phosphorylate and activate each other at 
multiple sites, with phosphorylation of tyrosines 1007 and 1008 being a mark of 
JAK2 activation76. The canonical JAK/STAT pathway results following the JAK 
activation and the formation of a binding site for STATs by phosphorylation of the 
cytoplasmic portion of the receptor. There are 7 STAT proteins (STAT1, STAT2, 
STAT3, STAT4, STAT5a, STAT5b and STAT6) which are phosphorylated by JAKs 
and dimerise before entering the nucleus and initiating a transcriptional 
programme (Figure 1.6).  
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Figure 1.6 Canonical JAK/STAT signalling 
 
Canonical JAK/STAT signalling relates to the activation of JAK following 
conformational change of the receptor after binding with its ligand. This then leads 
to phosphorylation of the receptor and the relevant STAT proteins, which dimerise 
and enter the nucleus to trigger the relevant transcriptional program.  
In haematopoiesis JAK2 is particularly important and associates with a number of 
key receptors including EPO receptor, TPO receptor, G-CSF receptor, GM-CSF 
receptor, IL-3 receptor and IL-6 receptor. It also combines with other JAK proteins 
in a number of important inflammatory cytokine receptors including IFN-γ receptor, 
IL-5 receptor and IL-12 receptor (Table 1.1). The importance of JAK2 in 
haematopoiesis, particularly erythropoiesis, was shown in Jak2 knockout mouse 
experiments where heterozygous mice were interbred. The Jak2-/+ offspring 
developed normally while the Jak2-/- phenotype resulted in embryonic lethality at 
12 days after conception with features of severe anaemia and little evidence of 
normal erythropoiesis in the foetal liver77.  
Table 1.1 Receptors associated with JAK/STAT signalling in myelopoiesis 
and inflammation 
Receptors JAK proteins STATs Cells expressing receptor 
EPO, TPO, G-CSF,  
GM-CSF 
JAK2/JAK2 STAT5 Myeloid progenitors 
IFN-γ JAK1/JAK2 STAT1 B + T cells and macrophages 
IFN-α JAK1/TYK STAT1  
IL-4 JAK1/JAK3 STAT6 B + T cells, NK and mast cells 
IL-7 JAK1/JAK3 STAT1,3,5 Pre-B cells, T cells and DCs 
31 
 
1.3.4.1 JAK2 signalling in the nucleus 
There is recent evidence showing that JAK2 enters the nucleus78 and mediates 
epigenetic alterations which lead to profound alterations in the transcriptional 
landscape79,80. JAK2 is unable to enter the nucleus alone as it lacks a nuclear 
translocation signal, a protein sequence allowing transfer of a protein from the 
cytoplasm to the nucleus. There are several different nuclear localisation signals 
used by different proteins to enter the nucleus81,82,83, but no sequence that would 
allow transport to the nucleus has been identified on JAK proteins. On activation 
and phosphorylation, particularly of the tyrosine residues at position 1007 and 
1008 (Y1007/1008), a chain of small ubiquitin-like molecule (SUMO) proteins is 
able to attach to JAK2 and allow it to enter the nucleus (Figure 1.7). This was 
shown by expressing truncated JAK2 or the constitutively active JAK2 V617F 
mutant in HEK-293 and there was a reduction of SUMOylation in the truncated 
JAK2 mutants, but an increase in SUMOylation of the JAK2 V617F mutant78.  
Figure 1.7 Nuclear translocation of JAK2 
 
Following activation JAK2 can be SUMOylated allowing it to enter the nucleus. 
JAK2 can then act on modifiers of histone activity and on histone H3 directly to 
alter global gene expression. 
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Histones are proteins that are important in the folding and unfolding of DNA to 
allow transcription of the genes necessary for each individual cells function. 
Histones undergo a range of post-translational modifications that “switch on” or 
“switch off” genes within the cell84.  On entering the nucleus it has been show that 
JAK2 phosphorylates a tyrosine residue on histone H3 at position 41 which leads 
to dissociation of the inhibiting regulatory protein heterochromatin protein 1 α 
(HP1α)79 and also separates methylosome protein 50 (MEP50) and protein 
arginine methyltransferase 5 (PRMT5) which together act as a repressor of 
transcription by modifying histones, transcriptional elongation factors and the 
tumour suppressor p5385. To better characterise the effect of JAK2 in the nucleus 
chromatin immunoprecipitation of the phosphorylated H3Y41 (H3Y41ph) mark and 
parallel DNA sequencing (ChIP-Seq) was carried out. This showed distinct 
patterns of localisation that overlapped other recognised epigenetic and 
transcription factor binding patterns. In particular JAK2 localised with the 
H3K4me3 histone mark, an indicator of active promoter sites, and with sites that 
were also known STAT5 binding sites80. This confirmed the role JAK2 plays in 
gene transcription through a multi-level interaction with the STAT transcription 
factors and directly through alteration of histone biology. 
 
 
 
 
 
 
 
 
 
33 
 
1.4 Myeloproliferative neoplasms  
The myeloproliferative neoplasms are a group of disorders that are characterised 
by the overproduction of the myeloid lineage with different genetic somatic 
mutations driving each of these conditions. Some of these occur only in the 
specific conditions, such as JAK2 Exon 12 mutations in polycythaemia vera (PV) 
and TEL-PDGFR in chronic myelomonocytic leukaemia (CMML), while others are 
associated with multiple conditions, such as t(9;22) in chronic myeloid leukaemia 
(CML) and acute lymphoblastic leukaemia (ALL), and JAK2 V617F in MPN, 
myelodysplasia (MDS) and acute myeloid leukaemia (AML). These mutations 
result in constitutively overactive proteins which drive an expansion of different 
parts of myelopoiesis resulting in disease specific phenotypes. 
Table 1.2 Myeloproliferative neoplasms and common mutations86 
Subclassification Condition Mutations 
BCR-ABL positive MPN Chronic myeloid leukaemia t(9;22) 
BCR-ABL negative MPN Polycythaemia vera 
 
Essential thrombocythaemia 
 
Myelofibrosis 
JAK2 V617F, JAK2 
Exon 12 
JAK2 V617F, CALR, 
MPL W515 
JAK2 V617F, CALR, 
MPL W515 
MPN/MDS overlap Chronic myelomonocytic 
leukaemia 
TEL-PDGFR 
 
1.4.1 Chronic myeloid leukaemia 
CML is a condition characterised by expansion of the myeloid lineage and the 
presence of a balanced translocation between chromosomes 9 and 22 resulting in 
the production of the novel oncoprotein, BCR-ABL. The first clinical description of 
CML was attributed to John Hughes Bennett in 1845 in the Edinburgh Medical and 
Surgical Journal87 who also drew the first microscope images of leukaemia. An 
abnormally small chromosome was identified in several patients with CML in 
Philadelphia in 196088 and was named after the city of its discovery. In 1973 it was 
recognised this abnormal chromosome arose from the t(9;22)89 and in 1982 it was 
found that the Ableson murine leukaemia viral oncogene homolog 1 gene (ABL) 
on chromosome 9 was translocated to the breakpoint cluster region gene (BCR) 
on 2290 resulting in the BCR-ABL fusion protein. This novel oncoprotein is a 
constitutively active tyrosine kinase that has effects on a large number of cellular 
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processes including apoptosis, proliferation, differentiation and cell adhesion. 
These are as a result of the effect of BCR-ABL on key signalling pathways 
including the JAK/STAT pathway, PI3K/Akt pathway, and Ras/Raf/MEK/Erk, which 
are all important in the regulation of proliferation and differentiation of myeloid 
cells52. BCR-ABL can exist in several different forms and is associated with 
different disease phenotypes; BCR-ABL p210 is commonly associated with CML, 
but can also occur in ALL. BCR-ABL p185 is typically associated with ALL91, while 
BCR-ABL p230 is associated with the extremely rare chronic neutrophilic 
leukaemia92. These different versions are a result of different breakpoints in the 
BCR and ABL genes resulting in different molecular weight proteins. The 
mechanism by which these different isoforms result in different disease 
phenotypes is unknown.  
Patients with CML may present with an asymptomatic leucocytosis identified on 
routine peripheral blood testing. When CML patients do present with symptoms 
these can be general, in the form of night sweats, fever and weight loss, or related 
to specific complications of disease such as abdominal discomfort from enlarged 
liver or spleen. CML progresses through three stages, chronic phase, accelerated 
phase and blast crisis. Patients can present at any stage, with about 85% 
presenting in chronic phase which carries a better prognosis and the remaining 
15% presenting in either accelerated phase or blast crisis93. Patients presenting in 
chronic phase can be stratified as low, intermediate or high risk based on clinical 
parameters at presentation using several prognostication tools. These tools can be 
used to predict the overall survival of these patients following treatment. There are 
three commonly used prognostication tools used in CML; the Sokal94, Hasford95 
and European treatment and outcomes study (EUTOS)96 scores. All three use 
clinical characteristics at diagnosis, prior to any treatment. The Sokal score is 
based on age spleen size palpable on examination, platelet count and peripheral 
blood blast count, with blast count and spleen size being the strongest predictors 
of survival. Most patients in this cohort were treated with single agent 
chemotherapy, mostly busulphan94. The Hasford score added peripheral blood 
eosinophil and basophil count, with most patients here being treated with 
interferon α alone or in combination95. The EUTOS score was developed more 
recently with most patients in this cohort being treated within 6 months of 
diagnosis with a tyrosine kinase inhibitor and is based only on the peripheral blood 
basophil count and spleen size96. This final score is used to predict the likelihood 
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of achieving a complete cytogenetic response, which had only been achieved in a 
small proportion of patients prior to the introduction of TKI therapy. 
Treatment of CML changed dramatically following the introduction of the tyrosine 
kinase inhibitor (TKI), imatinib. This is a small molecule inhibitor of BCR-ABL, with 
additional activity against platelet derived growth factor receptor alpha 
(PDGFRA)97 and c-kit98, that acts though competitive inhibition by blocking the 
ATP binding site99. It was developed by Novartis and entered into clinical trial use 
in the late 1990s and was approved for use in the treatment of CML in early 
2000s.  Prior to this time patients were treated with IFN-α and hydroxycarbamide, 
which could control the disease for a time, but did not prevent progression for the 
majority of patients100. For the majority of patients the only long term solution was 
allogeneic bone marrow transplantation and this was only available to patients 
who were both fit and had a donor option available. A proportion of patients did 
achieve prolonged remissions with IFN-α, but the side effects of sweats and 
lethargy frequently made it difficult to tolerate100.  
The introduction of imatinib changed this after it was shown it could induce deep 
molecular remissions and maintain them over time in patients with blast crisis 
CML101 and subsequently in newly diagnosed chronic phase patients102. This led 
to the development of several other TKIs, with a total of five currently available to 
clinicians in the treatment of CML; imatinib, nilotinib, dasatinib, bosutinib and 
ponatinib. This has led to drastic alterations in the expectations of patient 
outcomes in CML with the majority expected to have a normal life span103. 
Unfortunately most patients need to remain on therapy lifelong as they continue to 
have a detectable level of BCR-ABL in the peripheral blood. Even those who 
manage to achieve a sustained complete molecular response will relapse following 
discontinuation of their imatinib in approximately 50% of cases104.  
Signalling of the JAK2 pathway in CML is enhanced by several mechanisms. 
BCR-ABL has a direct effect on phosphorylation of JAK2 and STAT5 as well as 
driving autocrine production of cytokines which signal through JAK2 associated 
receptors. Recently an additional mechanism has been identified in the formation 
of a complex between JAK2 and BCR-ABL through a third protein, Ableson helper 
integration site 1 (AHI-1). This complex may be important for the maintenance of 
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leukaemic stem cells in CML and may offer a therapeutic target for eradication of 
the disease105.  
1.4.2 BCR-ABL negative myeloproliferative neoplasms 
The myeloproliferative neoplasms have been recognised as clinical entities for 
over a century with the first description of myelofibrosis (MF) occurring in 1879 by 
Heuck106, while PV was first described in 1892 by Vaquez107 and essential 
thrombocythaemia (ET) in 1934 by Epstein and Goedel108. Additionally a report in 
1903 classified polycythaemia into primary polycythaemia, polycythaemia 
secondary to other causes and relative polycythaemia as a result of reduced 
plasma volume, which is still in use today109.  
The MPNs are conditions where there is excess proliferation of cells of the myeloid 
lineage. ET is characterised by thrombocytosis with or without leukocytosis, while 
PV has an increase in red cell mass with or without thrombocytosis and 
leukocytosis. MF is often associated with cytopenias, but can also have 
thrombocytosis or leukocytosis and is diagnosed by the presence of reticulin 
fibrosis on bone marrow trephine. All three conditions can be associated with 
splenomegaly, cytokine driven symptoms, such as sweats, fevers and lethargy, 
chronic inflammation and thrombotic complications. The diagnosis of these 
conditions was purely based on clinicopathological appearances which included 
peripheral blood and bone marrow appearances in combination with the clinical 
history leading to the generation of clinical guidelines to improve diagnostic 
accuracy86. In 2005 a point mutation in exon 14 of the JAK2 gene was identified 
and reported by 4 groups110,111,112,113. This mutation causes a substitution of 
phenylalanine for valine at position 617 (JAK2 V617F), resulting in loss of the 
inhibitory effect of the pseudokinase domain and constitutive activation of the 
JAK2 tyrosine kinase, leading to chronic uncontrolled activation of the JAK2/STAT 
pathway without the need for receptor activation by ligand.  
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Figure 1.8 Structure of JAK2 protein 
 
 
JAK2 is a tyrosine kinase with a typical structure. The FERM domain allows 
localisation with the cytokine receptor while the SH2 domain allows docking of 
proteins phosphorylated by JAK2. The pseudokinase domain negatively regulates 
the kinase activity of JAK2 and the kinase domain contains the active site of JAK2.      
FERM 4.1 – ezrin – radixin – moesin, SH2 Src Homology 2. 
The JAK2 V617F mutation is the most common, occurring in 97% of PV patients, 
60% of ET patients and 60% of MF patients and led to a search for additional 
mutations associated with MPN. This has led to an additional three groups of 
driver mutation being identified; the JAK2 exon 12 mutations occur in 2% of JAK2 
V617F negative PV patients and have a distinct clinical phenotype compared to 
the V617F positive patients114, activating mutations of the gene for the TPO 
receptor, MPL, which signals through JAK2, and is mutated in 5-10% of ET and 
MF patients115,116, and calreticulin mutations occurring in 25-30% of ET and MF117. 
Calreticulin is involved in calcium homeostasis in the endoplasmic reticulum118, 
however the mutated form of the protein found in MPN is able to activate the MPL 
receptor directly leading to activation of JAK2 and STAT119. As a result these 
patients retain  a gene expression profile associated with JAK/STAT signalling 
confirming that this pathway remains the key driver of disease120. One of these 
four mutations is required to initiate and maintain disease and they rarely occur 
simultaneously. Additional mutations are seen in MPN (ASXL, IDH1/2, SRSF2) 
which affect prognosis when present, but are not required to initiate disease121,122. 
Interestingly there is evidence that suggests the clinical course of disease is 
altered by the order in which mutations are acquired123. The discovery of these 
mutations has led to incorporation of them into diagnostic algorithms and as 
prognostic markers, particularly in MF where patients with the CALR mutation 
have a better prognosis than those with JAK2 or MPL mutations and those with no 
identifiable driver mutation doing worse than either group. The additional 
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mutations attenuate these risks and worsen the prognosis if found with any of the 
driver mutations124,125. 
Many of these patients are asymptomatic or have low grade chronic symptoms 
which they attribute to minor complaints. As a result patients are often diagnosed 
when bloods are done for another reason or when they present with a 
complication directly attributable to the underlying MPN, particularly arterial or 
venous thrombosis although the latter is becoming less common with increasing 
use of routine blood testing in the community. 
The seriousness of arterial or venous thrombosis as a complication underlies the 
current treatment recommendations for PV where patients are started on 
cytoreductive therapy due to the high risk for thrombotic complications, with age 
and previous vascular events being the best predictors for further thrombosis126. 
The efficacy of low-dose aspirin to reduce thrombosis was shown in the ECLAP 
study127, where 100mg aspirin daily was shown to reduce the risk of non-fatal 
myocardial infarction and stroke or death from cardiovascular causes by 41%. At 
present there is no definite predictive model for risk of transformation to MF or to 
AML although higher leucocyte count has been associated with an increased risk 
of fibrotic transformation128. Therefore the aim of therapy is to minimise further 
arterial and venous thrombotic events through antiplatelet therapy and aggressive 
management of cardiac risk factors for all patients in combination with 
cytoreduction.  
The mechanism underlying thrombosis is complex. Peripheral counts have a part 
to play as a result of altering the viscosity of blood. There is also evidence showing 
that controlling counts, particularly platelets and leucocytes, in the normal range 
reduces the risk of thrombosis127, however the fact that this risk does not return to 
baseline for age suggests there is more contributing to the risk. The JAK2 V617F 
mutation has been shown to play a role in thrombosis with ET patients who are 
JAK2 V617F positive being more likely to have a thrombotic event than those who 
are negative. In patients with PV a higher JAK2 V617F allele burden is associated 
with an increased risk of thrombosis particularly in those with an allele burden over 
75%. Additionally there is evidence that a higher leukocyte count is associated 
with an increase in the risk of thrombosis, although there is no evidence that 
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reduction to the normal range of the leucocytes results in a reduction in thrombosis 
risk.  
In the last decade there has been increasing interest in the inflammatory state 
associated with MPN. Patients have elevated inflammatory cytokine (IL-6, IL-18, 
TNF-α) and elevated markers of inflammation (CRP, pentraxin 3). Interestingly 
there is evidence suggesting a link with higher levels of inflammatory cytokines 
and increased risk of thrombosis which is unrelated to peripheral blood cell counts. 
There is clear evidence that increased peripheral counts increases the risk of 
thrombosis which is thought to relate to rheological abnormalities induced by 
increased blood viscosity related to elevated counts. However there is clear 
evidence that platelets and white cells are more active than normal with ET and 
PV patients excreting increased thromboxane A2 metabolites, and neutrophils 
expressing higher levels of CD11b, a marker of activation.  
Figure 1.9 Model of MPN associated thrombophilia 
 
A model of the thrombophilia associated with MPN showing the central role of 
inflammation in combination with platelet and leukocyte activation as drivers of 
endothelial dysfunction and risk of thrombosis. 
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The MPNs occur in between 0.5-1.5 per 100,000 per year in Western populations. 
Population studies prior to the introduction of the JAK2 inhibitor ruxolitinib show an 
overall median survival of about 6 years from diagnosis for MF35 compared to 14 
years for PV34 and almost 20 years for ET36.  All three conditions have a median 
survival less than age matched controls36. The commonest causes of death for 
these patients are thrombosis, haematological malignancy and second non-
haematological malignancy34.  
All patients have an increased risk of thrombosis with arterial and venous events 
being a common presenting complaint of patients, with the MPN diagnosis being 
suspected on admission bloods. The underlying cause of thrombosis is thought to 
be partly related to the elevated counts and certainly it is recognised that 
controlling peripheral counts with cytoreductive therapy or therapeutic venesection 
can reduce the risk of thrombotic events, however patients with MPN continue to 
have a higher than expected risk of thrombotic events. It is thought this is a major 
contributor to the documented poorer life expectancy seen in these patients 
compared to age matched controls in ET and PV129. 
The current treatment options for ET and PV remain largely unchanged over the 
last few decades with cytoreduction using venesection (PV only), 
hydroxycarbamide or anagrelide as appropriate. Venesection controls the 
production of red cells by inducing a therapeutic iron deficiency, but can also 
cause cognitive impairment and restless legs. Hydroxycarbamide inhibits 
ribonuclease reductase resulting in a decrease in the production of 
deoxyribonucleotides, which in turn leads to a reduction in DNA synthesis and 
control of the peripheral counts, with potential side effects of cytopenias, 
gastrointestinal upset and skin ulceration. Anagrelide is only used to control the 
platelet count as it inhibits the maturation of platelets from megakaryocytes, 
although the precise mechanism underlying this is unclear. None of these 
therapies alter the natural history of the disease or affect disease burden130,131.  
The identification of the JAK2 V617F mutation as the driver of myeloproliferative 
neoplasms and the success of imatinib in CML led to the development of JAK2 
specific inhibitors to use in the treatment of these disorders. The first to 
successfully enter routine clinical use for the treatment of symptomatic MF was 
ruxolitinib132, a specific inhibitor for JAK1 and JAK2, which has been shown to 
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have a significant improvement in symptoms burden in patients with MF. It has 
also shown some survival benefit for these patients, thought to be as a result of 
improved nutritional status132. Unfortunately about 50% of patients who start 
ruxolitinib have to stop it either as a result of cytopenias, through other side effects 
or through lack of efficacy132.  
Trials have been done looking at ruxolitinib in patients with PV who were intolerant 
of or had an inadequate response to hydroxycarbamide therapy with the 
RESPONSE trial looking at 222 patients randomised to ruxolitinib or best available 
therapy (BAT) and assessing symptom improvement, spleen size reduction and 
haematocrit control. The patients treated with ruxolitinib had a higher rate of 
complete haematological response, improvement in symptoms and reduction in 
allele burden compared to those treated with BAT. This indicates that in PV there 
are patients who will benefit from therapy with ruxolitinib133, which has recently 
been licenced for PV patients who are intolerant or unresponsive to 
hydroxycarbamide. Other JAK2 inhibitors have entered clinical trial, but have had 
to be withdrawn due to unacceptable side effects. Fedratinib was withdrawn after 
patients on the JAKARTA trials developed significant neurological toxicity134. 
Pacritinib was also recently put on clinical hold by the FDA following deaths from 
cardiac complications135.  
It has long been recognised that over the course of the disease the MPNs can 
transform. Most commonly this is ET to PV or MF, or PV into MF, but all three can 
transform directly to AML (Figure 1.10), which tends to be poorly responsive to 
current chemotherapies and therefore has a poor outcome136. This is particularly 
the case for older or less physically fit patients as the option of allogeneic bone 
marrow transplantation is not available, which remains the only real curative option 
for these patients.  
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Figure 1.10 Progression of MPN 
 
The myeloproliferative neoplasms can transform as shown above. This occurs in 
approximately 10% of patients, with the majority of patients continuing with the 
condition they were first diagnosed with. 
The mechanism behind transformation is complex. There appears to be an 
increased JAK2 V617F mutation allele burden with progression from ET, through 
PV into MF, and patients presenting with de novo ET tend to have a lower allele 
burden than those with either de novo PV or MF, suggesting that the increase in 
aberrant JAK2 signalling leads to an alteration of phenotype and worsening 
severity of disease137. In addition to this there is often acquisition of additional 
mutations as the disease progress136. It is felt these are as a result of genomic 
instability consequent on the increased proliferation and reduced apoptosis 
associated with these conditions. 
1.4.3 Malignant JAK/STAT signalling 
Abnormal signalling through the JAK/STAT pathway has been found to be 
important in many malignancies, both haematological138 and solid tumours139,140. 
In myeloid malignancies aberrant JAK2 signalling is associated with poor 
prognosis in AML141, and has been shown to be important in the maintenance of 
CML105,2. Activating mutations of JAK2 have been found in ALL142 as well as 
MPN111, and various translocations involving JAK2 have been described in 
atypical CML143, AML and ALL144. Amplification at 9p24, the gene locus containing 
JAK2, has been shown to confer a worse outcome for breast cancer patients139 
and inhibition of JAK2 and STAT3 increases apoptosis in colon cancer cells in 
vitro145,146.  
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1.5 Inflammation 
Immunity is a complex process that developed to combat infective micro-
organisms and is tightly controlled in normal circumstances to prevent damage to 
self. There are two major components to the immune response, an innate 
response designed to immediately mobilise to remove any infection147, and 
adaptive immunity, which results in production of antibodies, therefore taking 
longer to initiate but is specific for each pathogen148. Innate immunity involves 
predominantly neutrophils, monocytes and macrophages, although macrophages 
are also important in triggering the adaptive immune system147. The adaptive 
immune system is mediated by T and B lymphocytes and results in antibody 
production which is specific for an individual pathogen. Inflammation results from 
the influx of immune cells of the innate response to the affected area and is 
characterised by localised swelling, erythema, pain and heat. Inflammation is part 
of the innate immune system and is mediated by granulocytes and the 
inflammatory cytokines released by these cells which help to control local tissue 
damage or infection. In most cases inflammation is localised to the area of 
damage, but in certain circumstances such as disseminated infection or in many 
rheumatological conditions inflammation occurs throughout the body. In the 
context of widespread infection treatment of this with antimicrobials will remove the 
trigger for inflammation and allow symptoms to settle. However in many incurable 
medical conditions there is chronic inflammation associated with an abnormal 
response within the body.  
1.5.1 Inflammation in MPN 
In MPN the presence of the JAK2 V617F mutation leads to an alteration in the 
signalling of haematopoietic cells important in inflammation with evidence of 
alteration of neutrophil reactive oxygen species generation149, alteration in serum 
inflammatory cytokine levels150 and an altered reactivity to these cytokines48. Of 
interest is the fact that the malignant clone is not the sole source of inflammatory 
cytokine production. MPN cells alter the surrounding stromal cells in the bone 
marrow to produce more inflammatory cytokines which give a survival advantage 
to the MPN clone compared to normal cells. This includes the production of TNF-α 
which reduces the proliferative activity of normal haematopoietic cells, but MPN 
cells are resistant to this and may actually proliferate more in the presence of TNF-
α151. This chronic inflammation is implicated in the thrombotic complications and 
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progression of MPN to acute leukaemia152. The incidence of cardiovascular event 
has been found to be increased in the presence of chronic inflammation in other 
conditions such as rheumatoid arthritis153 and cardiovascular disease itself is now 
viewed as an inflammatory disease of the endothelium154. In MPN the chronic 
inflammation, in addition to excessively reactive platelets, hyperviscosity from 
elevated red cell and white cell counts and altered vessel rheology combine to 
make thrombosis a particular issue for patients155. In addition to this the chronic 
inflammatory milieu results in damage to HSCs leading to attrition of the HSC 
numbers and may be the driver for the development of AML, which in MPN rarely 
retains the driver mutation responsible156.  
1.6 Promyelocytic leukaemia protein and SUMOylation 
Within eukaryotic cells there are a number of sub-nuclear structures which exist to 
carry out specific functions within the nucleus. These nuclear bodies include 
nucleoli, Cajal bodies, splicing speckles and PML nuclear bodies (NB)157 and are 
involved in regulating and coordinating many aspects of normal nuclear 
functioning. PML NBs comprise multiple PML units in combination with Sp100 and 
SUMO 1, 2 and 3 chains158. These SUMO chains are important in maintaining the 
structure of the NBs but also interact with other proteins that localise there158. At 
least 50 other proteins have been shown to interact with NBs, involved in 
numerous cellular processes, including apoptosis, by potentiating signalling via 
FAS ligand159 and TNF-α160, DNA repair161, transcriptional control by sequestering 
or marking for degradation transcriptional regulators, p53 function through 
inhibition of mouse double minute 2 (MDM2) and post-translational modification of 
p53162, and response to viral infections through the type I and II IFNs163.   As a 
result dysfunction of these nuclear bodies has been related to numerous 
pathological processes. Generally PML is viewed as a tumour suppressor as a 
result of these functions. This is confirmed by the finding that solid tumours have 
abnormally low or absent levels of PML164. The exception to this is leukaemia stem 
cells in CML, where there is an unexpectedly high level of PML mRNA 
transcripts165. 
An important disease that led to the identification of PML, is acute promyelocytic 
leukaemia (APML)166,167, a rare acute myeloid leukaemia characterised by a 
translocation between chromosomes 15 and 17. The product of this translocation 
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was found to be a fusion protein combining PML with the retinoic acid receptor α 
(PML-RARA). This fusion protein led to disruption of the normal PML nuclear body 
structure and dispersal of the fusion protein throughout the nucleus168. This 
abnormality seemed to be sufficient to produce the entire clinical phenotype of 
maturation arrest and uncontrolled proliferation of abnormal promyelocytes 
indicating an important role for PML NBs in myeloid proliferation and 
differentiation169.  
Other that the pathogenic role in APML and unexpectedly high levels in CML stem 
cells, little is known about PML in myeloid malignancies. In MPN the chronic 
inflammation seen would be expected to increase the levels of PML. In addition to 
this the requirement for SUMOylation to allow JAK2 to enter the nucleus would 
allow JAK2 to interact with PML NBs, raising the possibility that JAK2 and PML 
interact directly to facilitate the nuclear effects of JAK2. 
1.7 Aims 
The overall aim of this study is to investigate novel effects of JAK2 overactivity in 
two haematological malignancies with increased JAK2 signalling; CML, where 
there is increased stimulation of normal JAK2, and PV, where there is constitutive 
activity as a result of the JAK2 V617F.   
 
1. To identify and characterise a direct JAK2 gene expression profile, and 
investigate if this is deregulated in myeloid malignancies with increased 
JAK2 activity. 
2. To examine the functional effects of JAK2 inhibition in myeloid 
malignancies. 
3. To explore the hypothesis that JAK2 may interact with PML and elicit its 
direct effects within the nuclear bodies. 
4. To investigate the inflammatory phenotype seen in JAK2 V617F positive 
PV. 
5. To examine the function of innate immune cells in JAK2 V617F positive PV. 
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2. Materials and Methods 
2.1 Materials 
2.1.1 Small molecule inhibitors 
Ruxolitinib, TG101209 and AT9283 were obtained from Stratech Scientific Ltd in 
powder form. Nilotinib was provided under MTA from Novartis Pharma. All 
inhibitors were dissolved in DMSO and stored at -200C as a stock solution of 
10mM. As2O3 was dissolved in 1M NaOH at a concentration of 100mM. This was 
made fresh for each use of the inhibitor. All inhibitors were diluted to final 
concentration in complete media for the cell type being treated. 
2.1.2 Tissue culture supplies 
Company Reagent Catalogue no 
Life Technologies, UK Roswell Park Memorial Institute (RPMI) 
1640 media 
Iscove's Modified Dulbecco's Medium 
(IMDM) 
L-Glutamine 
Sterile water 
Foetal bovine serum (FBS) 
Phosphate buffered saline (PBS) 
21875-034 
 
21980-032 
 
25030-081 
A12873-04 
10270-106 
10010015 
Promocell, Germany Monocyte Attachment Medium  
Macrophage Base Medium DXF 
Macrophage Detachment Solution DXF 
C-28051 
C-28057 
C-41330 
Stem Cell 
Technologies, UK 
Stemspan SFEM II 09655 
Labtech, UK  Biosera foetal calf serum (FCS) FB-1001S 
Sigma Aldrich, UK Horse serum 
Histopaque®-1077 
XTT salt (2,3-Bis-(2-Methoxy-4-Nitro-5-
Sulfophenyl)-2H-Tetrazolium-5-
Carboxanilide) 
Phenazine methosulphate 
Arsenic trioxide 
Lipopolysaccharides from E. Coli 
H1138 
10771 
X4626 
 
 
P9625 
A1010 
L5293 
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0111:B4 
Peprotech, UK Human IL-3 
Human IL-4 
Human IL-6 
Human G-CSF 
Human GM-CSF 
Human M-CSF 
Human stem cell factor (SCF) 
Human FLT-3 ligand (FLT-3L) 
Human IFN γ 
200-03 
200-04 
200-06 
300-23 
300-03 
300-25 
300-25 
300-19 
300-02 
Greiner Bio One, UK 25mm3 tissue culture flasks 
75mm3 tissue culture flasks 
75mm3 suspension cell culture flasks 
6 well plates 
12 well plates 
24 well plates 
96 well plates 
690175 
658175 
658195 
657160 
665180 
662102 
655180 
Thermo Fisher 
Scientific, UK 
Nunc 25mm3 flasks 
Nunc 75mm3 flasks  
Delta-coated 6 well plates 
Delta-coated 24 well plates 
8-well Nunc™ Lab-Tek™ II Chamber 
Slide™  
Sodium hydroxide 
Portex Kwill filling tube 
136196 
178905 
140685 
142485 
154534 
 
10396240 
1317493 
Stratech Ruxolitinib 
TG101209 
AT9283 
S1378-SEL 
S2692-SEL 
S1134-SEL 
Miltenyi LS columns 
CliniMACS® CD34 reagent 
130-042-401 
171-01 
Acros Organics Dextran, high fraction AC40626 
Octapharma Human serum albumin 20% (Albunorm) PL10673/0031 
Bio-Rad Bio-Plex Pro™ Human Cytokine 27-
plex Assay 
Bio-Plex Pro™ Human IFNα2 
M500KCAF0Y 
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Bio-Plex Pro™ Human Gro-α 
Molecular Devices SpectraMax M5 Microplate Reader 
SoftMax Pro 
 
 
2.1.3 Flow cytometry reagents 
Company Reagent Catalogue no 
BD Bioscience, UK Annexin V FITC 
7-AAD 
Propidium iodide (PI)/RNase staining 
buffer 
Mouse anti-human CD14 FITC 
Mouse anti-human CD16 APC 
Mouse anti-human CD68 FITC 
Mouse anti-human CD80 PE-Cy7 
Mouse anti-human CD86 BV421TM 
Mouse anti-human CD163 PerCP-
CyTM 5.5 
Mouse anti-human CD206 PE 
Mouse anti-human CD34 APC 
Mouse anti-human CD45-FITC 
FACSCanto 
556420 
559925 
550825 
 
555397 
561304 
562117 
561135 
562432 
563887 
 
555954 
555624 
555482 
eBioscience Affymetrix Ultracomp beads 01-2222-41 
PAA Hanks buffered saline solution (HBSS) H15-008 
   
 
2.1.4 Polymerase chain reaction reagents 
Company Reagent Catalogue no 
Qiagen RNEasy Plus mini kit 
RNEasy Plus micro kit 
Multiplex PCR kit 
74134 
74034 
206143 
Life Technologies Superscript® III reverse transcriptase 
RNaseOUT™ recombinant 
ribonuclease inhibitor 
GeneAmp® dNTP blend 
18080-044 
10777-019 
 
N8080260 
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PicoPure® RNA isolation kit KIT0204 
Fluidigm 2x Assay loading reagent 
20x DNA binding dye 
85000736 
100-3783 
Bio-Rad SsoFast™ EvaGreen Supermix with 
low ROX 
1725210 
New England BioLabs Exonuclease I (E. coli) 
Exonuclease I reaction buffer 
M0293 
B0293 
Integrated DNA 
Technologies 
Custom Oligo-dT  
 
2.1.5 Immunoblotting 
Company Reagent Catalogue no 
Sigma Aldrich Ammonium persulphate (APS) 
Sodium azide 
N,N,N′,N′-Tetramethylethylenediamine 
(TEMED) 
Glycerol 
Ponceau S 
Sigma 7-9® 
Sodium dodecyl sulfate (SDS) 
Glycine 
Sodium Chloride 
Bromophenol blue 
2-Mercaptoethanol 
Ethylenediaminetetraacetic acid 
disodium salt dehydrate (EDTA) 
Methanol 
Phenylmethanesulfonyl fluoride 
(PMSF) 
Sodium metavanadate 
Sodium Fluoride 
Sodium Molybdate 
Pepstatin A 
Aprotinin 
A9164 
S8032 
T9281 
 
G6279 
P7170 
T1378 
L3771 
G8898 
S7653 
114391 
M7522 
E5134 
 
24229 
P7626 
590088 
S7920 
243655 
P4265  
A1153 
L2884 
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Leupeptin 
Soyabean trypsin inhibitor 
NP-40 
T9777 
T6522 
NP40 SIGMA 
Roche Bovine Serum Albumin Fraction V 10735094001 
Marvel Skimmed milk powder  
Santa Cruz Rabbit anti-human JAK2 antibody 
Mouse anti-human PML antibody 
Rabbit anti-human STAT1 antibody 
Rabbit anti-human STAT5 antibody 
Mouse anti-human B-Actin antibody 
Rabbit anti-human SHPTP2 antibody 
sc-294 
sc-966 
sc-343 
sc-835 
sc-47778 
sc-280 
Cell signalling Rabbit anti-human phospho-STAT1 
antibody 
Rabbit anti-human phospho-STAT5 
antibody 
PathScan® BCR-ABL activity assay 
7649 
 
9351 
 
5300 
Abcam Mouse anti-human SUMO 2/3 antibody ab81371 
Millipore Rabbit anti-human phospho-JAK2 
antibody 
Rabbit anti-human JAK2 antibody 
Immobilon™ Western 
Chemiluminescent HRP substrate 
04-1098 
 
06-1310 
WBKLS0500 
Thermo Fisher 
Scientific 
Mouse anti-human JAK2 antibody 
CL-XPosure™ Film  
MA5-15632 
34089 
Dako Goat anti-rabbit HRP conjugated 
antibody 
Goat anti-mouse HRP conjugated 
antibody 
P0448 
 
P0447 
GE Healthcare Life 
Sciences 
Amersham Protran 0.45Nitrocellulose 
membrane 
Whatman™ 3mm CHR blotting paper 
10600002 
 
3030-917 
Bio-Rad Quick Start Bradford Protein Assay Kit 500-0201 
Kodak Autoradiography Cassette  
Konica Minolta Xomat SRX-101A Developer  
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2.1.6 Immunofluorescence and Duolink 
Company Reagent Catalogue no 
Sigma Aldrich Poly-L-Lysine 
Sodium tetraborate 
Ovalbumin 
Triton X-100 
Sodium azide 
Duolink® in-situ PLA® probe anti-
mouse MINUS 
Duolink® in-situ PLA® probe anti-
rabbit PLUS  
Duolink® in-situ  detection reagents 
RED 
Duolink® in-situ mounting medium with 
DAPI 
P9155 
221732 
A5378  
T9284 
S8032 
DUO92004 
 
DUO92002 
 
DUO92008 
 
DUO82040 
C. A. Hendley 10 well multispot slides PH088 
Roche Bovine Serum Albumin Fraction V 10735094001 
GPR Paraformaldehyde 294474L 
Thermo Fisher 
Scientific 
Acetone 10162180 
Vector Laboratories Vectashield® mounting media with 
DAPI 
H-1200 
Santa Cruz Rabbit anti-human JAK2 antibody 
Mouse anti-human PML antibody 
Normal mouse IgG 
Normal rabbit IgG 
sc-294 
sc-966 
sc-2025 
sc-2027 
Abcam Mouse anti-human SUMO 2/3 antibody ab81371 
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2.2 Preparation of media and solutions 
2.2.1 Tissue culture cells and media 
2.2.1.1 Cell lines 
Cell line Origin Karyotype 
K562 Established from pleural 
effusion of  patient with blast 
crisis CML 
61-68<3n>XX, -X, -3, +7, -13, -18, 
+3mar, del(9)(p11/13), 
der(14)t(14;?)(p11;?), 
der(17)t(17;?)(p11/13;?), 
der(?18)t(15;?18)(q21;?q12), 
del(X)(p22) 
UKE1 Established from peripheral 
blood of patient with ET at 
leukaemic transformation 
and retaining JAK2 V617F 
mutation 
48 XX, +8, +19 [14] 
45 XX, -7, del(11)(p14) [8] 
SET2 Established from peripheral 
blood of patient with ET at 
leukaemic transformation 
and retaining JAK2 V617F 
mutation 
46-47<2n>XX, +13, -14, +21, +mar, 
add(4)(p15), der(5)t(5;19)(q11;q13), 
der(7)t(7;14)(q31;q11), 
del(9)(p11p24)ins(9;?21)(p11;p11p12), 
add(9)(q11)t(9;22)(p24;q12), 
der(13)del(13)(q11-
q13)t(13;21)(q34;q11-12), 
der(13)t(13;21)(q34;q11-12), 
ins(16;9)(q22;?p23p24), 
der(19)t(9;19)(p24;q13), 
ider(?21;9)(p10p13;p24), 
der(21)r(21;9)(p1?1q1?1;p24p2?3); 
carries multiple rearrangements 
affecting 9p24 amplification; 
resembles published karyotype 
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2.2.1.2 Media for cell lines 
Cell line Complete media Volume 
K562 RPMI 1640  
FBS          
L-Glutamine           
500ml 
50ml 
5ml 
UKE1 IMDM                 
FCS 
Horse serum 
L-Glutamine 
500ml 
50ml 
50ml 
5ml 
SET2 RPMI 1640 
FCS 
L-Glutamine 
500ml 
100ml 
5ml 
 
2.2.1.3 Resuspension solution 
Human serum albumin 20% 50ml 
PBS 950ml 
EDTA 1mM 
 
2.2.1.4 Freezing solution for CML CD34 cells 
Human serum albumin 5% 40ml 
DMSO 10ml 
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2.2.1.5 Media for CML primary samples 
High growth factor media  
Stemspan II 20ml 
SCF 100ng/ml 200μl 
FLT-3L 100ng/ml 200μl 
IL-3 20ng/ml 40μl 
IL-6 20ng/ml 40μl 
G-CSF 20ng/ml 40μl 
Low growth factor media  
Stemspan II 30ml 
SCF 3μl 
FLT-3L 3μl 
IL-3 0.6μl 
IL-6 0.6μl 
G-CSF 0.6μl 
 
2.2.1.6 Macrophage generation 
M1 polarisation  
Macrophage Base Medium DXF  
GM-CSF 5ng/ml 
M1 stimulation  
Macrophage Base Medium DXF  
LPS 100ng/ml 
IFN-γ 20ng/ml 
M2 polarisation  
Macrophage Base Medium DXF  
M-CSF 50ng/ml 
M2 stimulation  
Macrophage Base Medium DXF  
M-CSF 10ng/ml 
IL-4 20ng/ml 
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2.2.2 Tissue culture solutions 
2.2.2.1 DAMP solution for thawing cryopreserved CD34+ cells 
DNase II solution 2ml 
MgCl2 1M 1.25ml 
Trisodium citrate 0.155M 53ml 
Human serum albumin 20% 25ml 
PBS without Ca2+ or Mg2+ 418.75ml 
 
2.2.3 Flow cytometry solutions 
2.2.3.1 PBS + 2% FBS 
PBS 49ml 
FBS 1ml 
 
2.2.4 PCR solutions 
2.2.4.1 Reverse transcription mix 1 
Oligo dT 1μl 
dNTPs 1μl 
RNA 500ng 
RNase free water 12μl – RNA volume 
 
2.2.4.2 Reverse transcription mix 2 
5x buffer 4μl 
DTT 1μl 
RNase 0.5μl 
Superscript III 0.5μl 
 
2.2.4.3 Pre-amplification mix 
Qiagen Multiplex PCR master mix 2.5μl 
500nM pooled primers 0.5μl 
RNase free water 0.75μl 
cDNA 1.25μl 
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2.2.4.4 Exonuclease treatment 
RNase free water 1.4μl 
Exonuclease I reaction buffer 0.2μl 
Exonuclease I (E. coli) 0.4μl 
 
2.2.4.5 Assay mix for Fluidigm qRT PCR 
2x Assay loading reagent 3μl 
TE buffer 0.3μl 
Mixed forward and reverse primer 2.7μl 
 
2.2.4.6 Sample mix for Fluidigm qRT PCR 
20x DNA binding dye 0.3μl 
SsoFast™ EvaGreen Supermix with low 
ROX 
3μl 
Pre-amplified sample 2.7μl 
 
 
2.2.4.7 Primer list 
Gene Primer pair (5’-3’) 
AURA ggcaaacacataccaagagacc 
gctcagagaagtacttgaacac 
AURB ggaagacaatgtgtggcacc  
gcatcacacaacgagacctatc 
B2M ttgtctttcagcaaggactgg 
atgcggcatcttcaaacctcc 
BACH 1 gagacagtgaatcctgttcagc 
gcacaagcttactccagaacag 
BCL2 gagaaatcaaacagaggccg 
ctgagtacctgaaccggca 
BCL2L1 ggtgagtcggatcgcagc 
cagcggttgaagcgttcc 
BID ggaaccgttgttgacctcac 
gaggagcacagtgcggat 
BNIP3L gtatcagactggtccagtagacc 
ccgcagaatttctgaaggtgttc 
CCNA2 ctaccatgaggatattcacacatacc 
gttctcctacttcaactaaccagtcc 
CCND1 tgcatctacaccgacaactcc 
ggagaacaaacagatcatccgc 
CCND2 tacaccgacaactccatcaagc 
cctcatgacttcattgagcacat 
CCNF cacaaagcatccatattgcactgc 
gtaggagctggtcagacatcc 
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CDC25B gaatcctccgaatcttctgatgc 
atagactggaagcgtctgatgg 
CDK1 aactacaggtcaagtggtagcc 
ggatgtgcttatgcaggattcc 
CDKN1B ggctaactctgaggacacgc 
gcaaccgacgattcttctactca 
CDYL tgtgcttgaggaatccaaagcc 
ggatggactccatgttaaagtacttg 
CENPF gccaagaatatgcacaacgtcc 
cattctccttgatctgactcgc 
CISH    151 catagccaagaccttctcctacc 
tgacagcgtgaacaggtagc 
CRLF2 gtgcaggtgacatggaatgc 
agagaatgtcgtctcgctgc  
DHX9-DEAH caactggaatccttggactagtagc 
gcaagcaatcttgcaggagag 
DUSP1 catcaagaatgctggaggaagg 
aggcgaagcatcatctctcc 
EGR1 atccacacaggccagaagc  
gatcttggtatgcctcttgc 
EGR2 ttgaccagatgaacggagtg 
tggtttctaggtgcagagacg 
ENOX2 gagctggagggaacctgattt 
cactggcactaccaaactgca 
EZH2 ctgaggatgtggatactcctcc 
gctcctctaaccatgtttacaactatc 
FOXM1 ggatgtgaatcttcctagaccacc 
ccaacatccagtggcttcga 
FOXO3A cggaccttcatctctgaactcc 
ggacctgctcacttcggact 
GAPDH acggatttggtcgtattggg 
attttggagggatctgctc 
GBP1 aggccacatcctagttctgc 
tccaggagtcattctggttgt 
GBP2 ccaggaggttaccgtctcttt  
gccacatcctccttggact 
GCSF actctggacagtgcaggaagc 
tggcacagcttgtaggtggc 
GCSFR aagcatgtccccacaactgtgtc 
tgattatgtgcaggcctgg 
GMCSF gtcatctcagaaatgtttgacctcc 
ttgtagtggctggccatcatgg 
GDF3 ctctctcaacagctccaattatgc 
gctctaccaggacaataatgacaat 
GN2BL tccacaccttgaccagcttg 
gcagattgtctctggatctc 
HDAC3 ctgtgtaacgcgagcagaac 
gcaaggcttcaccaagagtc 
HOXA9 ctgttcaacatgtacctcaccag 
gaccgagcaaaagacgagtga 
HOXB4 ctggatgcgcaaagttcac 
agcggttgtagtgaaattcctt 
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HSP90 cataacgatgatgagcagtacgc 
caatctcctttattcttcgttcctcc 
ID1 cggaatccgaagttggaacc 
gacacaagatgcgatcgtcc 
IFIT1 agaacggctgcctaatttacag 
gctccagactatccttgacctg 
IFIT3 acttgaggcagacaggaagact 
cagggaattcttggtgacctc 
IFNAR1 agcacacaccatggatgaaa 
tcaagaagactttcgcagca 
IFNAR2V1 agtcttgaggcaaggtctcg 
cttaatcactggggcacagg 
IFNAR2V2 tagcctccccaaagtcttga 
cttaatcactggggcacagg 
IFNGR1 tgcataccgaagacaatcca 
gatgctgccaggttcagact 
IFNGR2 ttctccaaacgctttgaacc 
tctcatgtctgcagggacag 
IKZF1 gtggccgaagctataaacagc 
cctatcttgcacaggtcttctgc 
IRF1 tgggacatcaacaaggatgc 
tggccttgctcttagcatct 
IRF2 gccagacatttgccaagttg 
gttgctgaggtactgtttgc 
IRF3 gaactcaggagttggggactt 
cccagtaactcatccagaatgtc 
IRF4 tgtcccatgacgtttgga 
tcctgtcacctggcaacc 
IRF5 tctacgaggtctgctccaatg 
aggcttggcaacatcctct 
IRF6 cgatcattaacccaggatcc 
ctgatccacagttctggaga 
IRF7 gagaagagcctggtcctggt 
aaggaagcactcgatgtcgt 
IRF8 ccaggactgatttgggagaa 
agtggctggttcagctttgt 
IRF9 catccccatctcctggaa 
gccctgaaagtacctgacca 
IRGM gcctgatgagcttactccagtg 
acccaatgcttatggtgtgg 
JAK2 ggatcctacacagtttgaagagag  
ccttctttcagagccatcatacg 
LMO2 cgtgcctatgagatgacaatgc 
ggacatctacgagtggactaaga 
MAPK1 taaggtgccatggaacaggc 
ggattgaagtagaacaggctctgg 
MCL1 cattcctgatgccaccttct 
tcgtaaggacaaaacgggac 
MGST3 cagaacacgttggaagtgtatcc 
gctcctcgactacgcttgc 
MPL gctagctcccaaggcttctt 
cttcctcttcgcagttctcc 
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mTOR gagagaagtttccagagaagattcc 
gcacaaggacagtgtcatgg 
NFKB1 gggatctactagaagtcacatctgg 
ggaagatgtggtggaggatttg 
NFKB2 acctggtaacacacagtgacc 
gcatgtgactaagaagaacatgatgg 
 NME1 gagacttctgcatacaagttggc 
ggtagattacacgagctgtgctc 
NOLA1 taaggtgccttatttcaatgctcc 
cagtggcagcagcttatatgg 
OAS1 gaaggcagctcacgaaacc 
agctgcctccaacccttt 
OAS2 cctgcctttaatgcactgg 
atgagccctgcataaacctc 
OAS3 ctggcactgggatttgcta 
caaacctgagcatccagca 
OBR tgggcacaaggacttaattttc 
tgaaattgtttcaggctcca 
PI3K gcatgccaattggtctgtatcc 
cgagatcctctctctgaaatcac 
PML tacgccttctccatcaaagg 
tctgggctgtcgttgtattg 
RanBP1 tgacgtcaagctcctgaagc 
ccactacatcacgccgatgat 
Rex1 atcatccctaagcgaatcgc 
caggtagatgttcttgctgg 
RNF20 ggtgtctcttcaacggaggaa 
tagtgaggcatcatcagtggc 
SENP1 atgttccacaagaagtgcagc 
gtttcgaggtaaagacttcggc 
SOCS1 gaccccttctcacctcttga 
taggaggtgcgagttcaggt 
SOCS2 gatcgactactatgttcagatgtgc 
ggtgagcctacagagatgctg 
SOCS3 gacttcgattcgggaccag 
aacttgctgtgggtgaccat 
SPRY2 agatccataagcacggtcagc 
aagctcacctggcttgagc 
STAT1 acctaacgtgctgtgcgtag 
cctgctccaggaattttgag 
STAT2 ttgggtgctactaccaggaga 
tgttgcagttcatccacctg 
STAT3 cctagatcggctagaaaactgg 
gggtcccctttgtaggaaac 
STAT4 cgttggtcgtggtcttaactc 
cccaggtgaggtgaccat 
STAT5  acagatcaagcaagtggtcc 
ccaggtcgaattctccatcc 
STAT6 ggtcgcagttcaacaagga 
gtccaggacaccatcaaacc 
SUMO2 gaaagcctattgtgaacgacagg 
catcctccatttccaactgtgc 
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SUMO3 ttcaagatcaagaggcacacg 
ggagtgtcagtttcattgattggc 
SURVIVIN tccgcagtttcctcaaattc 
gttgcgctttcctttctgtc 
TAF1 ggaccaatgaagaaggataaggacc 
tgtgttgcttcctgaggtcc 
TFDP1 taacggcacaaggttctctgc 
cgatgacttcaacgagaatgacg 
TNFSF10 gaaagaggtcctcagagagtagc 
cattcattcctgagcaacttgc 
TYW1 attgtcatcaagacgcagggc 
gttgcgaatcccttcgctgtt 
UBA2 aagatcaaaggcacaggttgc 
gcattcataaccagtataaactgtcgg 
UBASH3B/STS1 ccatgagacattacaggtcatctacc  
ggacgtgccatagatccaacc 
UBC9 cacgatgaacctcatgaactgg 
cgggtgaaataatggtggttcg 
 
2.2.4.8 Taqman probes 
Gene Probe ID 
ABCA1 Hs00194045_m1  
ATP5B Hs00969569_m1 
AXL Hs01064444_m1 
B2M Hs00984230_m1 
Cathepsin B Hs00947433_m1 
Cathepsin D 70 Hs00157205_m1  
Cathepsin L Hs00964650_m1  
Cathepsin S Hs00175407_m1  
CCL13 Hs00234646_m1  
CCL17 Hs00171074_m1  
CCL18 Hs00268113_m1  
CCL2  Hs00234140_m1  
CCL2 Hs00234140_m1  
CCL20 Hs01011368_m1 
CCL22 Hs00171080_m1  
CCL24 Hs00171082_m1  
CD13 Hs00174265_m1  
CD14 Hs00169122_g1  
CD16 Hs00275547_m1  
CD163 Hs00174705_m1  
CD204 (MSR1) Hs00234007_m1  
CD206 (MRC1) Hs00267207_m1  
CD280 (Mrc2) Hs00195862_m1 
CD36 Hs01567185_m1  
CD68  Hs02836816_g1 
CD91  Hs00233856_m1  
CD93 Hs00362607_m1  
COX1 Hs00924803_m1 
COX2 Hs00153133_m1  
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CSF1 Hs00174164_m1  
CSF-1R 30 Hs00911250_m1  
CXCL10 Hs00171042_m1  
CXCL4 Hs00427220_g1 
CXCL8 Hs00174103_m1 
CXCL9 Hs00171065_m1  
CYC1 Hs04187151-g1 
E-Cadherin 60 Hs01013958_m1  
EGF Hs01099999_m1  
EMP1 Hs00608055_m1  
ENOX2 Hs00197268_m1 
Fibronectin 1 Hs00900058_m1 
FOXP3 89 Hs01085834_m1 
GAPDH Hs99999905_m1 
Gas6 Hs01090305_m1  
GATA3 Hs00231122_m1 
GPNMB Hs01095679_m1  
GUSB Hs99999908_m1 
HMOX Hs01110250_m1 
IFNγ Hs00989291_m1  
IGF1 Hs01547656_m1 
IGF1 50 Hs01547656_m1 
IL10 Hs00174086_m1  
IL12a Hs01073447_m1  
IL13 Hs00174379_m1  
IL-1b Hs00174097_m1  
IL21 Hs00222327_m1 
IL23α  Hs00372324_m1 
IL4 Hs00174122_m1  
IL6                            Hs00174131_m1  
IL8 Hs00174103_m1 
iNOS  Hs00167248_m1  
Lamp2 Hs00174474_m1 
LGALS3 (galectin 3) Hs00173587_m1  
LYVE-1 Hs01119300_g1  
Mer TK Hs01031973_m1 
MMP1 Hs00899658_m1  
MMP12 40 Hs00899662_m1  
MMP2 Hs01548727_m1  
MMP3 Hs00968305_m1  
MMP9 Hs00234579_m1 
MPO  Hs00924296_m1 
NOS3 Hs01574659_m1  
PARG Hs00608256_m1  
PDGFC Hs01044219_m1  
PGE2R Hs00168754_m1  
PLAU Hs01547054_m1  
PPARg Hs01115513_m1 
Psap  Hs01551096_m1  
RORγ Hs00536545_m1 
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SEPP1 Hs01032845_m1  
SOCS3 Hs01000485_g1  
STAT1 Hs00234829_m1 
STAT3 Hs00374280_m1 
STAT4 Hs00231372_m1  
STAT5A Hs00234181_m1  
STAT5B Hs00273500_m1  
STAT6 Hs00598625_m1  
t-BET Hs00894391_g1 
TBP Hs99999910_m1 
TGFb1 Hs00171257_m1  
Tie 1 Hs00892696_m1  
TIMP2 Hs00234278_m1  
TNFa Hs00174128_m1  
TREM2 Hs00219132_m1  
TYW1 Hs00936870_m1 
UBE2D2 Hs00366152_m1 
VEGFA Hs00173626_m1  
VEGFC Hs00153458_m1  
 
2.2.5 Immunoblotting solutions 
2.2.5.1 Tris HCl 
Sigma 7-9® 1M  
Hydrochloric acid Added dropwise to pH 
8.8, 7.5 or 6.8 
 
2.2.5.2 Protein solubilisation buffer 
Sigma 7-9® pH 7.5 50mM 
Sodium Chloride 150mM 
Nonidet P40 (NP-40) 1% 
Glycerol  10% 
Ethylenediamine Tetraacetic acid (EDTA) 5mM 
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2.2.5.3 Phosphatase and Protease Inhibitor concentrations 
Sodium Orthovanadate 1mM   
Sodium Molybdate 1mM   
Sodium Fluoride 1mM   
Phenylmethylsulphonyl Fluoride 4μg/mL  
Pepstatin A 0.7μg/mL  
Aprotinin 10μg/mL  
Leupeptin 10μg/mL 
Soybean trypsin inhibitor 10μg/mL  
 
2.2.5.4 Polyacrylamide gels 
 7.5% 8% 10% 5% stacking gel 
ddH2O 5.6ml 5.35ml 4.35ml 6ml 
1M Tris HCl pH8.8 5.6ml 5.6ml 5.6ml - 
1M Tris HCl pH6.8 - - - 1.25ml 
10% SDS  250μl 250μl 250μl 150μl 
30% Acrylamide  3.75ml 4ml 5ml 1.67ml 
10% APS  100μl 100μl 100μl 50μl 
TEMED 20μl 20μl 20μl 20μl 
 
2.2.5.5 Tris-buffered saline (TBS) pH7.5 
Sigma 7-9® 20 mM 
Sodium Chloride 150 mM 
Hydrochloric acid Added dropwise 
to pH 7.5 
 
2.2.5.6 TBS NP-40 (TBS-N) 
Sigma 7-9® pH 7.5 20 mM 
Sodium Chloride 150 mM 
Hydrochloric acid Added dropwise 
to pH 7.5 
NP-40 0.05% 
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2.2.5.7 Running buffer 
Glycine 192mM 
Sigma 7-9® 25mM 
Sodium dodecyl sulfate 3.5mM 
 
2.2.5.8 Semi dry transfer buffer 
Glycine 40mM 
Sigma 7-9® 48mM 
Sodium dodecyl sulfate 1.3mM 
 
2.2.5.9 5x BSA blocking solution (dissolved in TBS) 
Bovine Serum Albumin Fraction V 5% 
Ovalbumin 1% 
Sodium azide 0.01% 
 
2.2.5.10 5x milk blocking solution (dissolved in TBS) 
Skimmed milk powder 5% 
Sodium azide 0.01% 
 
2.2.6 Immunofluorescence and Duolink solutions 
2.2.6.1 Poly-L-lysine 
Poly-L-lysine 0.5mg/ml 
Sodium tetraborate 100mM 
 
2.2.6.2 5x Block in PBS 
Bovine Serum Albumin Fraction V 5% 
Ovalbumin 1% 
Triton X100 0.2% 
 
2.2.6.3 PLA probe mix 
Duolink® in-situ PLA® probe anti-mouse MINUS 3μl 
Duolink® in-situ PLA® probe anti-rabbit PLUS 3μl 
5x block in PBS 9μl 
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2.2.6.4 Ligation mix 
Duolink® 5x Ligation master mix 3.2μl 
Duolink® Ligase 0.4μl 
ddH2O 12.4μl 
 
2.2.6.5 Amplification mix 
Duolink® 5x Amplification master mix 3.2μl 
Duolink® Polymerase 0.2μl 
ddH2O 12.6μl 
 
2.2.6.6 Wash buffer A (pH 7.4) 
Tris hydrochloride 10mM 
Sodium Chloride 150mM 
Tween 20 0.05% 
 
2.2.6.7 Wash buffer B (pH 7.5) 
Tris hydrochloride 200mM 
Sodium Chloride 100mM 
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2.3 Methods 
2.3.1 Cell culture and cellular techniques 
2.3.1.1 Culture of cell lines 
K562 cells were cultured in RPMI 1640 medium supplemented with 10% FBS and 
1% L-glutamine. UKE-1 cells were cultured in IMDM supplemented with 10% 
horse serum, 10% FCS and 1% L-glutamine. SET-2 cells were cultured in RPMI 
1640 supplemented with 20% heat inactivated FCS and 1% L-glutamine. 
2.3.1.2 XTT bioreduction assay 
XTT (2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-2H-Tetrazolium-5-Carboxanilide) 
bioreduction assays were used to assess the  growth of K562, UKE1 and SET2 
cells, when cultured in the presence or absence of the JAK2 inhibitors or As2O3. 
The cells were cultured for 72 hours in 96 well plates in the presence of a serially 
diluted concentration of each inhibitor allowing for 11 different concentrations for 
each drug. 1x104 cells were seeded in each well in 100μl of media. Following 
culture, 25µl of solution containing 1 mg/ml XTT salt and 25µM phenazine 
methosulfate (PMF) was added to each well and incubated at 37˚C for 2-4 hours. 
During this incubation, live cells metabolise the reagents to soluble formazan. This 
leads to a colour change in the media which can be measured by visual 
absorbance at 495nm on a SpectraMax M5 plate reader. Results were analysed 
using SoftMax Pro software. 
2.3.1.3 Cell viability by trypan blue exclusion 
1x105/ml K562, UKE1 or SET2 cells were cultured and treated with increasing 
concentrations of the JAK2 inhibitors for 72 hours. The cell suspension and 1% 
trypan blue were mixed 1:1 and 10µl was placed on a counting chamber. Trypan 
blue exclusion cell counts were carried out at 24, 48 and 72 hours to assess cell 
viability. 
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2.3.1.4 Peripheral blood mononuclear cell isolation 
Peripheral blood was obtained from consented patients and healthy controls then 
diluted with an equal volume of 1x PBS before being carefully layered on the 
surface of room temperature Histopaque 1077. The samples were then 
centrifuged at 400xg for 30 minutes. The interface containing the mononuclear 
cells was removed, washed in PBS then either frozen in human albumin and 
DMSO (2.2.1.4) and stored at -80˚C or had RNA and protein extracted by the 
protocols described below (Sections 2.3.3.1 and 2.3.4.1). 
2.3.1.5 Culture of CML CD34+ cells 
CML CD34+ cells were separated using positive selection through LS columns 
and CliniMACS® CD34 reagent. The quality of enrichment was assessed by flow 
cytometry using CD45 and CD34, before samples were placed in resuspension 
solution and mixed 1:1 with freezing solution. Cells were frozen in a controlled 
manner overnight to -80˚C and stored in liquid nitrogen. CML CD34+ cells were 
subsequently defrosted at 37˚C before slowly adding DAMP solution drop-wise 
over 20 minutes while gently agitating the sample. Following centrifugation at 
192xg for 10 minutes, the pellet was loosened and washed in DAMP solution twice 
before counting and resuspending in 20 ml Stemspan II with high growth factors 
(Table 2.2.1.5) and culturing overnight in suspension cell culture flasks at 37˚C 
with 5% CO2. Cells were then counted again the next morning to ensure adequate 
cell viability before separating for treatment with ruxolitinib 1μM and nilotinib 5μM 
alone or in combination. Cells were cultured for 8 hours in Stemspan II with low 
growth factors (Table 2.2.1.5) and appropriate treatment in 6 well plates at 37˚C 
with 5% CO2, before being processed for RNA and protein. 
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2.3.1.6 Neutrophil separation 
Whole peripheral blood was mixed with 10% dextran solution and incubated at 
room temperature for 20 minutes in a 50ml syringe. The top layer was then 
removed by carefully ejecting through a Kwill filling tube until the red cell layer 
reached the tip. This was then mixed with 1x PBS before passing through a Ficoll 
gradient as described above (2.3.1.4). Neutrophils were taken from the densest 
layer before washing in PBS 3 times with centrifugation between washes for 10 
minutes at 350xg. 1x106 neutrophils were then cultured in 2ml Promocell DXF 
base media on Nunc Delta coated 12 well plates for 24 hours alone, with 20% 
normal or PV serum with or without LPS stimulation. The media was then 
harvested and centrifuged at 350xg to remove cells, then 3000xg to remove 
debris. The media was then snap frozen and stored at -80˚C before analysis by 
Luminex cytokine profiling. 
2.3.1.7 Culture of PV PB MNCs 
Polycythaemia vera  and normal control PB MNCs were separated as above, 
washed 3 times in 1x PBS with centrifugation for 10 minutes at 350xg between 
washes. 1x106 cells were immediately resuspended in  2ml Stemspan II media 
with ruxolitinib 500nM or As2O3 1μM alone or in combination and cultured for 24, 
48 and  72 hours in 12 well plates at 37˚C with 5% CO2. At those time points cells 
were  prepared for apoptosis (Section 2.3.2.1) and cell cycle analysis (Section 
2.3.2.2) as described below. 
2.3.1.8 Macrophage generation 
Peripheral blood MNCs were isolated as described above and resuspended in 
Promocell monocyte adhesion media (MAM) on Nunc Delta coated plates for 
cytokine analysis and in Labtech chambered slides for immunofluorescence. After 
incubating at 37˚C for 1.5 hours, non-adherent cells were washed off using MAM.  
Macrophages were generated according to the Promocell® macrophage 
generation protocol. Briefly, the remaining adherent cells were cultured in M1 or 
M2 polarisation media for 5 days (2.2.1.4) before supplementing with an additional 
50% by volume of fresh polarisation media and culturing for another 3 days. 
Following this, the media was removed and non-adherent cells centrifuged at 
350xg for 10 minutes and resuspended in appropriate media for the following 
culture conditions (Figure 2.1) with serum making up 20% of the final volume. 
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Figure 2.1 Experimental conditions for macrophage and neutrophils culture 
 
Culture conditions for generation of macrophages from peripheral blood 
monocytes. M1 polarisation media was the Promocell® macrophage differentiation 
base media supplemented with GM-CSF 5ng/ml, with stimulation media using the 
same base media supplemented with LPS 100ng/ml and IFNγ 20ng/ml. M2 
polarisation media was the Promocell® macrophage differentiation base media 
supplemented with M-CSF 50ng/ml, with stimulation media using the same base 
media supplemented with M-CSF 10ng/ml and IL-4 20ng/ml.   
After 24 hours, media was collected, snap frozen in liquid nitrogen, stored at -80˚C 
and subsequently analysed using Luminex cytokine analysis. Immunofluorescence 
samples were processed as described below (Section 2.3.5). 
2.3.1.9 Processing of patient serum samples 
Patient samples were collected following informed consent into serum separator 
tubes. These were then allowed to sit at room temperature for 1 hour to allow 
coagulation to occur. Samples were then centrifuged at 3000xg for 10 minutes and 
serum snap frozen in liquid nitrogen before storing at -80˚C. Samples were then 
analysed using Luminex cytokine analysis. 
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2.3.1.10 Luminex cytokine analysis 
Using the Bio-Rad Bio-Plex Pro™ Human Cytokine 27-plex Assay and adding Bio-
Plex Pro™ Human IFNα2 and Bio-Plex Pro™ Human Gro-α following 
recommended dilutions from the manufacturer, media samples and serum 
samples were analysed as per the manufacturers’ protocol. This assay is based 
on uniquely colour-coded magnetic beads which are able to detect one specific 
protein and are identified by one laser in a specific flow cytometry machine. The 
beads are incubated with the sample and bind the protein of interest. This is then 
detected by a biotinylated antibody which is detected with streptavidin-PE. The 
beads are then drawn up in single file and the second laser is able to identify the 
level of protein bound to each bead based on the fluorescence intensity. This is 
then compared to a standard curve run at the same time to calculate the 
concentration. 
2.3.2 Flow cytometry 
Fluorescence activated cell sorting (FACS) or flow cytometry is a technique that 
allows identification of cellular characteristics through the application of fluorescent 
labelled antibodies or proteins. Coloured lasers excite the fluorochrome when the 
antibody is attached to a cell and the emitted light is detected. This allows the 
number of cells expressing a particular protein to be quantified as a percentage of 
the total number of cells. Multiple antibodies can be added at a time providing they 
are labelled with fluorochromes that emit different colours. Cells are then passed 
through a BD Bioscience FACS Canto which is capable of detecting up to 8 
colours simultaneously based on 3 lasers.  
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2.3.2.1 Apoptosis analysis 
1x105/ml K562, UKE1, SET2 cells, PV and normal PB MNCs were cultured in the 
presence of the JAK2 inhibitors or As2O3 for 24, 48 and 72 hours, as indicated. 
The cells were counted and 2x105 cells were taken for each condition then 
washed twice with PBS supplemented with 2% FBS with centrifugation at 400xg or 
5 minutes between washes. The cells were then suspended in HBSS with 
5μl/1x106 cells of FITC-conjugated Annexin V and 5μl/1x106 cells of 7AAD for 15 
minutes prior to analysis by flow cytometry using the BD FACSCanto. Annexin V 
will attach to phosphatidylserine when it appears on the cell surface during 
apoptosis, while 7AAD is a DNA binding dye which is unable to pass through intact 
cell membranes. Therefore live cells will not bind either of these while cells in late 
apoptosis will bind both. The data was then analysed using Flowjo software 
(Figure 2.2) 
Figure 2.2 Apoptosis assay 
 
Apoptosis assay using Annexin V and 7AAD separates cells by apoptotic state 
based on differential uptake of Annexin V and 7AAD. Quadrant markers are by 
7AAD/Annexin V. 
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2.3.2.2 Propidium iodide staining and cell cycle analysis 
1x105/ml K562, UKE1, SET2 cells, PV and normal PB MNCs cells were cultured in 
the presence of the JAK2 inhibitors for 24, 48 and 72 hours, as indicated. The cells 
were counted and 2x105 cells were taken and washed twice with PBS 
supplemented with 2% FBS. The cells were fixed in 1ml of ice cold 70% ethanol 
while agitating cells on a vortex machine at 1200rpm and stored at -20˚C for 
between 1 and 7 days. The cells were then washed again in PBS and suspended 
in 200µl of PI/RNase staining buffer for 15 minutes before analysis by flow 
cytometry. The data was then analysed using Flowjo software using a histogram to 
separate cells into G0-G1 and S-G2-M based on the peaks and troughs seen in 
the control sample (Figure 2.3). 
Figure 2.3 Propidium iodine assessment of cell cycle 
 
Propidium iodide binds to DNA and will indicate a change in cell cycle as the 
amount of DNA increases in the cell through mitosis until the cell divides. Prior to 
adding the PI the cell needs to be fixed in ethanol for at least 24 hours to 
permeabilise the cell membrane to allow PI to enter the cell. 
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2.3.2.3 Monocyte subset assessment 
Following separation of MNCs from PB, 5x105 cells were washed with PBS + 2% 
FBS twice. Cells were then incubated for 15 minutes with mouse anti-human 
CD14 FITC and mouse anti-human CD16 APC. Monocytes were identified using 
forward and side scatter before being separated into classical, non-classical and 
intermediate subsets according to CD14 and CD16 expression (Figure 2.4). 
Figure 2.4. Monocyte subset analysis 
 
Using flow cytometry the monocytes were identified using forward and side scatter 
to identify the size and granularity of the peripheral blood cells. The monocytes 
were than assessed for CD14 and CD16 to identify classical, non-classical and 
intermediate subsets. 
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2.3.3 PCR techniques 
K562, UKE1 and SET2 cells were cultured in complete media with JAK2 inhibitors 
for 24 hours before harvesting for RNA extraction and gene expression analysis. 
Patient samples and normal controls were harvested and processed immediately 
following Histopaque 1077 separation as described above (2.3.1.4). 
 
2.3.3.1 RNA extraction 
Cells were harvested, lysed and total RNA was prepared using the RNA extraction 
kits as per manufacturer’s instructions. Briefly, for the Qiagen RNEasy Mini and 
Micro Plus kits, cells were suspended in the suggested volume for cell number of 
guanidine-thiocyanate-containing lysis buffer and homogenised using a 1ml 
syringe and 26G needle. 
 
Table 2.1. RNA extraction kits used for cell number 
Extraction kit Cell line cell 
number 
Primary sample 
cell number 
Volume of RNase-
free water 
Qiagen RNEasy 
Mini Plus 
0.5-5x106 cells 1-10x106 cells 30µl 
Qiagen RNEasy 
Micro Plus 
0.2-0.5x106 cells 0.5-1x106 cells 14µl 
PicoPure® RNA 
isolation kit 
- <0.5x106 cells 11µl 
 
The homogenised lysate was then passed through a genomic DNA removal 
column by centrifuging the column at 10,000xg for 30 seconds. 70% ethanol is 
then mixed with the flow through and transferred to a spin column which binds the 
RNA in the sample. The sample is then cetrifuged at 10,000xg for 15 seconds and 
washed three times with the provided buffers with centrifugation at 10,000xg for 15 
seconds between each wash. Finally the column is dried with a one minute 
centrifugation at 14,000xg for the RNEasy Mini kit or 5 minutes with an open lid for 
the RNEasy Micro kit.RNase free water is added to the spin column membrane to 
elute the RNA during a final centrifugation step. RNA concentration and quality 
was determined on the Nanodrop Spectrophotometer using 2µl of the sample, at 
260nm and stored at -20˚C before use or at -80˚C for long term storage. 
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2.3.3.2 Quantitative real time PCR by Fluidigm® 
Quantitative real-time PCR (qRT PCR) is a technique used to determine the level 
of gene transcription to messenger RNA (mRNA). After RNA is extracted from 
cells it is turned into cDNA. By using oligo dT to attach to the poly-A tail of mRNA 
as the basis for the reverse transcription there is selection for mRNA over other 
types of RNA. cDNA for different genes is therefore produced in the same 
proportions as the mRNA it was derived from. This can then be used in 
quantitative PCR reactions where a fluorescent label (e.g. Evagreen) that binds to 
double stranded DNA is used as a measure of the abundancy of the gene of 
interest. This is achieved by amplifying the DNA with specific primers and setting a 
threshold level of fluorescence to indicate when the signal becomes positive. 
Therefore high abundance genes will cross this threshold in the early PCR cycles, 
while low abundance genes will have a higher cycle threshold (CT) value. This CT 
value represents the point at which a real signal is detected over a background 
level. This CT value can then be compared to a normal or no drug control using 
calculations which use the average of a number of control, or housekeeping, 
genes, the difference between the gene of interests CT and the housekeeping CT 
(the ΔCT), and the difference between the delta CT of the sample of interest and 
its control (the ΔΔCT). The 2-ΔΔCT method170 can then be used to show the relative 
expression of the gene of interest compared to normal, where normal is expressed 
as 1. 
2.3.3.3 Reverse transcription 
Up to 500ng of RNA was reverse transcribed to cDNA using the high fidelity 
reverse transcriptase Superscript III. The first step is to attach the oligo dTs to the 
mRNA using reverse transcription mix 1 (2.2.4.1) and the cycling conditions for 
step 1 (Table 2.2). 6μl of reverse transcription mix 2 (2.2.4.2) is then added to 
each sample and put through step 2 of the cycling conditions below (Table 2.2). 
Table 2.2 Reverse transcription cycling conditions 
Reverse 
transcription 
Step 1 Step 2 
Temperature 65˚C 55˚C 70˚C 
Time 5 minutes 60 minutes 15 minutes 
 
76 
 
Samples were pre-amplified for the genes to be studied and housekeeping genes 
using the pre-amplification mix (2.2.4.3) for 16 cycles (Table 2.3). Remaining 
primers were removed following pre-amplification using the exonuclease mix 
(2.2.4.4) and the cycling conditions below (Table 2.4). 
Table 2.3. Pre-amplification cycling conditions 
Pre-
amplification 
Denature 
step 
Cycling Final 
extension 
Temperature 94˚C 94˚C 60˚C 72˚C 72˚C 
Time 15 minutes 30 seconds 90 seconds 90 seconds 10 minutes 
 
Table 2.4. Exonuclease treatment cycling conditions 
Exonuclease treatment Step 1 Step 2 
Temperature 37˚C 80˚C 
Time 30 minutes 15 minutes 
 
Real-time PCR was then carried out in triplicate for each sample with a no sample 
control in each run, using Fluidigm Biomark technology using the 48:48 or 96:96 
Fluidigm chips according to the manufacturer’s instructions. The chips were 
initially primed with line control fluid before loading the primer and samples, where 
the primers were loaded as part of the assay mix (2.2.4.5) and the samples as part 
of the sample mix (2.2.4.6). The design of the chip allows each sample to be 
tested with each primer set from loading into a single well generating 2304 data 
points for the 48:48 chip and 9216 data points for the 96:96 chip. Data was 
analysed using the 2-ΔΔCT compared to control to show a fold change in 
expression. Internal sample control was provided by averaging 5 housekeeping 
genes (GN2BL, B2M, RNF20, TYW1 and ENOX2) within each sample. 
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Table 2.5. Quantitative RT-PCR by Fluidigm 
Fluidigm qRT 
PCR 
Hot start Cycling Melting curve 
Temperature 95˚C 95˚C 60˚C 60˚C to 95˚C 
Time 60 seconds 5 seconds 20 seconds 1˚C increase every 
3 seconds 
 
2.3.4 Immunoblotting techniques 
2.3.4.1 Protein extraction 
1-5x106 cells were harvested following culture in JAK2 inhibitors or As2O3 and 
washed three times with 1xPBS without Ca2+ or Mg2+ and centrifuged at 400xg for 
5 minutes. The pellet was resuspended in ice-cold solubilisation buffer 
supplemented with phosphatase and protease inhibitors and resuspended at 
30µl/1x106 cells for K562 and SET2 or 20µl/1x106 for UKE1 and left to solubilise 
for 30 minutes on ice. The cell debris was pelleted by centrifugation at 21,000xg 
for 10 minutes at 4˚C and the supernatant stored at -20˚C for short-term storage or 
-80˚C for long-term storage. The cell lysate concentration was quantified using the 
Quick Start Bradford Protein Assay Kit with BSA used for the standards to 
generate a standard curve. This is a colorimetric protein assay based on a shift of 
absorbance of Coomassie Brilliant Blue dye when bound to protein under acidic 
conditions. This results in a change of colour from brown to blue and can be 
measured by visual absorbance at 595nm on the SpectraMax M5 plate reader 
using SoftMax Pro software. 
2.3.4.2 SDS-PAGE Western blotting 
Gel solutions were prepared as per Table 2.6. 7.5% gels were used to separate 
proteins larger than 50 kDa and 10% gels were for proteins smaller than 50 kDa. 
20µg of cell lysates were fractionated by SDS-PAGE in 1x Running Buffer (Table 
4.) at 80 Volts for 30 minutes and 180 Volts for 45 minutes. The separated 
proteins were then transferred to nitrocellulose membranes (Amersham Protran) 
using a semi-dry transfer method. The membranes and nitrocellulose were 
saturated in 1x semi-dry transfer buffer. The gel was placed on top of the 
membrane and was sandwiched between eight 9cm x 6cm Whatman paper strips 
(4 on bottom and 4 on top), and were compressed to remove any air bubbles. The 
proteins were transferred at 40mA/gel for 60 minutes and the transfer was 
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confirmed using Ponceau S Solution staining. The membranes were then washed 
in 1xTBS to remove Ponceau S. The nitrocellulose was blocked in 5% BSA or 5% 
milk (Table 2.6) to prevent non-specific binding for 1-2 hours. Following blocking, 
the nitrocellulose was incubated in primary antibody and 1x blocking solution 
overnight with gentle agitation on a rocker. Unbound antibody was washed with 1x 
TBS-N pH 7.5 4 times each for 10 minutes. Secondary antibodies which were 
conjugated to horseradish peroxidase (HRP) were used at a dilution of 1:10,000 
and incubated for 1-2 hours. Secondary antibody was then washed with 1x TBS-N 
as before, and was followed by three 1x TBS washes. The membranes were 
placed in chemiluminescent HRP substrate for 2 minutes, and then placed in a 
cassette before they were exposed to X-ray film. The film was developed using a 
Konica Minolta SRX-101A developer in a dark room. 
Table 2.6. Antibodies for SDS-PAGE Western blotting 
Antibody Dilution Block 
JAK2  1:1000 5% BSA 
Phospho-JAK2  1:1000 5% BSA 
PML  1:500 5% BSA 
SUMO 2/3  1:2000 5% milk 
Daxx  1:2000 5% milk 
Sp100  1:1000 5% milk 
BCR-ABL Pathscan  1:1000 5% BSA 
pSTAT1  1:1000 5% BSA 
STAT1  1:1000 5% BSA 
pSTAT5 1:1000 5% BSA 
STAT5  1:1000 5% BSA 
 
2.3.5 Immunofluorescence techniques 
2.3.5.1 Immunofluorescence for K562, monocytes and macrophages 
PTFE glass slides were prepared by adding 30 µl/well of 5 µg/ml Poly-L-Lysine in 
Borate buffer and allowed to air dry. Wells were washed twice with PBS 
immediately before use. Cells were harvested, counted, resuspended in an 
appropriate volume of the culture media used in each experiment and seeded at 
6x104/well and the slides incubated at 37˚C for 45 minutes. The wells were 
washed once with PBS and 4% formaldehyde was added to fix cells for 10 
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minutes at room temperature. The cells were then washed x3 with PBS and 0.5% 
Triton-X in PBS was added to permeabilise the cells at room temperature, for 15 
minutes. Following PBS wash, cells were then blocked at room temperature with 
5x block for 1-2 hours. The blocking solution was removed and the wells washed 
once with PBS. Appropriate concentrations of primary antibody were added to 
each well and the slides were incubated at 4˚C overnight. The primary antibody 
was removed and the wells were washed x5 with PBS. 1:200 dilutions of 
appropriate secondary antibody were prepared (Alexa Fluor 488 or 594; mouse or 
rabbit) and 25-30 µl was added to appropriate wells and left for 1 hour. Secondary 
antibody was removed and the wells washed x5 with PBS. DAPI mounting solution 
was used to fix and seal the slides with cover slips. The slides were visualised on 
a Zeiss TS 100 inverted microscope and pictures were taken using Axio-vision 
software. 
2.3.5.2 Immunofluorescence for UKE1 and SET2 cells 
PTFE glass slides were prepared as above (2.1.1.1).  Cells were harvested, 
counted, resuspended in ice cold acetone at a concentration of 6x106/ml to fix and 
permeabilise the cells. 10µl of the cell suspension was immediately added to each 
well and incubated on ice for 20 minutes. The slides were then allowed to air dry 
prior to washing 3 times with PBS. Cells were then blocked in 5x blocking solution 
without Triton X100 and processing thereafter was as above. 
2.3.5.3 Duolink® 
PTFE glass slides were prepared as outlined above up to and including the 
blocking stage. Following blocking, appropriate concentrations of two primary 
antibodies (Table 2.7), one raised in rabbit and one in mouse, were added to each 
well and the slides were incubated at 4˚C overnight. The primary antibody was 
removed and the wells were washed x5 with PBS. The PLA probe mix was 
prepared and incubated at room temperature for 20 minutes prior to adding 15μl to 
each well and incubating in a humidified chamber at 37˚C for 1 hour. The cells 
were washed x5 with 1x wash buffer A, then ligation mix was prepared and 16μl 
added to each well before incubating in a humidified chamber at 37˚C for 30 
minutes. Following a further five washes with 1x wash buffer A, 16μl of 
amplification mix was added and incubated in the dark in a humidified chamber at 
37˚C for 100 minutes. This was then removed and the slides washed x5 with 1x 
wash buffer B and twice with 0.01x wash buffer B. DAPI mounting solution was 
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used to fix and seal the slides with cover slips. The slides were visualised on a 
Zeiss TS 100 inverted microscope and images recorded using Axio-vision 
software. Comparative fluorescence was measured using Image J software 
(National Institute for Health) for corrected total cell fluorescence using the 
equation overall cell fluorescence-(area of cell measured x mean background 
fluorescence) where overall cell fluorescence is measured using integrated density 
and the mean background fluorescence is measured using the mean grey value 
for at least 10 areas in the image with no cells present171. 
Table 2.7. Primary antibodies for immunofluorescence and Duolink 
Antibody Dilution 
JAK2  1:200 
Phospho-JAK2  1:100 
PML  1:50 
SUMO 2/3  1:100 
JAK2 1:100 
Daxx  1:100 
Sp100 (sc-25568) 1:100 
 
2.3.6 Statistics 
Statistical analysis was carried out using GraphPad Prism 6. The statistical 
method used is described in each figure and include one way ANOVA, two way 
ANOVA, and Students t test. Statistical significance is defined as p≤0.05. 
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3 Activity of JAK2 in CML 
3.1 Introduction 
As previously discussed CML is characterised by the presence of the BCR-ABL 
oncogene which results from the Philadelphia chromosome, t(9;22)88,89,90. This 
protein has tyrosine kinase activity which drives aberrant signalling in a number of 
pathways, leading to its characteristic phenotype of myeloid expansion and 
reduced adhesion of precursors in the bone marrow172. In addition to the 
abnormalities seen in the peripheral blood patients often present with inflammatory 
symptoms of fevers, night sweats and weight loss. This inflammatory phenotype is 
driven by a cocktail of cytokines produced by the CML clone, which helps to 
support the expansion of the disease173. Many of these cytokines are produced in 
an autocrine fashion and so do not result in an increase in serum levels. In fact 
with G-CSF there is a decrease in serum concentrations in chronic phase disease 
compared to normal individuals, which starts to increase again as the disease 
progresses through accelerated phase and blast crisis174,175. CML cells do produce 
G-CSF and it is thought that production of soluble G-CSF receptor is responsible 
for reducing the level in the serum. Interestingly another cytokine important in 
myeloid differentiation, IL-3, does not change its levels at all in the serum of 
patients with CML compared to normal individuals175. 
BCR-ABL is known to interact with the JAK2/STAT5 pathways through several 
mechanisms105. BCR-ABL positive cells produce cytokines which have a paracrine 
effect on the cells, often signalling through JAK2-associated receptors173. In 
addition to this BCR-ABL directly phosphorylates both JAK2 and STAT5 resulting 
in ongoing activation of the pathway without the need for ligand binding to 
receptors176,2. Finally BCR-ABL and JAK2 form a complex with Ableson helper 
integration site 1 (AHI-1), where AHI-1 acts as a bridging complex between BCR-
ABL and JAK2. BCR-ABL attaches to the WD40-repeat domain of AHI-1, while 
JAK2 interacts with the N-terminal105. Disruption of this complex using imatinib and 
TG101209 led to an increase in apoptosis in CML cells which was particularly 
marked in the CD34+ve stem/progenitor cell compartment105. These studies all 
indicate the importance of JAK2 signalling in CML and suggest that combining 
therapies targeting both ABL and JAK2 kinase activity may be able to overcome 
the resistance to single agent BCR-ABL targeted therapy especially in the 
leukaemia stem cell compartment.  
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3.2 Results 
3.2.1 Microarray data of JAK2 targets 
JAK2 as a target has generated a lot of interest as a result of its role in cell 
signalling in both normal tissues and in disease177. JAK2 is known to be essential 
for haematopoiesis especially in response to cytokines which drive myelopoiesis. It 
is known to be associated with many cytokine receptors and is best known for its 
role in inflammation and haematopoiesis17. JAK2 signalling is abnormal in many 
haematological malignancies2,112,141,178 and so identifying gene targets of JAK2 
signalling has been of particular interest over the last decade. In this project two 
microarrays were identified and used as a basis for the gene expression 
experiments79,179. The first used the JAK2 null cell line γ2A and compared the 
gene expression in a microarray with the same cells transduced with wild type 
JAK2 (GEO accession number GSM16418). This identified 621 genes with at least 
a two-fold alteration in expression, many requiring only the presence of JAK2 in 
the cell to result in alteration with no need for ligand activation of JAK2179. The 
second paper looked at the entry of JAK2 into the nucleus and its ability to 
phosphorylate histone 3, analysis revealed that one of the key alterations occurred 
in LMO2 expression, which does not have a STAT5 binding site, and was 
downregulated by inhibition of JAK2 in the JAK2 V617F containing HEL cell line79. 
Using the information available in these two microarrays, and with permission from 
the authors, we approached Dr Lisa Hopcroft, a bioinformatician, who analysed 
the data and produced transcriptional regulation maps using Metacore software 
(Figure 3.1). Using this map, genes were selected at hubs of interaction and at 
downstream points from these interactions to study pathways in detail. Some 
genes were subsequently not pursued due to lack of expression in the cells being 
studied, such as androgen receptor. In addition to this, to validate these targets, 
known genes affected by JAK2 were identified from the literature and included in 
the gene expression studies. The pathways identified included; 
 Cell cycle- CDC25B, CDKN1B, TFDP1, CCND2 
 Apoptosis- TNFSF10 (TRAIL2), BNIP3L (NIX), BCL2L1, FOXO3A 
 Differentiation and proliferation- HOXA9, LMO2, FOXM1, UBASH3B 
(STS1), EGR1 
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 Transcription factors- DHX9-DEAH (DDX9), BACH1, RXRB, TFDP1, TAF1, 
HSP90, IKZF1 
 JAK2 associated receptors- CRLF2, GM-CSF, G-CSF 
 JAK2 pathway- JAK2, STAT5, SOCS2 
 IFN response- IRF 1-9, IFN-α and -γ receptors 
Figure 3.1 Metacore interaction map of JAK2 dependent transcriptional 
regulators 
 
Data from the microarrays were entered into Metacore and genes associated with 
transcription were mapped to identify JAK2 dependent targets. The genes used in 
gene expression experiments are circled. 
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3.2.2 Gene expression of K562 cells treated with JAK2 
inhibitors 
The abnormal signalling pathway activity induced by JAK2 leads to deregulation of 
a number of important genes in CML samples, these abnormalities are sometimes 
the same in CML CD34+ cells and CML mononuclear cells (MNC), while others 
have very different expression patterns depending on the maturity of the cells. This 
may indicate a true difference in the CML cells as they differentiate, or reflect an 
alteration in the expression of these genes in normal cells. The abnormalities 
cover a wide range of cellular processes including apoptosis, cellular 
differentiation, transcriptional regulation, and inflammation showing a global 
dysregulation of the gene expression in this condition. The expression patterns 
confirm some previously described abnormalities, including increased expression 
of G-CSF, which is important in myeloid cell development, and decreased 
expression of IRF8, which is thought to play a key role in the switch between 
granulocytic and monocytic differentiation (Figures 3.2 and 3.3).  
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Figure 3.2 Heatmap of the gene expression of CML CD34+ cells 
 
 
Using the data from the microarrays, genes were selected and primers designed to 
look at JAK2 dependent genes and the interferon response (Table 2.2.4.8). Fluidigm 
quantitative real time PCR was performed and the relative expression of the genes 
compared to normal controls was calculated using the 2-ΔΔCT method. A base 10 
logarithmic transformation was then performed and this data was entered in to 
PermutMatrix to generate a heatmap representation of the gene expression. PB 
MNC samples were run on multiple chips with different primer sets. 
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Figure 3.3 Heatmaps of the gene expression of CML PB MNCs 
  
 
Using the data from the microarrays, genes were selected and primers designed to 
look at JAK2 dependent genes and the interferon response (Table 2.2.4.8). Fluidigm 
quantitative real time PCR was performed and the relative expression of the genes 
compared to normal controls was calculated using the 2-ΔΔCT method. A base 10 
logarithmic transformation was then performed and this data was entered in to 
PermutMatrix to generate a heatmap representation of the gene expression. PB 
MNC samples were run on multiple chips with different primer sets. 
The heatmaps give useful information about the overall abnormal expression in 
these cells. However it is interesting to separate these by cellular process to get a 
better idea of how these are altered by the presence of the BCR-ABL oncogene in 
more primitive stem and progenitor populations compared to the more mature 
peripheral blood MNC. 
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3.2.2.1 Changes in expression profiles of apoptosis genes in CML 
Apoptosis is the process of programmed cell death which is important in 
preventing abnormal cells from expanding. These abnormalities can be due to 
abnormal DNA replication, and therefore pose a threat of neoplastic disease, or 
can be a defence mechanism against infection, particularly intracellular organisms, 
such as viral disease180. In CML apoptosis of the abnormal clone is reduced as a 
direct result of the BCR-ABL oncogene altering the apoptotic pathways through 
constitutive pro-survival signalling. BCR-ABL increases protein expression of the 
anti-apoptotic BCL2 and BCL2L1 as well as preventing release of cytochrome C 
from the mitochondria leading to inhibition of the apoptotic pathway and a survival 
advantage to the malignant clone181. Figure 3.4 demonstrates a significant 
increase in the gene expression of BCL2L1 in CML CD34+ cells when compared 
to normal donor CD34+ cells, this in keeping with the reported literature. In 
addition to this there is a reduction in MCL1 in CD34+ cells which does not persist 
as the cells mature. MCL1 exists in several isoforms with the longer product acting 
as an inhibitor of apoptosis, while the shorter form promotes it182. The increase in 
BCL2L1 persists as the cells differentiate while the pro-apoptotic protein, BNIP3L, 
becomes significantly increased. Aberrant expression of BNIP3L has recently 
been identified as part of a high risk panel of genes predicting failure to achieve an 
early molecular response in chronic phase CML treated with imatinib183, while a 
reduced expression in solid tumours is also associated with a poor prognosis184.  
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Figure 3.4 Apoptosis in CML  
 
 
Fluidigm® quantitative real time PCR was carried out on RNA extracted from 
chronic phase CML patient samples. The fold change compared to normal was 
calculated using the 2-ΔΔCT method. The data points were then graphed using 
GraphPad Prism 6 and a two tailed Students t-test was used to calculate 
significance (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001). The two dotted lines indicate a 2- 
fold change from the control, indicated by the dashed line. 
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3.2.2.2 Changes in expression profiles of cytokine signalling genes in CML 
Cytokine signalling plays a key role in the maintenance of CML cells, with 
JAK2/STAT5 and PI3K signalling previously identified as being important in the 
signalling profile of CML. These data show that in CD34+ve cells mRNA 
production of  STAT2, STAT4 and STAT5 are increased when compared to 
normal, along with an increase in the transcription of G-CSF, GM-CSF and G-CSF 
receptor, while STAT1 is unexpectedly decreased in PB MNCs. Interestingly 
mRNA transcription of the important deregulated signalling pathways involved in 
CML, JAK2 and PI3K were not altered in CD34+ve cells, but PI3K appears to be 
decreased in PB MNCs. Lastly the JAK2 regulatory proteins are also differentially 
expressed in CD34+ve cells when compared to PB MNCs with no significant 
changes in the negative regulators CISH or SOCS2 in CD34+ve cells, while in PB 
MNCs there is a significant increase in the expression of both CISH and SOCS2. 
(Figure 3.5). 
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Figure 3.5 Cytokine signalling in CML 
 
 
Fluidigm® quantitative real time PCR was carried out on RNA extracted from 
chronic phase CML patient samples. The fold change compared to normal was 
calculated using the 2-ΔΔCT method. The data points were then graphed using 
GraphPad Prism 6 and a two tailed Students t-test was used to calculate 
significance (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001). The two dotted lines indicate a 2- 
fold change from the control, indicated by the dashed line. 
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3.2.2.3 Changes in expression profiles of transcriptional regulation genes 
in CML 
Regulation of gene transcription lies at the heart of all cellular processes, with 
signalling and responses designed to alter transcriptional machinery activity and 
thereby enhance or inhibit target gene expression. This then leads to targeted 
increases or decreases in protein levels, which in turn affect cellular activity. 
Transcriptional regulation in CML is complex with numerous signalling pathways 
and nuclear processes having been reported to be altered. In Figure 3.6 there is 
clear alteration in the transcriptional activator PIM1 in both CD34+ve cells and PB 
MNCs. PIM1 has been shown to be elevated in CML as a result of BCR-ABL 
induced STAT5 activation and leads to a reduction in expression of pro-apoptotic 
Bclxs altering the function of BAD
185,186, which ultimately leads to a reduction in 
apoptosis in these cells (Figure 3.4).  
FOXM1 controls the expression of several cell cycle genes including CCNA2 and 
CCND1. It also regulates the degradation of CDK2 inhibitors CDKN1A and 
CDKN1B187. It is therefore not surprising that FOXM1 is expressed in proliferating 
cells, but not in terminally differentiated or quiescent cells. In both the CD34+ve 
cells and PB MNCs there is an increase in the expression of FOXM1. This is likely 
to represent a genuine increase in the CD34+ve cells, however in the PB MNCs 
this probably relates to the low levels of expression seen in normal PB cells as 
these are terminally differentiated, whereas in CML a large number of  immature 
cells occur in the peripheral blood (Figure 3.6). 
Other interesting alteration include the increase in Rex1, a marker of pluripotency 
found in undifferentiated embryonic stem cells, which is markedly downregulated 
as the cells begin to differentiate188. This increase in Rex1 has not been previously 
reported in CML CD34+ and may play an important role in sustaining the self-
renewal of the early stem/progenitor cells. Interestingly reports of Rex1 in solid 
tumours relates to a reduction in levels compared to normal tissue (Figure 3.6)189.  
 
 
 
 
92 
 
Figure 3.6 Transcriptional regulation in CML 
 
 
Fluidigm® quantitative real time PCR was carried out on RNA extracted from 
chronic phase CML patient samples. The fold change compared to normal was 
calculated using the 2-ΔΔCT method. The data points were then graphed using 
GraphPad Prism 6 and a two tailed Students t-test was used to calculate 
significance (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001). The two dotted lines indicate a 2- 
fold change from the control, indicated by the dashed line. 
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3.2.2.4 Changes in expression profiles of cell cycle genes in CML 
Regulation of cell cycle is critical to the maintenance of normal cell numbers within 
a tissue. Over activity of the cell cycle leads to proliferation of cells and expansion 
of a tissue. In CML BCR-ABL upregulates a number of cell cycle proteins and 
downregulates inhibitors of the cell cycle in the myeloid lineage leading to marked 
expansion of all stages of granulopoiesis172. The gene analysis data confirms the 
upregulation of several key regulators of cell cycle progression including CCND2 
in CD34+ve cells and CCNA2 in PB MNCs. In addition to this there is upregulation 
of CCNF in both CD34+ve cells and in PB MNCs. Interestingly there is also an 
increase in the expression of the cyclin-dependent kinase inhibitor CDKN1B in 
both PB MNCs and CD34+ve cells. It is likely this is driven by a negative feedback 
loop attempting to regulate the over active cell cycle (Figure 3.7).  
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Figure 3.7 Cell cycle regulation in CML 
 
 
Fluidigm® quantitative real time PCR was carried out on RNA extracted from 
chronic phase CML patient samples. The fold change compared to normal was 
calculated using the 2-ΔΔCT method. The data points were then graphed using 
GraphPad Prism 6 and a two tailed Students t-test was used to calculate 
significance (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001). The two dotted lines indicate a 2- 
fold change from the control, indicated by the dashed line. 
95 
 
3.2.2.5 Changes in expression profiles of inflammation genes in CML 
At presentation many patients complain of symptoms common to a number of 
haematological malignancies, namely sweats, fevers, weight loss and fatigue. 
Weight loss and fatigue can be explained by the tumours use of nutrients; however 
fevers and sweats are more likely to relate to a degree of inflammation associated 
with the condition. The cells affected by CML are intrinsic to the innate immune 
system and are intimately involved in the production of cytokines involved in 
regulating the immune system. It is therefore not surprising that the expression 
profile of genes associated with inflammation, specifically the interferon response, 
are abnormal. In the gene expression profiles below this is borne out with several 
of the interferon response genes being either up- or down-regulated. Previous 
work has shown that IRF8 is down regulated in CML190 and is confirmed here. 
There is also evidence that reintroducing IRF8 into BCR-ABL positive cells will 
rescue the abnormal gene expression profile seen in CML190. The reduced 
expression of IRF4 has also been previously reported191, this appears to relate to 
a deficiency in the T cell compartment expressing this response factor, with an 
increase following initiation of interferon α therapy correlating to a good response. 
Interestingly mouse models with IRF8-/- developed a CML-like disease, which was 
more severe when IRF4 was also knocked out. IRF1 and IRF6 were also up 
regulated, however there is little information about IRF6 in CML, with most data 
relating to abnormal keratinocyte differentiation in the context of inactivating 
mutations192. The altered profile of IRF expression reflects the imbalance/altered 
sensitivity of cytokine/chemokine signalling occurring in CML, which is probably 
driven by the combination of autocrine secretion of cytokines and BCR-ABL 
mediated JAK2 activation, observed in these patients (Figure 3.8). 
Small-ubiquitin modifiers (SUMO) are involved in post-translational modifications 
of numerous proteins in a wide range of cellular processes. The addition of a 
SUMO chain can alter protein activity, cellular localisation, or mark it for 
degradation. It is interesting to note that in CML samples there is an increase in 
SUMO cycle gene expression. This may reflect this increased cellular activity seen 
in the disease, but it is not something that has previously been studied and 
warrants further investigation (Figure 3.8). 
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Figure 3.8 Inflammation in CML 
 
 
Fluidigm® quantitative real time PCR was carried out on RNA extracted from 
chronic phase CML patient samples. The fold change compared to normal was 
calculated using the 2-ΔΔCT method. The data points were then graphed using 
GraphPad Prism 6 and a two tailed Students t-test was used to calculate 
significance (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001) The two dotted lines indicate a 2- 
fold change from the control, indicated by the dashed line. 
Taken together these data confirm that JAK related/mediated downstream gene 
expression in CML is markedly deregulated with a wide range of cellular 
processes affected.  
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3.2.3 Establishing the dose of JAK2 inhibitors for K562 cells 
We decided to look at the effect of JAK2 inhibition on CML cells, as JAK2 plays an 
important role in the pathogenesis of the disease. In order to do this we used the 
K562 cell line, an CML blast crisis cell line that retained the Philadelphia 
chromosome on transformation. Initially we determined a range of concentrations 
of three JAK2 inhibitors (Figure 3.9), two of which are relatively specific for JAK2 
with only a few additional targets at higher concentrations (TG101209193 and 
ruxolitinib194), with the third having a wider range of additional targets (AT9283195) 
including aurora kinase activity at approximately the same concentrations as the 
effect of JAK2. Aurora kinase regulation was identified as a downstream mediator 
of JAK2 from the microarray analysis in Figure 3.1, making dual inhibition by 
AT9283 an interesting avenue to investigate in CML. The additional kinase targets 
of TG101209 include FLT3, which has been shown to be of significance in 
progression of CML196, and RET which has not been shown to have a role in CML, 
but has been shown to be mutated in other malignancies such as papillary thryroid 
cancer197. The main additional target of ruxolitinib is JAK1. While there is data 
about the role of JAK2 in CML, the role of JAK1 is not clear. It may be that in the 
CML clone itself JAK1 has little importance, however the effect of the CML cells on 
other haematopoietic and inflammatory cells may mean JAK1 has a peripheral role 
in the disease.  
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Figure 3.9 XTT assay results for JAK2 inhibitors 
 
XTT assays were carried out in 8 simultaneous wells with the mean plotted in the 
above graphs +/-standard deviation. Solid line indicates the dose of inhibitor 
necessary to reduce the metabolic activity by 50%. The no drug control is indicated 
by the plot point furthest to the left on the X axis. 
K562 cells were cultured in the presence of serially diluted JAK2 inhibitors for 72 
hours before adding the XTT/PMF solution. After 4 hours the visual absorbance 
was measured as a surrogate for metabolic activity. For each JAK2 inhibitor this 
gave an indication of the drug effects which could be used to narrow the range for 
trypan blue exclusion counts. Trypan blue exclusion was carried out at 24, 48 and 
72 hours and the IC50 dose calculated based on these results (Table 3.1). 
Following identification of the IC50 a lower and higher dose were also included that 
were shown to result in an alteration in cell counts at 72 hours, but had live cells 
present at 24 hours.  These doses were then used to analyse changes in gene 
expression and protein expression using Western blotting and 
immunofluorescence techniques. The IC50 doses identified here are comparable to 
those previously reported for these inhibitors in K562 cells176,198. 
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Table 3.1 Doses chosen for K562 cells following trypan blue exclusion 
Cell line Ruxolitinib TG101209 AT9283 
K562 10μM 
20μM 
50μM 
0.1μM 
1μM 
5μM 
0.01μM 
0.1μM 
1μM 
Concentrations of each JAK2 inhibitor used in subsequent experiments, based on 
the results of trypan blue exclusion testing. 
3.2.4 Effect of JAK2 inhibitors on downstream targets of JAK2 
in K562 cells 
K562 cells were cultured in each of the three concentrations of ruxolitinib 
TG101209 and AT9283 for 24 hours as outlined above, before having protein 
extracted and prepared for Western blotting (Section 2.3.4). The activity of JAK2 
inhibitors in K562 cells was assessed by probing protein samples for 
phosphorylation of downstream targets of JAK2. AT9283 was able to affect 
phosphorylation of BCR-ABL directly as previously reported, with the reduction in 
activity of BCR-ABL seen by the reduction of phosphorylation of CRKL at the 
higher doses of AT9283. Phosphorylation of JAK2 was affected by AT9283 in a 
dose dependent manner, while with TG101209 it appeared to increase with the 
lower doses before decreasing with 5μM TG101209. A similar effect on 
phosphorylation of STAT3 was seen with TG101209 where there was an initial 
increase with the lower doses and a decrease with the 5μM dose. Ruxolitinib 
increased the phosphorylation of CRKL without any alteration of phosphorylation 
of BCR-ABL, and although there have been reports of activity of ruxolitinib on 
BCR-ABL activity at doses above 20μM this was not seen in this study. Despite an 
initial increase in phospho-STAT3 with 10μM ruxolitinib there was a subsequent 
reduction with 50μM ruxolitinib. The sample treated with DMSO alone did not alter 
protein expression compared to untreated samples and probing with SHP2 as a 
loading control indicates protein loading was equal (Figure 3.10). 
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Figure 3.10 Western blotting of protein lysates from K562 cells treated with 
JAK2 inhibitors for 24 hours 
 
Protein samples were obtained from K562 cells following 24 hours of culture in 
media alone or supplemented with increasing doses of ruxolitinib, TG101209 or 
AT9283. The lysates were then run according to the protocol described previously 
(2.4.4.2). The nitrocellulose membranes were then probed using antibodies to the 
proteins indicated above and detected using HRP-conjugated antibodies. Equal 
protein loading of the samples was ensured by probing for SHP2. Three 
independent experiments were carried out with this image being representative of 
these. 
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3.2.5 Effect of JAK2 inhibition on gene expression of JAK2 
targets in K562 cells 
K562 cells were treated for 24 hours with the doses of each inhibitor indicated 
above, as at this time point in the trypan blue counts there was little cell death, and 
therefore cells were still viable for RNA extraction. RNA was then processed to 
prepare for Fluidigm® real time PCR as described previously (Section 2.4.3). With 
K562 cells 39 genes (Table 2.2.4.7) were analysed for each of the 3 JAK2 
inhibitors. The heat map demonstrates that treatment with JAK2 inhibitors results 
in an alteration of the gene expression in K562 cells. The expression pattern is 
most similar when cells are treated with ruxolitinib and TG10209, with more 
marked changes observed with the higher drug doses, while AT9283 produces a 
different pattern of alteration. This likely reflects the wider range of cellular targets 
affected by AT9283 (Figure 3.11).  
Figure 3.11 Gene expression heat map of K562 cells treated with JAK2 
inhibitors 
 
Fluidigm® quantitative real time PCR was performed on RNA extracted from K562 
cells treated with increasing doses of JAK2 inhibitors and the relative expression of 
the genes compared to untreated cells was calculated using the 2-ΔΔCT method, 
values represent the mean of 3 independent experiments. A base 10 logarithmic 
transformation was then performed and this data was entered in to PermutMatrix to 
generate a heat map representation of the gene expression of K562 cells treated 
with JAK2 inhibitors.  
 
102 
 
Examining the analysed data of K562 cells treated with each of the JAK2 inhibitors 
separately, the significant alterations in gene expression achieved by the highest 
dose of each inhibitor were graphed below. Ruxolitinib achieved the least number 
of significant alterations in gene expression and these were predominantly related 
to transcriptional regulators of haematopoiesis (LMO2) and cell cycle progression 
(RanBP1 and TFDP1). There is a significant reduction in the expression of STAT5 
which acts as a downstream target of both JAK2 and BCR-ABL, and is a key 
transcriptional regulator of many gene targets of both of these kinases (Figure 
3.12).   
Figure 3.12 Gene expression of K562 cells following treatment with 
ruxolitinib 
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Fluidigm® quantitative real time PCR was carried out on RNA extracted from K562 
cells treated with ruxolitinib 50μM for 24 hours. The fold change compared to 
untreated samples was calculated using the 2-ΔΔCT method. The data points were 
then graphed using GraphPad Prism 6 and a two tailed Students t-test was used to 
calculate significance (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001). The two dotted lines 
indicate a 2- fold change from the control, indicated by the dashed line. 
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When K562 cells were treated with TG101209 there was a wider range of 
significant alterations in gene expression. CCND2 is important in the transition of 
G1 to S phase in the cell cycle, it is increased in primary CML samples and a 
known target of JAK2 signalling. Treatment with TG101209 lead to a marked 
reduction in the expression of CCND2 compared to untreated cells. This alteration 
was accompanied by an increase in the expression of CDKN1B, an inhibitor of 
several CDK proteins. Cytokine signalling genes are also affected with reduction in 
the expression of two negative regulators of JAK2 signalling CISH and SOCS2. 
Again both of these are altered in CML primary samples with an increase in the 
level of both in CML PB MNCs. Both CISH and SOCS2 are targets of 
JAK2/STAT5 signalling acting as negative regulators and the decrease in 
expression following treatment is likely to reflect the reduction in signalling through 
this pathway. Alterations in RanBP1, RXRB and TFDP1 are similar to those seen 
in ruxolitinib treated cells (Figure 3.13). 
Figure 3.13 Gene expression of K562 cells following treatment with 
TG101209 
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Fluidigm® quantitative real time PCR was carried out on RNA extracted from K562 
cells treated with TG101209 5μM for 24 hours. The fold change compared to 
untreated samples was calculated using the 2-ΔΔCT method. The data points were 
then graphed using GraphPad Prism 6 and a two tailed Students t-test was used to 
calculate significance (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001). The two dotted lines 
indicate a 2- fold change from the control, indicated by the dashed line. 
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AT9283 is an inhibitor with a wide range of cellular targets predominantly the 
aurora kinases, JAK2 and JAK3. This leads to a different pattern of altered gene 
expression, although the reduction in negative regulators of JAK2 signalling is still 
seen in these cells with a reduction in CISH and SOCS2. Previous reports have 
suggested that JAK2 inhibition leads to a reduction in LMO2 expression, however 
here there is an increase. There is also an unexpected increase in CCND2, which 
may relate to the effect of AT9283 on other targets such as the aurora kinases, 
however the reduction in CDK1 and increase in CDKN1B is more in keeping with 
the expected effect of JAK2 inhibition (Figure 3.14).  
Figure 3.14 Gene expression of K562 cells following treatment with AT9283 
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Fluidigm® quantitative real time PCR was carried out on RNA extracted from K562 
cells treated with AT9283 1μM for 24 hours. The fold change compared to untreated 
samples was calculated using the 2-ΔΔCT method. The data points were then graphed 
using GraphPad Prism 6 and a two tailed Students t-test was used to calculate 
significance (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001). The two dotted lines indicate a 2- 
fold change from the control, indicated by the dashed line. 
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3.2.6 Apoptosis is increased in K562 cells following treatment 
with JAK2 inhibitors 
In order to confirm the functional significance of the changes in gene expression 
induced by the inhibitors, apoptosis was assessed by culturing K562 cells in JAK2 
inhibitors for 24, 48 and 72 hours. At each of these time points cells were washed 
and incubated with Annexin V and 7AAD to identify cells undergoing apoptosis. At 
24 hours the only significant alteration was in the cells treated with TG101209 5μM 
with a reduction in live cells and an increase in those entering early apoptosis. By 
48 hours all treatment groups were showing evidence of undergoing significant 
apoptosis (Tables 3.2). 
Cells treated with ruxolitinib for 72 hours showed no significant changes in the 
number of apoptotic or dead cells at 10μM and 20μM concentrations. However 
when this was increased to 50μM there was a significant decrease in the 
percentage of live cells and increase in dead cells and those in late apoptosis 
compared to the other concentrations of ruxolitinib and to untreated cells (Figure 
3.15). A similar outcome was seen in cells treated with TG101209 alone, with the 
highest concentration of 5μM producing more marked effects on live cells, late 
apoptosis and dead cells compared to the other concentrations of TG101209 and 
to untreated cells (Figure 3.16). However with AT9283 there was a significant 
alteration seen in the cells treated at both 0.1μM and 1μM compared to untreated 
cells and those treated with 0.01μM (Figure 3.17). The cells treated with ruxolitinib 
produced the smallest change in apoptosis. This is consistent with the gene 
expression changes where there were no significant alterations in apoptotic genes 
following treatment with ruxolitinib, while treatment with TG101209 and AT9283 
resulted in a wider range of alteration in gene expression including a reduction in 
anti-apoptotic BCL2L1 following treatment with AT9283 and an increase in pro-
apoptotic BNIP3L. 
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Table 3.2 Apoptosis at 24 and 48 hours in K562 cells treated with JAK2 
inhibitors 
24 hours Live +/- Early +/- Late +/- Dead +/- 
NDC 84% 6.0 9.3% 5.0 5.6% 1.4 1.1% 0.8 
Ruxolitinib 10μM 84.1% 4.9 11.7% 2.5 3.5% 4.3 0.7% 3.3 
Ruxolitinib 20μM 85% 8.7 10.3% 2.8 4% 6.3 0.7% 6.8 
Ruxolitinib 50μM 79.8% 29.8 12.9% 13.9 5.8% 2.7 1.5% 1.1 
TG101209 0.1μM 91.6% 11.7 3.2% 6.5 3.6% 0.6 1.6% 0.3 
TG101209 1μM 86.2% 10.3 7.5% 4.4 5.4% 0.4 0.9% 0.3 
TG101209 5μM 60.6% 12.9 29% 4.5 9.2% 0.7 1.2% 0.8 
AT9283 0.01μM 83.7% 3.2 4.9% 1.8 7.5% 1.4 3.8% 0.9 
AT9283 0.1μM 69.1% 7.5 8.7% 2.7 14.2% 1.9 7.9% 0.5 
AT9283 1μM 59.9% 29.0 29.8% 7.6 8.7% 1.7 1.6% 0.6 
 
48 hours Live +/- Early +/- Late +/- Dead +/- 
NDC 94.8% 0.3 1.3% 0.5 2.3% 0.3 1.6% 0.1 
Ruxolitinib 10μM 96% 0.2 0.8% 0.2 1.3% 0.4 1.9% 0.7 
Ruxolitinib 20μM 91.8% 1.3 1.3% 0.6 2.8% 0.4 4.1% 1.7 
Ruxolitinib 50μM 79.5% 9.2 6.3% 3.2 9.8% 4.8 4.5% 1.5 
TG101209 0.1μM 96.1% 0.8 1.2% 0.6 1.2% 0.4 1.5% 0.2 
TG101209 1μM 92.4% 2.4 2.8% 1.2 1.9% 0.4 2.9% 1.1 
TG101209 5μM 62.1% 3.3 8.4% 1.9 19.6% 2.3 9.9% 1.4 
AT9283 0.01μM 90.6% 3.0 1.1% 0.2 3.6% 1.5 4.6% 1.8 
AT9283 0.1μM 62.3% 3.3 7.9% 1.2 17.8% 0.9 12.1% 2.8 
AT9283 1μM 38.8% 2.6 4.1% 0.5 12.8% 3.2 44.3% 3.6 
The tables show the percentage of events analysed by FACS for Annexin V and 
7AAD in each of the four quadrants on the equating to the live cell population, 
those cells undergoing the early and late stages of apoptosis and dead cells. The 
SEM is in the column to the right of each condition (n=3). Statistical analysis was by 
two-way ANOVA with Tukeys post-test correction. Significant changes compared to 
NDC are highlighted in red (p ≤ 0.05). 
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Figure 3.15 Apoptosis in K562 cells treated with Ruxolitinib 
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The dot plots show representative results from the apoptosis assay by FACS. The 
bar graphs show the changes in live cells, early and late apoptosis, and dead cells 
treated with ruxolitinib at 72 hours presented as the mean +/- SEM (n=3). Statistical 
significance was determined by two-way ANOVA with Tukey’s post-test correction 
for multiple comparisons (* p≤0.05, ** p≤0.01, ***p p≤0.001, **** p≤0.0001). The tables 
show the significance of each comparison for each stage of apoptosis. 
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Figure 3.16 Apoptosis in K562 cells treated with TG101209 
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The dot plots show representative results from the apoptosis assay by FACS. The 
bar graphs show the changes in live cells, early and late apoptosis, and dead cells 
treated with TG101209 at 72 hours presented as the mean +/- SEM (n=3). Statistical 
significance was determined by two-way ANOVA with Tukey’s post-test correction 
for multiple comparisons (* p≤0.05, ** p≤0.01, ***p p≤0.001, **** p≤0.0001). The tables 
show the significance of each comparison for each stage of apoptosis. 
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Figure 3.17 Apoptosis in K562 cells treated with AT9283 
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The dot plots show representative results from the apoptosis assay by FACS. The 
bar graphs show the changes in live cells, early and late apoptosis, and dead cells 
treated with AT9283 at 72 hours presented as the mean +/- SEM (n=3). Statistical 
significance was determined by two-way ANOVA with Tukey’s post-test correction 
for multiple comparisons (* p≤0.05, ** p≤0.01, ***p p≤0.001, **** p≤0.0001). The tables 
show the significance of each comparison for each stage of apoptosis. 
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As shown there is a progressive increase in apoptosis at 72 hours of treatment. 
This ability to induce a greater degree of apoptosis by AT9283 treatment likely 
reflects its wider range of targets, enabling inhibition of multiple pathways within 
the cells, in particular cellular proliferation and division through its ability to inhibit 
JAK2 and Aurora kinases respectively. There is also some evidence that AT9283 
has activity against BCR-ABL198, which we also confirmed by western blotting with 
reduced pABL and pCRKL levels following treatment of K562 cells with AT9283. 
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3.2.7 Cell cycle is altered in K562 cells following treatment with 
JAK2 inhibitors 
Cell cycle alterations play an important role in the expansion of the malignant CML 
clone. As shown above there is alteration in the gene expression of key regulators 
of the cell cycle which results in the malignant cells dividing more frequently. This, 
in combination with a reduction in apoptosis, leads to a proliferative advantage 
over the normal cells. Following on from the alterations in cell cycle genes 
observed, next we looked at the effect of the JAK2 inhibitors on the cell cycle in 
K562 cells.  
Following treatment with ruxolitinib for 72 hours there is an increase in the 
percentage of cells in S, G2 and M phase which suggests that cells have entered 
the cell cycle, but become blocked at this stage (Figure 3.18). This is not seen in 
cells treated with TG101209 (Figure 3.19), which would suggest that JAK2 
inhibition alone is insufficient to achieve this alteration in cell cycle. Cells treated 
with AT9283 were more difficult to assess due to the effect of Aurora kinase B 
inhibition which is known to cause a failure of mitosis and accumulation in the cells 
of multiple nuclei (Figure 3.20). The cell cycle assay relies on the staining 
properties of propidium iodide, which binds to DNA with a fluorescence intensity 
proportional to the amount of DNA present. As a result of the increased number of 
nuclei present in the cells treated with AT9283 it was not possible to extract useful 
information about the cell cycle. 
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Figure 3.18 Cell cycle analysis of K562 cells following treatment with 
ruxolitinib 
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G0-G1     S-G2-
M 
   
Rux10 NS    Rux10 NS   
Rux20 NS NS   Rux20 NS NS  
Rux50 *** * NS  Rux50 *** * NS 
 NDC Rux10 Rux20   NDC Rux10 Rux20 
The histogram plots show representative results from FACS and show the gating 
strategy used. The bar graphs show the changes in cell cycle following treatment 
with ruxolitinib for 72 hours, highlighting those actively undergoing cell cycle (S-
G2-M) and those that are quiescent (G0-G1). They are presented as the mean +/- 
SEM (n=3). Statistical significance was determined by two-way ANOVA with Tukey’s 
post-test correction for multiple comparisons (* p≤0.05, ** p≤0.01, ***p p≤0.001, **** 
p≤0.0001). 
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Figure 3.19 Cell cycle analysis of K562 cells following treatment with 
TG101209 
 
 
 
 
G0-G1     S-G2-
M 
   
TG0.1 NS    TG0.1 NS   
TG1 NS NS   TG1 NS NS  
TG5 NS NS NS  TG5 NS NS NS 
 NDC TG0.1 TG1   NDC TG0.1 TG1 
The histogram plots show representative results from FACS and show the gating 
strategy used. The bar graphs show the changes in cell cycle following treatment 
with TG101209 for 72 hours, highlighting those actively undergoing cell cycle (S-
G2-M) and those that are quiescent (G0-G1). They are presented as the mean +/- 
SEM (n=3). Statistical significance was determined by two-way ANOVA with Tukey’s 
post-test correction for multiple comparisons (* p≤0.05, ** p≤0.01, ***p p≤0.001, **** 
p≤0.0001). 
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Figure 3.20 Cell cycle analysis of K562 cells following treatment with AT9283 
 
The histogram plots show representative results from the PI staining and FACS 
analysis. When the normal gating strategy was applied it was difficult to extract any 
meaningful data from cells treated with AT9283. 
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3.2.8 Immunofluorescence of K562 cells following treatment 
with JAK2 inhibitors or IFN-γ 
To further assess the effect of JAK2 inhibition on protein expression and 
interaction we looked at the interaction of JAK2 with two important proteins in the 
inflammatory response SUMO2/3 and PML. Phosphorylated JAK2 has previously 
been shown to acquire the ability to enter the nucleus following the addition of a 
SUMO2/3 chain78. Additionally it has been shown that JAK2 interacts with histone 
3 to increase transcription at important sites for haematopoiesis79,80. However it is 
still unclear as to how JAK2 interacts with H3 within the nucleus, one possibility is 
the role of PML nuclear bodies (NBs) in transcriptional and epigenetic changes. 
NB’s are known to assemble SUMOylated proteins within precise sites and to be 
regulated by inflammation. We therefore postulated that JAK2 may interact directly 
with PML NBs, a sub-nuclear structure with an important regulatory role in many 
cellular processes, which interacts with proteins in the nucleus based on the 
presence of SUMO chains. As a result we decided to look at the interaction of 
JAK2 with SUMO2/3 following stimulation with IFNγ, which is known to increase 
SUMO protein expression. In addition we then investigated what effects JAK2 
inhibitors would have on this process. K562 cells were treated for 24 hours with 
each treatment arm before being processed for immunofluorescence to determine 
cellular location by the Duolink immunofluorescent co-localisation assay.  
Immunofluorescence was used to identify the localisation of proteins in the 
cytoplasm and nucleus. As expected, PML is seen in discrete structures within the 
nucleus and increases in abundance when cells are treated with IFNγ. JAK2 is 
seen in both the cytoplasm and in the nucleus which is consistent with previous 
reports and SUMO2/3 is located throughout the cell with higher fluorescence seen 
in a similar distribution as PML, which is likely to reflect the high concentrations of 
SUMOylated proteins seen within the PML NBs (Figure 3.21).  
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Figure 3.21 Immunofluorescence of K562 cells following treatment with 
JAK2 inhibitors or IFN-γ 
a) K562 cells probed for JAK2 and PML 
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b) K562 cells probed for JAK2 and SUMO2/3 
 
K562 cells were treated for 24 hours then prepared for immunofluorescence 
as described previously. 3 separate experiments were carried out and 
representative images are shown above with cells being assessed for JAK2 
and PML in a) and for JAK2 and SUMO in b). 
Duolink indicated that following 24 hours of stimulation with IFNγ there was little 
change in the association of JAK2 and SUMO2/3, while there was a marked 
increase in the association of JAK2 with PML. Conversely ruxolitinib treatment 
resulted in an increase in the association of JAK2 with SUMO2/3 and a reduction 
in JAK2 and PML. TG101209 treatment led to a slight, but non-significant increase 
in the association of JAK2 with PML and a significant increase in the association of 
JAK2 with SUMO2/3 (Figure 3.22 b). The reasons for the increase in association 
with JAK2 and SUMO2/3 following JAK2 inhibition may relate to the mechanism of 
action of the inhibitors, as they do not alter the phosphorylation status of JAK2 at 
the Y1007/1008 site, essential for the binding of SUMO. What is interesting is that 
this increase in the association does not lead to an increase in the association of 
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JAK2 with PML, but instead either led to a small change or a significant decrease 
in the association depending on the inhibitor used (Figure 3.22b). This suggests 
the interaction of JAK2 with PML requires more than just the presence of a SUMO 
chain. 
Figure 3.22 Duolink co-localisation assay in K562 cells treated with JAK2 
inhibitors 
a) 
 
b) 
 
K562 cells were treated for 24 hours then prepared for Duolink immunofluorescent 
co-localisation assay as described previously. 80 cells were counted for each 
treatment in 3 separate experiments with the corrected total cell fluorescence 
calculated. The images (3a) are representative of the experiments while the graphs 
(3b) show the average of the corrected total cell fluorescence for all 3 experiments 
+/- SEM. AT9283 was not included due to a lack of adherence of sufficient cells for 
analysis. Statistical significance was determined by one way ANOVA with Dunnett’s 
correction for multiple comparisons (* p≤0.05, ** p≤0.01, *** p≤0.001, **** p≤0.0001). 
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3.2.9 Effect of JAK2 inhibition on JAK2 downstream targets in 
CML CD34 +ve cells 
In order to determine the efficacy of ruxolitinib on JAK2 downstream targets in 
primary samples, CML CD34+ve cell were treated with nilotinib and ruxolitinib 
either alone or in combination. The inhibitors chosen were within the clinical dose, 
with concentrations of; nilotinib 5μM and ruxolitinib 1μM chosen as physiologically 
achievable doses. Three CD34+ve chronic phase CML samples were treated with 
these two inhibitors alone and in combination. Following the defrosting process 
two samples had sufficient cells for both RNA and protein to be made, with the 
remaining sample only having a sufficient number of cells for RNA. As a result 
three samples were used for Fluidigm® real time PCR to assess gene expression, 
while only two were assessable in Western blots. The protein extracted from these 
experimental arms was probed for downstream targets to confirm specificity of the 
inhibitors. The results showed that nilotinib effectively inhibited the phosphorylation 
of CRKL, JAK2 and STAT5, while ruxolitinib reduced the phosphorylation of 
STAT5 compared to untreated samples, but was unable to completely inhibit the 
phosphorylation alone as a single agent as BCR-ABL is known to directly 
phosphorylate STAT5. It is interesting that there is still a reduction in STAT5 
phosphorylation, suggesting that JAK2 still has a role to play in the overall 
activation of STAT5 despite the activity of BCR-ABL directly on STAT5 (Figure 
3.23). 
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Figure 3.23 Western blotting of CML CD34+ve samples treated with nilotinib 
and ruxolitinib 
 
Protein samples were obtained from CML CD34+ve selected samples following 
eight hours of culture in media alone or supplemented with nilotinib 5μM, 
ruxolitinib 1μM, or both in inhibitors together. The lysates were then run according 
to the protocol described previously (2.4.4.2). The nitrocellulose membranes were 
then probed using antibodies to the proteins indicated above and detected using 
HRP-conjugated antibodies. Equal protein loading of the samples was ensured by 
probing for SHP2. 
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3.2.10 Alteration in gene expression of JAK2 targets in CML 
CD34 +ve cells treated with nilotinib and ruxolitinib 
Next we examined the effects of nilotinib and ruxolitinib alone and in combination 
on the JAK2 target genes previously investigated from the microarray analysis 
(Figure 3.1).  The graphs below show genes known to be deregulated in untreated 
patient samples (Figure 3.2). They also show the effects on gene expression in the 
samples following treatment with nilotinib and ruxolitinib alone and in combination 
(Figure 3.24). As shown in the heatmap the three samples did not always result in 
the same response to treatment, however there is a clear effect from each of the 
inhibitors, which is often compounded when added together. The individual graphs 
highlight genes shown to be deregulated in untreated samples which displayed 
interesting responses following treatment. 
Figure 3.24 Heatmap of CML CD34+ve samples treated with nilotinib and 
ruxolitinib 
 
Fluidigm quantitative real time PCR was performed on 3 CML CD34+ve samples 
following treatment with nilotinib and ruxolitinib alone and in combination. Each 
sample was run in triplicate. The relative expression of the genes compared to the 
no drug control for each sample was calculated using the 2-ΔΔCT method. A base 10 
logarithmic transformation was then performed and this data was entered in to 
PermutMatrix to generate a heatmap representation of the gene expression with the 
three samples grouped together according to treatment arms. 
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CISH is a negative regulator of JAK2 signalling, and is increased in CML PB 
MNCs. When CML CD34+ve samples were treated with nilotinib, there was little 
change in expression compared with no treatment with a fold change similar to 
baseline, while ruxolitinib achieved a two-fold reduction in the expression, 
compared to normal. However, when combined nilotinib and ruxolitinib produced a 
significant alteration compared to the other treatment conditions. This is likely to 
represent a reduction of the requirement for negative regulation of cytokine 
signalling as a result of the combined inhibition of BCR-ABL and JAK2 activity 
(Figure 3.25). 
Figure 3.25 CISH expression in CML CD34+ve samples following treatment 
with nilotinib and ruxolitinib 
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Fluidigm® quantitative real time PCR was carried out on RNA extracted from 
chronic phase CML CD34+ve samples following treatment with nilotinib 5μM and 
ruxolitinib 1μM alone and in combination. The fold change compared to normal was 
calculated using the 2-ΔΔCT method. The data points were then graphed using 
GraphPad Prism 6 and a two tailed Students t-test was used to calculate 
significance (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001), with comparisons made between 
untreated samples and between each treatment arm. The two dotted lines indicate a 
2- fold change from the control, indicated by the dashed line. 
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BCL2L1 is an anti-apoptotic gene altered in both the CD34+ve cells and PB MNCs 
of CML samples, while BNIP3L is involved in apoptosis of cells following exposure 
to cellular stresses and is convincingly increased in the peripheral blood cells, but 
was more borderline in the CML CD34+ve cells when compared to normal 
CD34+ve cells. When treated with nilotinib or ruxolitinib alone there was little effect 
seen in BCL2L1 expression in CD34+ve cells although the alteration seen in 
ruxolitinib treated cells is significant due to the compactness of the results. When 
combined the dual inhibition resulted in a significant reduction in the expression of 
BCL2L1 compared to each treatment arm and untreated cells. However with 
BNIP3L there was an increase in the expression, which suggests the combination 
of BCR-ABL and JAK2 inhibition produces a sufficient stress on the cells to drive 
apoptotic cell death (Figure 3.26) 
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Figure 3.26 BCL2L1 and BNIP3L expression in CML CD34+ve samples 
following treatment with nilotinib and ruxolitinib 
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Fluidigm® quantitative real time PCR was carried out on RNA extracted from 
chronic phase CML CD34+ve samples following treatment with nilotinib 5μM and 
ruxolitinib 1μM alone and in combination. The fold change compared to normal was 
calculated using the 2-ΔΔCT method. The data points were then graphed using 
GraphPad Prism 6 and a two tailed Students t-test was used to calculate 
significance (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001), with comparisons made between 
untreated samples and between each treatment arm. The two dotted lines indicate a 
2- fold change from the control, indicated by the dashed line. 
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EGR1 is an early response transcription factor which induces the expression of 
many proteins involved in cell growth and differentiation, apoptosis and stress 
responses. In CML CD34+ve cells there was a wide range of expression with 
some patients displaying up- and others down-regulation whereas others were 
unchanged when compared to normal CD34+ cells. However in PB MNCs there 
was a consistent and significant increase in EGR1 expression compared to normal 
MNCs, although this analysis was performed in a smaller cohort of samples. When 
treated with nilotinib CML CD34+ve cells express EGR1 at the same levels as 
untreated cells, while there was a significant decrease in expression when cells 
were treated with ruxolitinib alone. In cells treated with dual inhibition there was a 
marked decrease in expression which is significant when compared with untreated 
cells and those treated with nilotinib alone. This suggests that although BCR-ABL 
has an effect on EGR1 expression this can be bypassed in the event of BCR-ABL 
inhibition, while JAK2 has a direct effect on EGR1 expression and may be the 
mechanism of ongoing activity in the presence of BCR-ABL inhibition as dual 
inhibition has a greater affect than either inhibitor alone (Figure 3.27).  
Figure 3.27 EGR1 expression in CML CD34+ve samples following treatment 
with nilotinib and ruxolitinib 
 
Fluidigm® quantitative real time PCR was carried out on RNA extracted from 
chronic phase CML CD34+ve samples following treatment with nilotinib 5μM and 
ruxolitinib 1μM alone and in combination. The fold change compared to normal was 
calculated using the 2-ΔΔCT method. The data points were then graphed using 
GraphPad Prism 6 and a two tailed Students t-test was used to calculate 
significance (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001), with comparisons made between 
untreated samples and between each treatment arm. The two dotted lines indicate a 
2- fold change from the control, indicated by the dashed line. 
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CCND2 is a key regulator in cell cycle progression which forms a complex with the 
cyclin dependent kinases 4 and 6 to initiate cell cycle transition from G1 to S 
phase. CCND2 is consistently elevated in CML CD34+ve cells and when these 
cells were treated with single inhibitors there was very little change in the 
expression levels, although these changes are significant by two tailed Students t-
test. However when the inhibitors were combined there was a significant reduction 
in the expression of this gene, both compared to untreated cells and to each 
inhibitor individually, which suggests that neither JAK2 or BCR-ABL is responsible 
for the control of CCND2 expression alone, and both kinases activate pathways 
involved in its regulation (Figure 3.28) 
Figure 3.28 CCND2 expression in CML CD34+ve samples following treatment 
with nilotinib and ruxolitinib 
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Fluidigm® quantitative real time PCR was carried out on RNA extracted from 
chronic phase CML CD34+ve samples following treatment with nilotinib 5μM and 
ruxolitinib 1μM alone and in combination. The fold change compared to normal was 
calculated using the 2-ΔΔCT method. The data points were then graphed using 
GraphPad Prism 6 and a two tailed Students t-test was used to calculate 
significance (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001), with comparisons made between 
untreated samples and between each treatment arm. The two dotted lines indicate a 
2- fold change from the control, indicated by the dashed line. 
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3.3 Discussion 
3.3.1 Proliferation and cell cycle in CML 
One of the defining characteristics of CML is the marked proliferation and 
expansion of myeloid cells at all stages, detected in the bone marrow and the 
peripheral blood. The cause of this is the effect of BCR-ABL activity on a number 
of cellular signalling pathways that regulate the proliferation of myeloid cells. JAK2 
signalling has been shown repeatedly to be upregulated, but there are differing 
opinions on whether JAK2 itself has any role to play2,176,199. There are some who 
feel that the activation of STATs directly by BCR-ABL makes the activity of JAK2 
less important. However there have been a number of papers in the last few years 
suggesting that the interaction of JAK2 and BCR-ABL in CML is important and the 
pathway is activated not just by the direct effect on STAT signalling. A paper by 
Gallipoli et al in 2014 showed that combining BCR-ABL inhibition using nilotinib 
with JAK2 inhibition with ruxolitinib lead to an increased toxic effect on CML 
CD34+ve cells when compared with the effects observed by each drug alone. 
Interestingly this combination did not affect normal CD34+ve cells to the same 
degree2. In 2013 Chen et al published work showing that BCR-ABL and JAK2 
interact directly through each binding to AHI-1, which is found in high levels in 
CML CD34+ve cells. Interrupting either of these interactions led to a marked 
increase in the sensitivity of CML CD34+ve cells to imatinib therapy, suggesting 
that the direct interaction of these three proteins play a significant part in the 
survival of CML stem cells following imatinib therapy105. 
In this work we showed that there are alterations in gene expression of 
downstream JAK2 targets in K562 cells following treatment with a range of JAK2 
inhibitors, however an alteration of cell cycle in these cells seemed to require the 
inhibition of additional kinases aside form JAK2, such as BCR-ABL itself or the 
Aurora kinases.  
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3.3.2 Apoptosis in CML 
Alteration of apoptosis either by increasing the activity of anti-apoptotic proteins or 
inhibiting pro-apoptotic pathways is a recognised mechanism used by many 
cancers to promote their survival. In CML, BCR-ABL activity protects the cells from 
stresses which would normally induce apoptosis, as well as allowing the cells to 
survive for longer without cytokine stimulation200. This is due to BCR-ABL 
increases the expression of anti-apoptotic Bcl-2 family members while interfering 
with the inhibitory effects of pro-apoptotic proteins, which leads to prevention of 
the activation of caspases by stopping the release of cytochrome-c from the 
mitochondria181. This interference leads to a survival advantage for the CML cells 
and allows expansion of the clone. Our data confirmed abnormalities of several 
genes involved in the regulation of apoptosis with an increase in BCL2L1 in both 
CD34+ve cells and in PB MNCs. There was also a decrease in the anti-apoptotic 
MCL-1 in CML CD34+ve cells which has previously been shown to be induced by 
BCR-ABL and inhibited by TKI therapy. Finally the decrease of TNFSF10 has 
previously been shown to be reduced in CML as a result of a BCR-ABL mediated 
increase of preferentially expressed antigen of melanoma (PRAME) which in turn 
inhibits the expression of TNFSF10 via EZH2201.  
The alterations in apoptotic genes led us to evaluate the functional effect of JAK2 
inhibitors on apoptosis in K562 cells. The use of TG101209 in imatinib resistant 
K562 cells has previously been shown to induce apoptosis at a similar dose range 
as used here. The role JAK2 has to play in prevention of apoptosis in K562 cells 
was confirmed by significant increases in apoptosis with the two other JAK2 
inhibitors.  
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3.3.3 Inflammation and cytokine driven interferon response in 
CML 
Patients with CML often present with symptoms suggestive of an activated 
inflammatory response, with fevers and sweats as well as weight loss. Nievergall 
et al recently showed that multiple inflammatory cytokines, chemokines and 
growth factors are elevated in the serum of patients with CML at diagnosis and 
that these can be used to identify patients with a failure to achieve an early 
molecular response202. In particular high TGF-α and IL-6 levels were shown to 
correlate well with a failure to achieve an early molecular response confirming the 
important role inflammation plays in these patients. Plasma levels of IFN-α and 
IFN-γ were evaluated in these patients and were not found to be significantly 
elevated in CML patients at diagnosis, however when plasma was extracted from 
bone marrow samples CXCL10 was found to be significantly elevated202. CXCL10, 
previously known as IFN-γ-inducible protein 10 (IP-10), is directly affected by IFN-
γ activation. In CML there is hyperactivity of JAK signalling which may result in an 
increase in IFN-γ signalling in the absence of a significantly increased level of IFN-
γ in the circulation. This postulated elevation in IFN signalling would explain the 
increase in the level of PML gene expression in CML cells compared to normal. 
3.3.4 The role on PML in cell cycle and apoptosis in CML 
The promyelocytic leukaemia protein has been shown to be down regulated in a 
number of solid tumours mostly through epigenetic alterations leading to gene 
silencing. As a result PML is normally considered a tumour suppressor164. 
However in CML there is an increase in PML expression in the leukaemia stem 
cells165 which is thought to aid in the survival of these cells following TKI therapy. 
Mouse models of CML with loss of PML showed that there was an increase in cell 
cycling and a loss of long-term repopulating ability suggesting that PML plays a 
critical role in maintaining the quiescent state of the most primitive disease cells165. 
In this study we demonstrate that PML interacts with JAK2, which has also been 
linked to the maintenance of primitive CML cells, which suggests that these two 
proteins may be of critical importance as targets for the eradication of CML 
progenitors. Given that there are drugs already in clinical use which target JAK2 
activity and PML stability, in the form of ruxolitinib and arsenic trioxide 
respectively, investigating this dual targeting approach would be an interesting 
area for further study. 
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4 Activity of JAK2 tyrosine kinase in JAK2 
V617F myeloproliferative disease 
4.1 Introduction 
Polycythaemia vera is a clonal abnormality of haematopoiesis characterised by 
uncontrolled signalling in the JAK2/STAT pathway. This is almost always due to 
the presence of the JAK2 V617F mutation, which causes a conformational change 
in the JAK2 protein leading to constitutive activation112,113,110,111. The most obvious 
clinical manifestation of this is myeloid expansion with elevated peripheral red 
blood cell, granulocyte and platelet counts203. These patients also have a 
significantly elevated risk of thrombosis, which is likely driven by a combination of 
hyperviscosity, hyper-reactivity of platelets and chronic inflammation203. PV 
patients have a well-recognised inflammatory phenotype which leads to the 
majority of the chronic symptomatology and reduced quality of life152. These 
symptoms include lethargy, itch (particularly aquagenic itch), and sweats which 
can occasionally be drenching. The current therapy for PV focuses on controlling 
peripheral blood counts and reduction of thrombotic risk, but is not particularly 
effective at controlling inflammatory symptoms133. Recently, JAK2 inhibitors have 
been developed and investigated aiming to reduce signalling through this pathway 
and therefore abrogate the disease. The only JAK2 inhibitor currently in use is 
ruxolitinib. This was initially approved for use in symptomatic myelofibrosis 
following the results of the COMFORT trials204. A further study into the use of 
ruxolitinib in PV has shown encouraging results in terms of blood count and 
symptom control133 leading to its approval for use in PV patients who are resistant 
to or intolerant of hydroxycarbamide.  
The cause of the inflammation in PV patients has been studied for some time, but 
it is clear that the mechanisms underlying the problem are still not fully elucidated. 
There are several areas that have been identified as abnormal, including 
increased reactive oxygen species (ROS) generation by neutrophils from PV 
patients149 and elevated circulating inflammatory cytokines, such as IL-6 and TNF-
α150. These cytokines are thought to play a role in mediating the symptoms and in 
supporting the malignant clone. In addition to this, there is evidence to show that 
there is platelet dysfunction205 and abnormal interactions of haematopoietic cells 
with endothelial cells206. We therefore decided to look at the alterations in PV and 
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whether these were corrected by treating cell lines containing the JAK2 V617F 
mutation with JAK2 inhibitors 
Many epigenetic and transcriptional regulators are known to interact with the PML 
NBs, which acts as a hub for active protein complexes necessary for these critical 
roles207. Proteins that interact with the PML NB are SUMOylated and bind to 
SUMO-interacting motifs within the NB158. Evidence shows that JAK2 requires 
SUMOylation to enter the nucleus before going on to effect alterations in 
epigenetic and transcriptional regulation within the nucleus78, and it would be 
possible that SUMOylation of JAK2 plays a dual role in both allowing nuclear 
localisation and interaction with the PML NB to mediate the nuclear JAK2 effects. 
In addition to this JAK2 is critical in mediating inflammatory cytokine signalling, 
such as IFN-γ, which is associated with increased size and number of PML 
NBs208. As a result the interaction of JAK2 and PML NBs may be an important 
regulator of the phenotype of JAK2 V617F mediated disease. 
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4.2 Results 
4.2.1 Gene expression of PV PB MNC 
Using the same gene expression array designed for analysis of JAK2-dependent 
genes and interferon-dependent genes as in the CML samples (chapter 3), RNA 
from the peripheral blood of patients with PV was analysed and compared to 
normal peripheral blood controls, with RNA extracted immediately after isolation of 
PB MNCs. The RNA was quantified and an equal amount of RNA from each 
sample was used to carry out gene expression analysis. This allowed a direct 
comparison of two alternative mechanisms by which over-activity of the JAK 
pathway occurs in MPN; CML samples where the JAK2 protein is normal but is 
over-stimulated, while in the PV samples the presence of the JAK2 V617F 
mutation leads to ligand independent activation of the JAK2 protein. 
Our results demonstrate several marked changes in the gene expression pattern 
of PV PB MNCs compared to normal. Interestingly, there was much more 
heterogeneity seen in the PV samples than in the CML samples which appear to 
maintain a much more consistent pattern of abnormalities between samples. This 
may be as a result of the increasing JAK2 V617F allele burden seen in PV patients 
over time as these patients had samples collected at various time points following 
diagnosis, while the CML patient samples were all collected at diagnosis. Here 
there are clear abnormalities in several cell cycle genes as well as transcriptional 
regulators and interferon-dependent genes, but this difference is less consistent 
between patients.  
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Figure 4.1 Gene expression heat map of PV PB MNC 
 
 
Using the data from the microarrays, genes were selected and primers designed to 
look at JAK2-dependent genes and the interferon response (Table 2.2.4.8). Fluidigm 
quantitative real-time PCR was performed and the relative expression of the genes 
compared to normal controls was calculated using the 2-ΔΔCT method. A base 10 
logarithmic transformation was then performed and this data was entered in to 
PermutMatrix to generate a heatmap representation of the gene expression.  
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The heatmap (Figure 4.1) shows alteration in the gene expression profile of a 
number of important genes in a range of cellular processes. These include cell 
cycle, differentiation, IFN response and SUMOylation. The heatmap clearly shows 
a global deregulation of many of these genes with several being markedly altered 
consistently in all samples. These particularly cluster in genes associated with the 
cell cycle and cell division, and may reflect the fact that patient samples were not 
collected at diagnosis, but often when patients were already on therapy, most 
frequently with hydroxycarbamide.  
Looking more closely at the cellular processes gives a better understanding of how 
the JAK2 V617F mutation affects different aspects of cellular function. However, it 
was important to try to identify alterations that could be accounted for by the use of 
hydroxycarbamide in the patients, which was not being used by the normal 
controls.  
As discussed previously, apoptosis is the process of programmed cell death and is 
often affected by the presence of oncogenes which can increase anti-apoptotic 
genes, while also decreasing pro-apoptotic genes. Here we can see that the 
presence of the JAK2 V617F mutation leads to changes in some samples, but not 
in all. As a result, there is little in the way of significant changes in apoptosis in PV 
PB MNCs. This differs from CML where there are clear alterations in BCL2L1 and 
BNIP3L. This may reflect the fact that the cells in the peripheral blood of CML 
patients have a higher proportion of immature granulocytes compared with normal 
donors and PV patients. In PV, the presence of immature cells in the peripheral 
blood is less pronounced and so the apoptosis of the terminally differentiated cells 
in PV more closely resembles that of normal donors. The use of MNCs for the 
assessment of gene expression meant that alterations in gene expression of any 
of the peripheral blood cells would be represented. However this also means that 
alterations are not specific to one lineage, and it would be of interest to carry out 
expression profiles on neutrophils, monocytes and lymphocytes to assess the 
effect the JAK2 V617F mutation had on each of these cell groups. 
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Figure 4.2 Apoptosis in PV 
 
Fluidigm® quantitative real-time PCR was carried out on RNA extracted from PV PB 
MNCs. The fold change compared to normal was calculated using the 2-ΔΔCT 
method. The data points were then graphed using GraphPad Prism 6 and a two 
tailed Students t-test was used to calculate significance (* p ≤ 0.05). The two dotted 
lines indicate a 2- fold change from the control, indicated by the dashed line. 
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Cytokine signalling plays a key role in many myeloid conditions, and PV is no 
exception. The major molecular abnormality, JAK2 V617F, directly affects the 
JAK2/STAT pathway through constitutive activation of JAK2 leading to ligand 
independent expansion of myeloid precursors in the bone marrow. This is reflected 
in the low levels of EPO seen in patients with PV, where there is uncontrolled 
erythroid lineage growth without the requirement for EPO to initiate signalling209. In 
the PV samples studied there was variability between samples. However some of 
the interesting alterations in gene expression were associated with cytokine 
signalling, with an increase in STAT1, a reduction in CISH, and variable MPL 
expression, depending on the patient.  
The thrombopoietin receptor is transcribed by MPL and mutations of this gene are 
seen in a proportion of patients with ET and MF, but are not seen in PV. MPL 
expression has been shown to be abnormal in MPN. Interestingly the expression 
seems to be high in patients with a low JAK2 V617F allele burden and low in those 
with a high allele burden210. This would explainthe spread in MPL expressionseen 
in this study although the allele burden data is not available.  
Cytokine-inducible SH2-containing protein is a negative regulator of cytokine 
signalling and is part of the SOCS family. Reduced expression of CISH has 
previously been reported in ET and in combination with FOSB, was found to 
discriminate between JAK2 V617F positive and negative status, with 
downregulation of CISH seen in patients negative for the JAK2 V617F mutation211. 
Interestingly, in the PV patients studied here, all were JAK2 V617F positive, with a 
significant decrease in the level of CISH expression. This reduced expression is 
unexpected as the increase in signalling through the JAK/STAT pathway should 
result in an increase in the expression of CISH in its negative regulatory capacity, 
and the paradoxical expression levels may be due to the STAT independent 
signalling engendered by constitutive JAK2 activation.  
STAT1 is an important regulator of IFN signalling and is usually considered a 
tumour suppressor in solid tumours, where there is an imbalance between the 
activity of STAT1 and STAT3212. In MPN there is evidence to suggest a differential 
in the expression of STAT1 in normal CD34+ve cells associated with either an ET-
like or PV-like phenotype, with increased expression tending towards an ET 
phenotype213. This study was carried out in erythroid precursors from ET and PV 
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patients and compared to JAK2 V617F negative erythroid precursors from the 
same patients213. The different results observed from our data may reflect the 
populations of cells studied, we investigated PB MNCs, with the cells in the 
peripheral blood exposed to the higher levels of circulating pro-inflammatory 
cytokines which occur in PV. This would lead to increased activation of cytokine 
receptors and an increase in transcription of target genes. Interestingly there is no 
significant alteration in the transcription of the other STAT proteins in the MNCs of 
PV patients.  
Figure 4.3 Cytokine signalling in PV 
 
Fluidigm® quantitative real-time PCR was carried out on RNA extracted from PV PB 
MNCs. The fold change compared to normal was calculated using the 2-ΔΔCT 
method. The data points were then graphed using GraphPad Prism 6 and a two 
tailed Students t-test was used to calculate significance (* p ≤ 0.05, ** p ≤ 0.01, *** p 
≤ 0.001). The two dotted lines indicate a 2- fold change from the control, indicated 
by the dashed line. 
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Unsurprisingly, there is alteration in the expression of numerous transcriptional 
regulators in PV, with many playing an important role in haematopoiesis. The 
transcription factor EGR1 plays an important role in maintenance of HSCs, but has 
been shown to be downregulated as cells start to differentiate and proliferate214. 
The increase in EGR1 in PB MNCs suggests that there is either more immature 
cells present in the peripheral blood or that the cells in the peripheral blood are 
maintaining a more immature gene expression profile despite terminal 
differentiation. This increase in EGR1 has been reported in neutrophils extracted 
from PV patients, although the reason for its elevation remains unclear215.  
An increase in EGR2, which is essential for the proliferation of inflammatory B- 
and T-cells216, was also shown. This supports the suggestion that inflammation in 
PV is multifactorial and involves the interaction of the whole immune system. Most 
research to date has focused on the effect of the JAK2 V617F mutation on 
granulocytes, as these cells harbour the mutation. Of interest, evidence suggests 
that when there is induced differentiation of haematopoietic cells there is an 
increase in the level of EGR2217. In the context of PV, where there is an increase 
in the proliferation of maturing haematopoietic cells, it may be that the increase in 
EGR2 observed is driven by this rather than a defect in T cell function, especially 
given the myeloid cell compartment is affected by the JAK2 V617F mutation. 
Other important transcription factors in cell differentiation and proliferation include 
TAF1 which is part of a regulatory complex that controls histone acetyltransferase 
activity in haematopoietic tissues218 and was decreased in PV samples, and 
TFDP1 which acts as a cofactor for E2F in the regulation of EZH2219, which was 
increased. Interestingly TFDP1, E2F and EZH2 tend to alter in the same way in 
samples with an increase in TFDP1 and E2F leading to an increase in 
transcription of EZH2, so the lack of change in EZH2 suggests that, although there 
is an increase in TFDP1, E2F expression may be unaffected. This might be an 
interesting pathway to investigate further in more immature cells, as it is important 
in the production of proteins necessary for the transition into S phase219,220. As a 
result, the abnormality in terminally differentiated peripheral blood cells may not 
give an adequate assessment of the role of these genes in the more primitive stem 
cell population which sustains the disease. 
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Figure 4.4 Transcriptional regulation in PV  
 
Fluidigm® quantitative real time PCR was carried out on RNA extracted from PV PB 
MNCs. The fold change compared to normal was calculated using the 2-ΔΔCT 
method. The data points were then graphed using GraphPad Prism 6 and a two 
tailed Students t-test was used to calculate significance (* p ≤ 0.05, ** p ≤ 0.01, *** p 
≤ 0.001). The two dotted lines indicate a 2- fold change from the control, indicated 
by the dashed line. 
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The expression of cell cycle genes in PV patient samples was unexpectedly 
reduced in most cases. This is likely to represent the effect of hydroxycarbamide 
on these genes, which all patients were taking. Even though these are mature 
cells they still have the capacity to proliferate (T & B cells) and undergo terminal 
differentiation (monocytes), therefore these genes are still expressed in normal PB 
MNCs and were reduced in PV samples (Figure 4.5). Hydroxycarbamide controls 
peripheral counts in people with myeloproliferative neoplasms by decreasing the 
production of deoxyribonucleic acids through inhibiton of ribonuclease reductase. 
This leads to a reduction in the rate of DNA synthesis and cell division, 
predominantly in rapidly dividing cells, and therefore inhibiting cell division. This 
inhibition of cell division would be expected to reduce the Aurora kinases, which 
are involved in spindle formation and mitosis, and regulators of the various stages 
of cell cycle. It would be interesting to collect samples from patients at diagnosis, 
prior to initiation of therapy, to compare to these results. 
Figure 4.5 Cell cycle in PV 
 
Fluidigm® quantitative real-time PCR was carried out on RNA extracted from PV PB 
MNCs. The fold change compared to normal was calculated using the 2-ΔΔCT 
method. The data points were then graphed using GraphPad Prism 6 and a two 
tailed Students t-test was used to calculate significance (* p ≤ 0.05, ** p ≤ 0.01, *** p 
≤ 0.001). The two dotted lines indicate a 2- fold change from the control, indicated 
by the dashed line. 
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Inflammation in PV has been a focus of research over the recent past to try and 
elucidate the role it plays in the presentation and progression of disease, as well 
as its place in the development of complications such as thrombosis and 
secondary malignancies152,221. The cause of the inflammation appears to be 
multifactorial, with reported alterations in inflammatory cytokines, neutrophil 
production of ROS and alteration of the interaction of platelets with the vascular 
endothelium.  
The expression of interferon-associated genes was variable between samples. 
Interestingly, consistent alterations include IRF6, IRF7 and PML which showed 
significant changes and an average of at least 2-fold alteration from normal. The 
role of IRF6 is not clearly elucidated, but is likely to be involved in Toll-like receptor 
signalling, while IRF7 is involved in the transcription of type I interferons and plays 
an essential role in the amplification of their signalling222,223. 
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Figure 4.6 Inflammation in PV 
 
Fluidigm® quantitative real-time PCR was carried out on RNA extracted from PV PB 
MNCs. The fold change compared to normal was calculated using the 2-ΔΔCT 
method. The data points were then graphed using GraphPad Prism 6 and a two 
tailed Students t-test was used to calculate significance (* p ≤ 0.05, ** p ≤ 0.01, *** p 
≤ 0.001). The two dotted lines indicate a 2- fold change from the control, indicated 
by the dashed line. 
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4.2.2 Dose finding of JAK2 inhibitors for UKE1 and SET2 cells 
Following the interesting results seen in the gene expression of PV patients, we 
decided to look at the effect of JAK2 inhibition on the activity of two JAK2 V617F 
cell lines, UKE1 and SET2. Both cell lines were created from patients with JAK2 
V617F positive ET who developed secondary AML, but, unusually, on 
transformation they retained the JAK2 V617F abnormality in the AML clone. As for 
K562 cells, the XTT metabolic assays were used to identify a range of doses for 
ruxolitinib, TG101209 and AT9283 (Figure 4.7), which were then carried forward 
into trypan blue exclusion testing. The trypan blue exclusion tests were then 
carried out at 24, 48 and 72 hours and the IC50 dose calculated based on these 
results. In addition, XTT assays were carried out using ATO, which causes PML to 
undergo SUMOylation and subsequent degradation, to identify a dose affecting 
the cellular growth to be used in combination studies. Following identification of 
the IC50, a lower and higher dose were identified that resulted in an alteration in 
cell counts at 72 hours, but had live cells present at 24 hours which could then be 
analysed for changes in gene and protein expression using Western blotting and 
immunofluorescence techniques. 
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Figure 4.7 XTT assays of JAK2 inhibitors and arsenic trioxide in UKE1 cells 
 
XTT assays were carried out in 4 simultaneous wells with the mean plotted in the 
above graphs +/-standard deviation. The solid line indicates the dose of inhibitor 
necessary to reduce the metabolic activity by 50%.  The no drug control is indicated 
by the first plot point at the Y axis. 
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Figure 4.8 XTT assays of JAK2 inhibitors and arsenic trioxide in SET2 cells 
 
XTT assays were carried out in 4 simultaneous wells with the mean plotted in the 
above graphs +/-standard deviation. The solid line indicates the dose of inhibitor 
necessary to reduce the metabolic activity by 50%.  The no drug control is indicated 
by the first plot point by the Y axis. 
Table 4.1 Doses chosen for further experiments with UKE1 and SET2 cells 
following trypan blue exclusion counting 
Cell line Ruxolitinib TG101209 AT9283 Arsenic trioxide 
UKE1 250nM 
750nM 
1000nM 
250nM 
700nM 
1000nM 
10nM 
15nM 
30nM 
2000nM 
SET2 50nM 
100nM 
200nM 
100nM 
250nM 
500nM 
10nM 
25nM 
50nM 
2000nM 
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4.2.3 Western blots 
The activity of the JAK2 inhibitors in UKE1 and SET2 cells were assessed by 
Western blotting. Antibodies to downstream proteins were used to evaluate the 
relative levels present in a cohort of samples. UKE1 cells were treated with each 
JAK2 inhibitor at three doses before having protein extracted and run on 
polyacrylamide gels. Following transfer to a nitrocellulose membrane the samples 
were probed for STAT1 and STAT5 in both the phosphorylated and 
unphosphorylated state, with SHPTP2 being used to confirm equal loading. 
Interestingly, at 24 hours there was a marked increase in the levels of phospho-
STAT1 and phospho-STAT5 following treatment with ruxolitinib compared to 
untreated cells. This seemed to be most pronounced in the lower doses of 
ruxolitinib, which may be due to the ability of the cells to overcome the inhibitory 
effect of the ruxolitinib more easily leading to a rebound overactivity of the 
pathway. There was also a reduction in the level of STAT1 in cells treated with 
ruxolitinib at the higher doses, with an associated reduction in the level of 
phospho-STAT1, while there is an increase in the level of phospho-STAT1 when 
cells are treated with ruxolitinib at 250nM without any alteration in the level of total 
STAT1 when compared to untreated cells. There is also an increase in the level of 
phospho-STAT5 in cells treated with TG101209, which appears consistent at all 
doses assessed, when compared to untreated cells. Treatment of cells with 
AT9283 appeared to lead to little alteration in phospo-STAT1 or phospho-STAT5 
levels. 
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Figure 4.9 Western blotting of UKE1 cells treated with JAK2 inhibitors at 24 
hours 
 
Protein samples were obtained from UKE1 cells following 24 hours of culture in 
media alone or supplemented with increasing doses of ruxolitinib, TG101209 or 
AT9283. The lysates were then run according to the protocol described previously 
(2.4.4.2). The nitrocellulose membranes were then probed using antibodies to the 
proteins indicated above and detected using HRP-conjugated antibodies. Equal 
protein loading of the samples was ensured by probing for SHPTP2. Three 
independent experiments were carried out with this image being representative of 
these. 
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Based on these appearances we looked at the effect of ruxolitinib on cells over a 
24 hour period. This showed that the effect of ruxolitinib on STAT5 
phosphorylation was relatively short lived with phospho-STAT5 only reducing from 
baseline for between 4 and 8 hours, returning to baseline signal by 8 hours of 
treatment and increasing to above the baseline signal for untreated cells by 24 
hours. 
Figure 4.10 Western blotting of UKE1 cells treated with ruxolitinib over 24 
hours 
  
Protein samples were obtained from UKE1 cells following 24 hours of culture in 
media alone or supplemented with increasing doses of ruxolitinib, TG101209 or 
AT9283. The lysates were then run according to the protocol described previously 
(2.4.4.2). The nitrocellulose membranes were then probed using antibodies to the 
proteins indicated above and detected using HRP-conjugated antibodies. Three 
independent experiments were carried out with this image being representative of 
these. 
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A similar, but less pronounced effect is seen in SET2 cells treated with JAK2 
inhibitors for 24 hours, with little alteration in STAT1 or STAT5 phosphorylation 
with AT9283 and an increase in STAT5 phosphorylation with ruxolitinib. The effect 
on phosphorylation of STAT1 was less clear as it proved difficult to get clear 
images despite short exposure times.  
Figure 4.11 Western blotting of SET2 cells treated with JAK2 inhibitors at 24 
hours 
 
Protein samples were obtained from SET2 cells following 24 hours of culture in 
media alone or supplemented with increasing doses of ruxolitinib, TG101209 or 
AT9283. The lysates were then run according to the protocol described previously 
(2.4.4.2). The nitrocellulose membranes were then probed using antibodies to the 
proteins indicated above and detected using HRP-conjugated antibodies. Equal 
protein loading of the samples was ensured by probing for SHPTP2. Three 
independent experiments were carried out with this image being representative of 
these. 
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Again samples were taken over a 24 hour period after treatment with ruxolitinib, 
and showed an even shorter effect of JAK2 inhibition in SET2 cells compared to 
UKE1 cells with recovery of STAT5 phosphorylation to baseline by 4 hours and an 
increase at 24 hours.  
Figure 4.12 Western blotting of SET2 cells treated with ruxolitinib over 24 
hours 
 
Protein samples were obtained from SET2 cells following 24 hours of culture in 
media alone or supplemented with increasing doses of ruxolitinib, TG101209 or 
AT9283. The lysates were then run according to the protocol described previously 
(2.4.4.2). The nitrocellulose membranes were then probed using antibodies to the 
proteins indicated above and detected using HRP-conjugated antibodies. Three 
independent experiments were carried out with this image being representative of 
these. 
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4.2.4 Gene expression of UKE1 cells treated with JAK2 
inhibitors 
UKE1 cells were treated for 24 hours with concentration of each inhibitor indicated 
above (Figure 4.7). RNA was then processed to prepare for Fluidigm® real-time 
PCR as described previously (Section 2.4.3). With UKE1 cells, 86 genes were 
analysed for each of the 3 JAK2 inhibitors. The heat map demonstrates that 
treatment with JAK2 inhibitors results in an alteration of the gene expression in 
UKE1 cells. Genes which failed to be expressed by Fluidigm, either in the 
treatment groups or in the control cells were removed. This leaves 81 genes which 
were mapped for alterations in the expression following treatment with the 
previously used JAK2 inhibitors. The heatmaps show that the gene expression of 
several key pathways are altered following treatment with JAK2 inhibitors. 
Treatment with ruxolitinib and TG101209 results in a similar pattern of alteration in 
UKE1 cells compared to treatment with AT9283.  
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Figure 4.13 Gene expression heat map of UKE1 cells treated with JAK2 
inhibitors 
 
 
Using the data from the microarrays, genes were selected and primers designed to 
look at JAK2 dependent genes and the interferon response (Table 2.2.4.8). Fluidigm 
quantitative real-time PCR was performed and the relative expression of the genes 
compared to no drug controls was calculated using the 2-ΔΔCT method. A base 10 
logarithmic transformation was then performed and this data was entered in to 
PermutMatrix to generate a heatmap representation of the gene expression of UKE1 
cells treated with JAK2 inhibitors.  
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Examining the analysed data of UKE1 cells treated with each of the JAK2 
inhibitors separately, the significant alterations in gene expression achieved by the 
highest dose of each inhibitor were graphed below (Figure 4.14). Treatment with 
ruxolitinib leads to alterations in the expression of genes over a range of cellular 
processes. The cell cycle genes AURA and CCNA2 were reduced in patient 
samples and are also further decreased following treatment of cell lines with 
ruxolitinib and TG101209, which supports the hypothesis that these changes in the 
patient samples are mediated by hydroxycarbamide. Interestingly, the increase in 
TFDP1 in patient samples is reversed following treatment of UKE1 cells with both 
ruxolitinib and TG101209 (Figures 4.14 and 4.15).  
In cytokine signalling, TG101209 appears to have a broader effect on the gene 
expression than ruxolitinib, but both affect STAT1 which is a key regulator of 
interferon signalling. In addition to this, the clear reduction in the STAT target gene 
PIM1 is in keeping with a reduction in the activity of the STAT proteins following 
JAK2 inhibition. This sustained alteration of gene expression is not in keeping with 
the changes seen in Western blotting where the effect of JAK2 inhibitors on 
phosphorylation of the STAT proteins appears to be relatively short lived. 
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Figure 4.14 Gene expression of UKE1 cells following treatment with 
ruxolitinib 
 
Fluidigm® quantitative real time PCR was carried out on RNA extracted from UKE1 
cells treated with ruxolitinib 1000nM for 24 hours. The fold change compared to 
untreated samples was calculated using the 2-ΔΔCT method. The data points were 
then graphed using GraphPad Prism 6 and a two tailed Students t-test was used to 
calculate significance (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001). The two dotted lines 
indicate a 2- fold change from the control, indicated by the dashed line. 
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Figure 4.15 Gene expression of UKE1 cells following treatment with 
TG101209 
 
Fluidigm® quantitative real time PCR was carried out on RNA extracted from UKE1 
cells treated with TG101209 1000nM for 24 hours. The fold change compared to 
untreated samples was calculated using the 2-ΔΔCT method. The data points were 
then graphed using GraphPad Prism 6 and a two tailed Students t-test was used to 
calculate significance (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001). The two dotted lines 
indicate a 2- fold change from the control, indicated by the dashed line. 
In contrast to the wide ranging effects of AT9283 on K562 cells the effects on 
UKE1 cells is very limited. The reason for this is unclear as the doses used 
resulted in marked reduction in the viability of cells and would be expected to 
result in significant alterations in various critical pathways in cellular functioning 
(Figure 4.16). The expression of IFNAR1 and NOLA were stastically significant 
following treatment with AT9283, but the alteration from baseline was minimal 
suggesting there was no real change compared to untreated cells.  
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Figure 4.16 Gene expression of UKE1 cells following treatment with AT9283 
 
Fluidigm® quantitative real time PCR was carried out on RNA extracted from UKE1 
cells treated with AT9283 30nM for 24 hours. The fold change compared to 
untreated samples was calculated using the 2-ΔΔCT method. The data points were 
then graphed using GraphPad Prism 6 and a two tailed Students t-test was used to 
calculate significance (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001).   
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4.2.5 Gene expression of SET2 cells treated with JAK2 
inhibitors 
Based on the experiments carried out with PV PB MNCs and UKE1 cells, a more 
limited gene expression panel was investigated with SET2 cells. A selection of 41 
genes were assessed and the results shown in the heatmap below (Figure 4.17) 
The changes induced in SET2 cells following JAK2 inhibition again cover a range 
of genes representing many aspects of cellular functions including cell cycle, 
transcriptional regulation and apoptosis. 
Figure 4.17 Gene expression heat map of SET2 cells treated with JAK2 
inhibitors 
 
Using the data from the microarrays, genes were selected and primers designed to 
look at JAK2-dependent genes and the interferon response (Table 2.2.4.8). Fluidigm 
quantitative real time PCR was performed and the relative expression of the genes 
compared to no drug controls was calculated using the 2-ΔΔCT method. A base 10 
logarithmic transformation was then performed and this data was entered in to 
PermutMatrix to generate a heatmap representation of the gene expression of SET2 
cells treated with JAK2 inhibitors. 
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The gene expression alterations in SET2 cells treated with the highest dose of 
each inhibitor were then graphed. Treating SET2 cells with ruxolitinib or TG101209 
led to reductions in the expression of STAT1 when compared to untreated cells. 
This reverses the increase seen in PV PB MNCs and matches the reduction seen 
following treatment of UKE1 cells with the same inhibitors.  
The reduction of UBA2, part of the E1 ligase complex in SUMOylation, following 
treatment with ruxolitinib or TG101209 has not been previously described. The 
SUMO system is known to play an important role in the regulation of JAK/STAT 
pathway, with several proteins undergoing post-translational SUMOylation78,224. 
Additionally SUMOylation plays an important role in many pathways and is a key 
component for bringing proteins in to PML nuclear bodies. Therefore the reduction 
of E1 ligase capability would have wide ranging and complex effects on the cell, 
and may play a role in the effect JAK2 inhibitors have on the interaction of JAK2 
and PML within the nuclear bodies.  
Figure 4.18 Gene expression of SET2 cells following treatment with 
ruxolitinib 
 
Fluidigm® quantitative real-time PCR was carried out on RNA extracted from SET2 
cells treated with ruxolitinib 200nM for 24 hours. The fold change compared to 
untreated samples was calculated using the 2-ΔΔCT method. The data points were 
then graphed using GraphPad Prism 6 and a two tailed Students t-test was used to 
calculate significance (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001). The two dotted lines 
indicate a 2- fold change from the control, indicated by the dashed line. 
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Figure 4.19 Gene expression of SET2 cells following treatment with 
TG101209 
 
Fluidigm® quantitative real time PCR was carried out on RNA extracted from SET2 
cells treated with TG101209 500nM for 24 hours. The fold change compared to 
untreated samples was calculated using the 2-ΔΔCT method. The data points were 
then graphed using GraphPad Prism 6 and a two tailed Students t-test was used to 
calculate significance (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001). The two dotted lines 
indicate a 2- fold change from the control, indicated by the dashed line. 
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SET2 cells treated with AT9283 showed few significant alterations in gene 
expression, but did have a similar effect on EGR1 to that seen in SET2 cells 
treated with ruxolitinib. The reduction in EGR1 following JAK2 inhibition suggests 
that the increase seen in PB MNCs is a direct effect of the over-activity of JAK2 
signalling. 
Figure 4.20 Gene expression of SET2 cells following treatment with AT9283 
 
Fluidigm® quantitative real-time PCR was carried out on RNA extracted from SET2 
cells treated with AT9283 50nM for 24 hours. The fold change compared to 
untreated samples was calculated using the 2-ΔΔCT method. The data points were 
then graphed using GraphPad Prism 6 and a two tailed Students t-test was used to 
calculate significance (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001). The two dotted lines 
indicate a 2- fold change from the control, indicated by the dashed line. 
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4.2.6 Apoptosis is increased in UKE1 cells following treatment 
with JAK2 inhibitors 
Again to assess the functional significance of the gene expression data, UKE1 
cells were cultured in the presence of each of the JAK2 inhibitors for 24, 48 and 72 
hours before being assessed for the degree of apoptosis induced. Table 4.2 
shows the changes seen at 24 and 48 hours following treatment with the three 
inhibitors. Interestingly, in this cell line, there are significant alterations in the 
percentage of live cells within 24 hours with some clear evidence of induction of 
apoptosis. This is more marked by 48 hours and there is a further increase by 72 
hours. Despite little effect on the expression of apoptotic genes in cells treated 
with AT9283, there is a clear and marked increase in apoptosis with this treatment, 
suggesting the alterations are either at a protein level, or the genes affected are 
not the ones looked at above. The reason for this may be that the genes that were 
altered by AT9283 were not investigated in this study. However, in the ruxolitinib 
and TG101209 treated cells the increase in apoptosis is in keeping with the 
reduction of the anti-apoptotic MCL1 seen in both these treatment groups.  
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Table 4.2 Apoptosis at 24 and 48 hours in UKE1 cells treated with JAK2 
inhibitors 
24 hours Live +/- Early +/- Late +/- Dead +/- 
NDC 83.3% 0.9 12.6% 1.2 3.6% 0.4 0.5% 0.1 
Ruxolitinib 250nM 83.7% 0.5 11.7% 1.3 3.9% 0.8 0.7% 0.3 
Ruxolitinib 750nM 81.0% 0.8 13.0% 1.5 5.0% 0.8 1.0% 0.2 
Ruxolitinib 1000nM 65.6% 1.7 23.6% 2.2 9.1% 1.2 1.7% 0.3 
TG101209 250nM 80.3% 3.1 13.3% 2.4 5.6% 1.7 0.8% 0.1 
TG101209 700nM 76.6% 1.1 15.1% 1.7 7.6% 1.7 0.8% 0.1 
TG101209 1000nM 74.7% 1.8 17.3% 1.9 7.4% 2.0 0.6% 0.1 
AT9283 10nM 81.1% 2.1 12.4% 2.3 5.4% 1.1 1.1% 0.4 
AT9283 15nM 70.4% 1.6 17.2% 2.3 11.3% 1.9 1.2% 0.5 
AT9283 30nM 64.0% 1.0 20.8% 3.7 13.9% 2.4 1.3% 0.4 
 
48 hours Live +/- Early +/- Late +/- Dead +/- 
NDC 81.9% 0.3 13.2% 1.0 4.5% 0.6 0.5% 0.1 
Ruxolitinib 250nM 76.9% 3.6 13.8% 2.6 7.5% 1.2 1.8% 0.9 
Ruxolitinib 750nM 63.4% 5.2 18.5% 4.0 14.6% 1.9 3.6% 1.7 
Ruxolitinib 1000nM 57.0% 4.7 25.2% 3.2 16.4% 2.6 1.4% 0.1 
TG101209 250nM 78.4% 3.1 12.4% 2.5 7.3% 0.8 1.9% 1.0 
TG101209 700nM 56.3% 3.8 20.5% 4.4 20.1% 0.7 3.1% 0.7 
TG101209 1000nM 39.1% 2.8 25.4% 5.0 30.9% 1.2 4.6% 0.9 
AT9283 10nM 82.1% 1.3 12.6% 1.6 4.4% 0.5 0.9% 0.1 
AT9283 15nM 75.1% 4.0 14.7% 2.8 7.5% 1.2 2.6% 0.8 
AT9283 30nM 44.5% 4.3 31.8% 3.0 20.3% 2.3 3.3% 1.0 
The tables show the percentage of events analysed by FACS for Annexin V and 
7AAD in each of the four quadrants equating to the live cell population, those cells 
undergoing the early and late stages of apoptosis and dead cells (Figure 2.2). The 
SEM is in the column to the right of each condition (n=3). Statistical analysis was by 
two-way ANOVA with Tukeys post-test correction. Significant changes compared to 
NDC are highlighted in red (p ≤ 0.05). NDC; no drug control. 
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Figure 4.21 Apoptosis in UKE1 cells treated with ruxolitinib 
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The dot plots show representative results from the apoptosis assay by FACS. The 
bar graphs show the changes in live cells, early and late apoptosis, and dead cells 
treated with ruxolitinib at 72 hours presented as the mean +/- SEM (n=3). Statistical 
significance was determined by two-way ANOVA with Tukey’s post-test correction 
for multiple comparisons (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001). The tables show the 
significance of each comparison for each stage of apoptosis. 
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Figure 4.22 Apoptosis in UKE1 cells treated with TG101209 
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The dot plots show representative results from the apoptosis assay by FACS. The 
bar graphs show the changes in live cells, early and late apoptosis, and dead cells 
treated with ruxolitinib at 72 hours presented as the mean +/- SEM (n=3). Statistical 
significance was determined by two-way ANOVA with Tukey’s post-test correction 
for multiple comparisons (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001). The tables show the 
significance of each comparison for each stage of apoptosis. 
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Figure 4.23 Apoptosis in UKE1 cells treated with AT9283 
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The dot plots show representative results from the apoptosis assay by FACS. The 
bar graphs show the changes in live cells, early and late apoptosis, and dead cells 
treated with ruxolitinib at 72 hours presented as the mean +/- SEM (n=3). Statistical 
significance was determined by two-way ANOVA with Tukey’s post-test correction 
for multiple comparisons (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001). The tables show the 
significance of each comparison for each stage of apoptosis. 
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4.2.7 Apoptosis is increased in SET2 cells following treatment 
with JAK2 inhibitors 
The effect of the three JAK2 inhibitors was then investigated in the SET2 cell line. 
The gene expression changes were more limited in this setting, but treatment with 
ruxolitinib did result in a significant decrease in the expression of the anti-apoptotic 
BCL2L1, indicating the effect of JAK2 inhibition in apoptosis programmes in these 
cells.  As with in the UKE1 cells, there are clear decreases in the live cell 
populations with all three inhibitors within 24 hours, which became more 
pronounced with further time spent in culture with the inhibitors. The higher 
concentrations of each inhibitor did have a more pronounced effect with a 
significant reduction in live cells in the highest concentration compared to the 
lowest with all three inhibitors. The marked effect that JAK2 inhibition has on 
apoptosis in these cells is not mirrored in the gene expression changes seen in 
SET2 cells treated with each of the JAK2 inhibitors, with only TG101209 causing a 
significant decrease in the anti-apoptotic BCL2L1. 
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Table 4.3 Apoptosis at 24 and 48 hours in SET2 cells treated with JAK2 
inhibitors 
24 hours Live +/- Early +/- Late +/- Dead +/- 
NDC 77.3% 1.1 9.4% 0.3 12.5% 1.6 0.7% 0.1 
Ruxolitinib 50nM 78.2% 1.7 8.5% 0.4 12.4% 1.4 1.0% 0.2 
Ruxolitinib 100nM 74.2% 1.5 10.4% 0.4 14.5% 1.4 0.9% 0.4 
Ruxolitinib 200nM 73.1% 1.8 9.9% 1.1 15.6% 1.3 1.4% 0.1 
TG101209 100nM 75.6% 2.4 11.2% 1.3 12.5% 1.8 0.6% 0.8 
TG101209 250nM 69.0% 1.9 13.6% 1.1 16.5% 2.2 0.9% 0.2 
TG101209 500nM 60.2% 2.6 15.7% 1.6 22.3% 2.8 1.9% 0.8 
AT9283 10nM 74.2% 1.9 12.7% 1.1 12.6% 1.9 0.5% 1.7 
AT9283 25nM 70.7% 1.5 12.6% 2.7 15.5% 2.2 1.1% 1.3 
AT9283 50nM 68.0% 2.7 14.6% 1.0 16.7% 4.5 0.7% 2.6 
 
48 hours Live +/- Early +/- Late +/- Dead +/- 
NDC 83.2% 0.8 4.3% 1.3 9.9% 0.7 2.6% 0.5 
Ruxolitinib 50nM 73.1% 1.8 7.1% 1.8 17.2% 2.6 2.6% 0.9 
Ruxolitinib 100nM 71.9% 0.9 4.0% 3.7 18.6% 2.0 5.5% 1.2 
Ruxolitinib 200nM 62.0% 0.9 5.2% 3.7 24.5% 3.9 8.3% 1.0 
TG101209 100nM 81.1% 0.8 2.5% 1.0 11.3% 2.4 5.1% 1.9 
TG101209 250nM 71.7% 3.9 3.9% 4.7 17.5% 0.8 6.8% 1.4 
TG101209 500nM 49.7% 1.9 4.8% 4.9 30.7% 3.1 14.9% 0.5 
AT9283 10nM 80.6% 5.2 2.2% 4.0 10.5% 2.5 6.7% 1.6 
AT9283 25nM 68.5% 4.1 4.2% 3.9 19.1% 2.3 8.2% 1.8 
AT9283 50nM 61.7% 5.0 6.5% 3.6 23.2% 3.4 8.5% 1.3 
The tables show the percentage of events analysed by FACS for Annexin V and 
7AAD in each of the four quadrants on the equating to the live cell population, 
those cells undergoing the early and late stages of apoptosis and dead cells. The 
SEM is in the column to the right of each condition (n=3). Statistical analysis was by 
two-way ANOVA with Tukeys post-test correction. Significant changes compared to 
NDC are highlighted in red (p ≤ 0.05). 
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Figure 4.24 Apoptosis in SET2 cells treated with ruxolitinib 
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The dot plots show representative results from the apoptosis assay by FACS. The 
bar graphs show the changes in live cells, early and late apoptosis, and dead cells 
treated with ruxolitinib at 72 hours presented as the mean +/- SEM (n=3). Statistical 
significance was determined by two-way ANOVA with Tukey’s post-test correction 
for multiple comparisons (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001). The tables show the 
significance of each comparison for each stage of apoptosis. 
169 
 
Figure 4.25 Apoptosis in SET2 cells treated with TG101209 
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The dot plots show representative results from the apoptosis assay by FACS. The 
bar graphs show the changes in live cells, early and late apoptosis, and dead cells 
treated with ruxolitinib at 72 hours presented as the mean +/- SEM (n=3). Statistical 
significance was determined by two-way ANOVA with Tukey’s post-test correction 
for multiple comparisons (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001). The tables show the 
significance of each comparison for each stage of apoptosis. 
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Figure 4.26 Apoptosis in SET2 cells treated with AT9283 
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The dot plots show representative results from the apoptosis assay by FACS. The 
bar graphs show the changes in live cells, early and late apoptosis, and dead cells 
treated with ruxolitinib at 72 hours presented as the mean +/- SEM (n=3). Statistical 
significance was determined by two-way ANOVA with Tukey’s post-test correction 
for multiple comparisons (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001). The tables show the 
significance of each comparison for each stage of apoptosis. 
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4.2.8 Cell cycle is altered in UKE1 cells following treatment with 
JAK2 inhibitors 
In JAK2 V617F mutated myeloproliferative neoplasms the cell cycle is deregulated 
with an increase in cell cycle in the malignant clone, giving it a survival advantage 
over normal cells. Interestingly, this advantage appears to emerge as the cells 
proliferate and mature rather than at the stem cell level. When the JAK2 V617F 
mutated UKE1 cells are treated with the JAK2 inhibitor ruxolitinib there was no 
significant change in any stage of the cell cycle when compared to untreated cells. 
However both TG101209 and AT9283 produced a significant alteration in cell 
cycle with the highest dose used compared to other treatment arms. Of interest is 
the fact that AT9283 did not disrupt the cell cycle analysis to the point where no 
useful data was obtained as seen in K562 cells (Figure 3.20). This would suggest 
the Aurora kinase effect is less marked with the doses used in this cell line, than in 
K562 cells, where a higher dose of AT9203 was used. However the alteration 
seen led to an increase in S-G2-M which may still reflect a degree of Aurora 
kinase activity and an accumulation of multinucleate cells. 
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Figure 4.27 Cell cycle analysis of UKE1 cells following treatment with 
ruxolitinib 
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The histogram plots show representative results from FACS and show the gating 
strategy used. The bar graphs show the changes in cell cycle following treatment 
with ruxolitinib for 72 hours, highlighting those actively undergoing cell cycle (S-
G2-M) and those that are quiescent (G0-G1). They are presented as the mean +/- 
SEM (n=3). Statistical significance was determined by two-way ANOVA with Tukey’s 
post-test correction for multiple comparisons (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, 
**** p ≤ 0.0001).. 
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Figure 4.28 Cell cycle analysis of UKE1 cells following treatment with 
TG101209 
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The histogram plots show representative results from FACS and show the gating 
strategy used. The bar graphs show the changes in cell cycle following treatment 
with ruxolitinib for 72 hours, highlighting those actively undergoing cell cycle (S-
G2-M) and those that are quiescent (G0-G1). They are presented as the mean +/- 
SEM (n=3). Statistical significance was determined by two-way ANOVA with Tukey’s 
post-test correction for multiple comparisons (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, 
**** p ≤ 0.0001).. 
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Figure 4.29 Cell cycle analysis of UKE1 cells following treatment with 
AT9283 
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The histogram plots show representative results from FACS and show the gating 
strategy used. The bar graphs show the changes in cell cycle following treatment 
with ruxolitinib for 72 hours, highlighting those actively undergoing cell cycle (S-
G2-M) and those that are quiescent (G0-G1). They are presented as the mean +/- 
SEM (n=3). Statistical significance was determined by two-way ANOVA with Tukey’s 
post-test correction for multiple comparisons and defined as * p≤0.05 ** p≤0.01. 
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4.2.9 Cell cycle is altered in SET2 cells following treatment with 
JAK2 inhibitors 
SET2 cells treated with each of the JAK2 inhibitors showed a clear G0-G1 arrest 
when treated with ruxolitinib or TG101209 at all doses compared to untreated 
cells. This pattern is more in keeping with published data where treatment of the 
JAK2 V617F containing erythroleukaemia cell line HEL with TG101209 induced a 
G0-G1 arrest, which was mimicked to a lesser degree in K562 cells used as a 
comparator in that paper193. This second finding was not replicated in K562 cells 
treated with TG101209 in our study (Figure 3.19). The expression data for these 
cells did not show any specific changes in cell cycle genes at 24 hours, but this 
would not preclude a cumulative effect over a 72 hour period leading to the 
changes seen in cell cycle here. Interestingly, the SET2 cells treated with AT9283 
had a similar appearance to that seen in K562 cells making it difficult to draw any 
meaningful conclusions in this cell type. The reason for this is not entirely clear, as 
the doses used in SET2 cells are similar to those used in UKE1 cells, but may 
represent a greater sensitivity in SET2 cells to the Aurora kinase activity of 
AT9283 compared to UKE1 cells. 
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Figure 4.30 Cell cycle analysis of SET2 cells following treatment with 
ruxolitinib 
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The histogram plots show representative results from FACS and show the gating 
strategy used. The bar graphs show the changes in cell cycle following treatment 
with ruxolitinib for 72 hours, highlighting those actively undergoing cell cycle (S-
G2-M) and those that are quiescent (G0-G1). They are presented as the mean +/- 
SEM (n=3). Statistical significance was determined by two-way ANOVA with Tukey’s 
post-test correction for multiple comparisons (* p≤0.05, ** p≤0.01, *** p≤0.001, **** 
p≤0.0001). 
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Figure 4.31 Cell cycle analysis of SET2 cells following treatment with 
TG101209 
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The histogram plots show representative results from FACS and show the gating 
strategy used. The bar graphs show the changes in cell cycle following treatment 
with ruxolitinib for 72 hours, highlighting those actively undergoing cell cycle (S-
G2-M) and those that are quiescent (G0-G1). They are presented as the mean +/- 
SEM (n=3). Statistical significance was determined by two-way ANOVA with Tukey’s 
post-test correction for multiple comparisons (* p≤0.05, ** p≤0.01, *** p≤0.001, **** 
p≤0.0001). 
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Figure 4.32 Cell cycle analysis of SET2 cells following treatment with AT9283 
 
The histogram plots show representative results from the PI staining and FACS 
analysis. When the normal gating strategy was applied it was difficult to extract any 
meaningful data from cells treated with AT9283. 
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4.2.10 Immunofluorescence of UKE1 cells following treatment 
with JAK2 inhibitors or IFN-γ 
Previous studies have shown that in CD34+ve cells the JAK2 V617F mutation 
accumulates preferentially in the nucleus compared to wild type JAK2225. This is 
supported by further data showing that JAK2 needs to be active and 
phosphorylated before SUMO proteins can attach and give the protein the ability 
to enter the nucleus78, and that the JAK2 V617F mutant can be SUMOylated and 
enter the nucleus. This combination of constitutive activation of JAK2 and the 
SUMOylation of phosphorylated JAK2 leads to the preferential entry of the JAK2 
V617F mutant into the nucleus of CD34+ve cells. Interestingly, this increase of 
JAK2 V617F in the nucleus was not seen in lineage-committed fractions of bone 
marrow cells225.  
UKE1 cells were cultured for 24 hours with ruxolitinib, TG101209 or IFNγ, used as 
a positive control of JAK2 activation in inflammation, before being processed for 
immunofluorescence or Duolink® immunofluorescent co-localisation assay. The 
immunofluorescence shows the presence of PML within the nuclear bodies, and 
SUMO 2/3 predominantly in the cytoplasm, but also existing within the nucleus in 
discrete structures. JAK2 follows a similar pattern in UKE1 cells, with 
predominantly cytoplasmic localisation, but also discrete punctate localisation 
within the nucleus (Figure 4.33). 
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Figure 4.33 Immunofluorescence of UKE1 cells following treatment with 
JAK2 inhibitors or IFN-γ 
a) UKE1 cells probed for JAK2 and PML 
 
b) UKE1 cells probed for JAK2 and SUMO 2/3 
 
UKE1 cells were treated for 24 hours then prepared for immunofluorescence as 
described previously. 3 separate experiments were carried out and representative 
images are shown above with cells being assessed for JAK2 and PML in a) and for 
JAK2 and SUMO in b). 
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Based on the immunofluorescence appearances, Duolink® colocalisation assay 
was carried out to assess the effect of JAK2 inhibition in UKE1 cells. Unfortunately 
the assay failed in SET2 cells on two separate experiments so results are not 
available for that cell line. As expected, treatment of UKE1 cells with IFNγ led to a 
marked increase in the localisation of JAK2 with both PML and SUMO2/3. 
Interestingly there is an unexpected increase in the localisation of JAK2 and PML 
following treatment with ruxolitinib, while TG101209 leads to a reduction in the 
localisation of JAK2 and SUMO2/3 (Figure 4.34b). The increase seen in the 
localisation following treatment with ruxolitinib is not what would be expected 
following inhibition of JAK2, but was consistent across each experiment.  
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Figure 4.34 Duolink co-localisation assay in UKE1 cells treated with JAK2 
inhibitors 
a) Duolink co-localisation images 
 
b) Corrected total cell fluorescence 
 
UKE1 cells were treated for 24 hours then prepared for Duolink immunofluorescent 
co-localisation assay as described previously. 80 cells were counted for each 
treatment in 3 separate experiments with the corrected total cell fluorescence 
calculated. The images (3a) are representative of the experiments while the graphs 
(3b) show the average of the corrected total cell fluorescence for all 3 experiments 
+/- SEM. AT9283 was not included due to a lack of adherence of sufficient cells for 
analysis. Statistical significance was determined by one way ANOVA with Dunnett’s 
correction for multiple comparisons (* p≤0.05, ** p≤0.01, *** p≤0.001, **** p≤0.0001). 
 
 
 
 
183 
 
4.2.11 Effect of Arsenic trioxide and ruxolitinib on protein 
expression in JAK2 V617F containing cell lines 
After showing the alteration in the interaction of JAK2 and PML following treatment 
with JAK2 inhibitors, we decided to treat UKE1 and SET2 cells with ruxolitinib in 
combination with arsenic trioxide. Arsenic trioxide is used in the treatment of acute 
promyelocytic leukaemia as it causes degradation of the aberrant PML-RARα 
protein through SUMO and ubiquitin mediated processes226. It has been shown 
that arsenic trioxide does the same to normal PML227 and therefore provides a 
useful tool for researching the functional importance of interference with both the 
JAK2 pathway and PML function. To assess the effect of ruxolitinib and arsenic 
trioxide on JAK2 signalling, SET2 cells were treated with each compound alone 
and in combination over a 24 hour time course with samples taken at 0, 1, 4, 8 and 
24 hours. The samples were then probed for phosphorylated and total STAT1 and 
STAT5. This showed the reduction and subsequent increase of phosphorylation of 
the two proteins with ruxolitinib seen previously and a mild reduction in 
phosphorylation of STAT5 with arsenic trioxide compared to untreated cells. This 
effect of arsenic trioxide leads to an attenuation of the ruxolitinib induced increase 
in phospho-STAT5 signal when both compounds are used together. 
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Figure 4.35 Western blotting of SET2 cells treated with ruxolitinib and 
arsenic trioxide alone and in combination over 24 hours 
 
Protein samples were obtained from SET2 cells following 24 hours of culture in 
media alone or supplemented with ruxolitinib and arsenic trioxide alone and in 
combination. The lysates were then run according to the protocol described 
previously (2.4.4.2). The nitrocellulose membranes were then probed using 
antibodies to the proteins indicated above and detected using HRP-conjugated 
antibodies. Equal protein loading of the samples was ensured by probing for β 
actin. Two independent experiments were carried out with this image being 
representative of these. 
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4.2.12 Ruxolitinib in combination with arsenic trioxide increases 
apoptosis in both UKE1 and SET2 cells 
After seeing the effect of ruxolitinib and arsenic trioxide on JAK2 signalling in 
SET2 cells, we went on to see if this had an effect on apoptosis and cell cycle. 
UKE1 cells were treated with the IC50 dose of ruxolitinib (750nM) in combination 
with a clinically achievable dose of arsenic trioxide (2μM)228. After 24 hours, there 
was a significant reduction in live cells treated with ruxolitinib and the combination 
of ruxolitinib and arsenic trioxide compared to untreated cells (Table 4.4). This 
alteration was more marked in the combination treatment than either compound 
alone and also increased with longer treatment, where at 72 hours there was a 
significant reduction in live cells in the combination arm compared to all other 
treatment groups (Figure 4.36). There was also a significant increase in late 
apoptotic cells compared to untreated cells.  
Table 4.4 Apoptosis at 24 and 48 hours in UKE1 cells treated with ruxolitinib 
and arsenic trioxide 
24 hours Live +/- Early +/- Late +/- Dead +/- 
NDC 84.3% 2.4 9.7% 1.3 4.8% 1.0 1.2% 0.7 
Ruxolitinib 750nM 74.8% 4.1 13.8% 1.3 9.4% 2.3 2.0% 0.9 
Arsenic Trioxide 2μM 81.4% 3.6 11.3% 1.7 5.9% 1.6 1.4% 0.3 
Ruxolitinib + Arsenic 69.0% 4.2 17.3% 1.2 10.1% 2.1 3.6% 1.6 
 
48 hours Live +/- Early +/- Late +/- Dead +/- 
NDC 79.5% 2.3 12.3% 1.6 7.0% 0.9 1.2% 0.7 
Ruxolitinib 750nM 69.6% 2.3 13.5% 1.6 10.7% 1.3 6.2% 3.2 
Arsenic Trioxide 2μM 76.9% 3.3 9.6% 2.0 7.3% 0.9 6.2% 3.9 
Ruxolitinib + Arsenic 55.4% 3.9 20.1% 4.4 16.2% 1.5 8.3% 7.1 
The tables show the percentage of events analysed by FACS for Annexin V and 
7AAD in each of the four quadrants which are the live cell population, those cells 
undergoing the early and late stages of apoptosis and dead cells. The SEM is in the 
column to the right of each condition (n=3). Statistical analysis was by two-way 
ANOVA with Tukeys post-test correction. Significant changes compared to NDC are 
highlighted in red (p ≤ 0.05). 
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Figure 4.36 Apoptosis in UKE1 cells treated with ruxolitinib and arsenic 
trioxide 
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The dot plots show representative results from the apoptosis assay by FACS. The 
bar graphs show the changes in live cells, early and late apoptosis, and dead cells 
treated with ruxolitinib and arsenic trioxide alone or in combination at 72 hours 
presented as the mean +/- SEM (n=3). Statistical significance was determined by 
two-way ANOVA with Tukey’s post-test correction for multiple comparisons (* p ≤ 
0.05, ** p ≤ 0.01, *** p ≤ 0.001). The tables show the significance of each comparison 
for each stage of apoptosis. 
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Subsequently SET2 cells were also treated with ruxolitinib at the previously 
identified IC50 dose (100nM) in combination with arsenic trioxide (2μM). This led to 
a significant reduction in live cells with the combination treatment at 24 hours. At 
48 hours (Table 4.5), all treatment groups had a significant reduction in live cells 
and increase in late apoptotic cells compared to the untreated group. At 72 hours, 
the cells treated with both compounds led to a significant decrease in live cells and 
increase in late apoptosis compared to all treatment groups. Each treatment group 
also had a significant reduction in live cells compared to untreated cells (Figure 
4.37).  
Table 4.5 Apoptosis at 24 and 48 hours in SET2 cells treated with ruxolitinib 
and arsenic trioxide 
24 hours Live +/- Early +/- Late +/- Dead +/- 
NDC 77.2% 1.4 12.1% 3.0 10.1% 2.5 0.6% 0.2 
Ruxolitinib 100nM 75.1% 2.1 12.1% 0.9 11.6% 2.8 1.2% 0.5 
Arsenic Trioxide 2μM 73.3% 3.6 12.9% 0.2 12.3% 3.2 1.5% 0.3 
Ruxolitinib + Arsenic 57.3% 2.7 25.4% 1.6 15.8% 3.7 1.6% 0.5 
 
48 hours Live +/- Early +/- Late +/- Dead +/- 
NDC 79.6% 1.4 9.7% 1.7 9.6% 0.7 1.0% 0.2 
Ruxolitinib 100nM 64.3% 2.4 13.7% 2.0 19.8% 0.8 2.3% 0.5 
Arsenic Trioxide 2μM 65.1% 0.9 14.0% 0.8 18.5% 1.2 2.5% 0.3 
Ruxolitinib + Arsenic 35.6% 2.4 22.8% 2.5 37.2% 0.7 4.4% 0.8 
The tables show the percentage of events analysed by FACS for Annexin V and 
7AAD in each of the four quadrants which are the live cell population, those cells 
undergoing the early and late stages of apoptosis and dead cells. The SEM is in the 
column to the right of each condition (n=3). Statistical analysis was by two-way 
ANOVA with Tukeys post-test correction. Significant changes compared to NDC are 
highlighted in red (p ≤ 0.05). 
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Figure 4.37 Apoptosis in SET2 cells treated with ruxolitinib and arsenic 
trioxide 
 
 
 
Live 
   
 
Early 
   
Rux *** 
  
Rux NS 
  
ATO ** NS 
 
ATO NS NS 
 
R+A **** **** **** R+A * NS NS 
  NDC Rux ATO   NDC Rux ATO 
  
Late 
   
Dead 
   
Rux * 
  
Rux NS 
  
ATO NS NS 
 
ATO NS NS 
 
R+A **** **** **** R+A NS NS NS 
  NDC Rux ATO   NDC Rux ATO 
The dot plots show representative results from the apoptosis assay by FACS. The 
bar graphs show the changes in live cells, early and late apoptosis, and dead cells 
treated with ruxolitinib and arsenic trioxide alone or in combination at 72 hours 
presented as the mean +/- SEM (n=3). Statistical significance was determined by 
two-way ANOVA with Tukey’s post-test correction for multiple comparisons (* p ≤ 
0.05, ** p ≤ 0.01, *** p ≤ 0.001). The tables show the significance of each comparison 
for each stage of apoptosis. 
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This shows that the combination of JAK2 inhibition and disruption of PML leads to 
a significant increase in apoptosis and reduced cell survival compared to either 
compound used alone. This interaction has not been previously investigated and 
the combination of two compounds currently in clinical use raises the possibility of 
investigating this further as a therapeutic modality in JAK2 V617F positive disease. 
 
4.2.13 The effect on cell cycle of ruxolitinib and arsenic trioxide 
in combination 
UKE1 and SET2 cells were treated with ruxolitinib and arsenic trioxide alone and 
in combination for 72 hours before being prepared for assessment of cell cycle as 
previously described. In UKE1 cells, there was no significant alteration in cell cycle 
in each of the treatment groups (Figure 4.38). Interestingly, in SET2 cells treated 
with ruxolitinib there was a G0-G1 arrest while the arsenic trioxide treated cells 
had an S-G2-M arrest. When both compounds were used together the two 
treatments appeared to cancel each other out and resulted in no significant 
alteration in cell cycle in the combination treated cells compared to untreated cells, 
but a significant alteration when compared to the cells treated with each 
compound alone (Figure 4.39).  
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Figure 4.38 Apoptosis in UKE1 cells treated with ruxolitinib and arsenic 
trioxide 
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The histogram plots show representative results from FACS and show the gating 
strategy used. The bar graphs show the changes in cell cycle following treatment 
with ruxolitinib for 72 hours, highlighting those actively undergoing cell cycle (S-
G2-M) and those that are quiescent (G0-G1). They are presented as the mean +/- 
SEM (n=3). Statistical significance was determined by two-way ANOVA with Tukey’s 
post-test correction for multiple comparisons (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, 
**** p ≤ 0.0001).. 
191 
 
Figure 4.39 Apoptosis in SET2 cells treated with ruxolitinib and arsenic 
trioxide 
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The histogram plots show representative results from FACS and show the gating 
strategy used. The bar graphs show the changes in cell cycle following treatment 
with ruxolitinib for 72 hours, highlighting those actively undergoing cell cycle (S-
G2-M) and those that are quiescent (G0-G1). They are presented as the mean +/- 
SEM (n=3). Statistical significance was determined by two-way ANOVA with Tukey’s 
post-test correction for multiple comparisons (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, 
**** p ≤ 0.0001). 
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4.2.14 Apoptosis in PV and normal PB MNCs following treatment 
with ruxolitinib and arsenic trioxide 
Based on the findings in cell lines we looked at the effect of ruxolitinib and arsenic 
trioxide treatment in PV and normal MNCs. Given that these cells are terminally 
differentiated, cell cycle was not assessed. At 72 hours treatment, there was 
marked variation between both normal and PV samples, but there was a non-
significant reduction in live cells in all the PV treatment groups compared to 
normal. However the only significant alteration within one group was the reduction 
in live cells in the PV samples treated with ruxolitinib compared to those treated 
with ruxolitinib and arsenic trioxide together (Figure 4.40).  
Figure 4.40 Apoptosis in PV PB MNCs treated with ruxolitinib and arsenic 
trioxide 
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The bar graphs show the changes in live cells, early and late apoptosis, and dead 
cells treated with ruxolitinib and arsenic trioxide alone or in combination at 72 
hours presented as the mean +/- SEM (n=3). Statistical significance was determined 
by two-way ANOVA with Tukey’s post-test correction for multiple comparisons (* p 
≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001). The tables show the significance of each 
comparison for each stage of apoptosis following 72 hours of treatment. 
 
194 
 
4.3 Discussion 
4.3.1 Proliferation and cell cycle in PV 
In JAK2 V617F positive disease there is a proliferation advantage in maturing cells 
leading to expansion of the clone151. This advantage drives the clinical phenotype 
of elevated peripheral counts, with the JAK2 V617F being found in the myeloid 
cells. In normal circumstances the activation of JAK2 leads to a controlled 
signalling cascade that transiently increases the proliferation of cells via the 
Akt/PI3K and Ras/MEK/ERK pathways as well as the actions of STATs178. 
However with the constitutive action conferred by the V617F mutation, there is 
ligand independent activity of these pathways which is not controlled by the 
inhibitory actions of negative regulators178. Of interest is the finding that similar 
pathways are altered by the JAK2 V617F mutation and BCR-ABL, but the clinical 
pictures are different in MPN compared to CML. This may be due to the fact that 
BCR-ABL is an abnormal protein which does not have appropriate negative 
regulation, while JAK2 V617F is an alteration of a normal protein which is still 
subject, to some degree, to normal homeostatic measures to control cytokine 
signalling.  
4.3.2 Apoptosis in PV 
In MPN patients, JAK2 inhibitors are able to improve symptoms, but in the majority 
of patients there is some improvement in disease burden, but there is not 
complete eradication of disease133, suggesting that in patients there is no real 
effect on apoptosis of the diseased cells. The reason for this is not entirely clear, 
but is may relate to the limitations of dose escalation as a result of JAK2 inhibitors 
affecting both normal and mutant JAK2 proteins, although there is more of an 
effect on the mutated protein194. As a result of this, there has been an interest in 
combining JAK2 inhibitors with other pharmacological agents targeting different 
pathways to induce apoptosis of abnormal cells in MPN. Our data shows it is clear 
that combining JAK2 inhibition with disruption of PML leads to a significant 
increase in apoptosis of JAK2 V617F containing cell lines, although this does not 
translate to a significant alteration in PB MNCs of patients with PV when compared 
to normal. However there did appear to be a trend towards an increase in 
apoptosis in terminally differentiated cells here and it would be interesting to see 
how this combination affected more primitive cells containing the JAK2 V617F 
mutation.  
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4.3.3 Inflammation and cytokine driven interferon response in 
PV 
Inflammation in PV has been an area of interest in recent years with increasing 
evidence of abnormal cytokine production leading to chronic inflammation150,4. A 
key driver of chronic inflammation, TNF-α, is elevated in PV, ET and MF, and the 
serum level has been shown to correlate with the JAK2 V617F allele burden151. 
Interestingly colony formation in the presence of TNF-α is reduced in normal 
controls, but JAK2 V617F positive cells are resistant to the suppressive effects of 
TNF-α. In addition to this knocking out TNF-α in a JAK2 V617F positive murine 
model led to attenuation of the MPN disease phenotype suggesting that the MPN 
progenitors gain a survival advantage by the presence of chronic inflammation151.  
Inflammation has also been linked to thrombotic complications in MPN, which is a 
major cause of morbidity and mortality in this patient group229155,230. A 
retrospective analysis of serum markers of inflammation, high sensitivity CRP (hs 
CRP) and pentraxin 3, showed a strong correlation between patients with the 
highest hs CRP and cardiovascular events, a PV phenotype and JAK2 V617F 
allele burden greater than 50%230. Pentraxin 3 was less able to differentiate 
between these feature in PV and ET patients, but lower levels were associated 
with an increased rate of thrombosis. Chronic inflammatory conditions are known 
to cause alterations in endothelial cell function and increase the risk of 
atherosclerotic disease in non-haematological conditions such as rheumatoid 
arthritis153, and in recent years it has become increasingly clear that 
cardiovascular disease is an inflammatory condition in itself231 with much of the 
protective effects of statins coming from an anti-inflammatory effect on the 
endothelium232. This would indicate that other conditions associated with chronic 
inflammation will be associated with an increase in the risk of thrombotic 
disease.In this study there is gene expression data indicating a significant 
alteration of many important regulators of inflammation. Consistent changes were 
seen in the expression of IRF6, IRF7 and PML, but many varied across the patient 
samples assessed. The genes with wide variation between patients may correlate 
with risk of thrombosis and disease progression, but would need to be assessed in 
a much larger patient cohort. 
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4.3.4 The role of PML in cell cycle and apoptosis in PV 
Promyelocytic leukaemia protein is a key component in PML NBs within the 
nucleus, in addition to Sp100 and SUMO proteins207. The NBs are found at 
transcriptionally active sites in the genome233 and appear to act as a hub for 
signalling proteins entering the nucleus to interact with each other158. The proteins 
that localise to the PML NBs are SUMOylated and attach to SUMO-interacting-
motifs (SIMs) within the nuclear body234. Several apoptotic pathways rely on the 
function of PML NBs to potentiate their signals including p53 dependent 
apoptosis162 and FAS ligand signalling235. In addition to this, it links IFN-α 
signalling with the tumour-necrosis factor superfamily, member 10 (TNFSF10) 
pathway236, resulting in a multi-faceted control of apoptosis. PML knockout mice 
have been shown to develop normally, but are resistant to the apoptotic effects of 
TNF-α and have an increased incidence of development of carcinomas and 
lymphomas following exposure to tumour-promoting agents237. 
In addition to the role PML plays in apoptosis, there is also a clear role for PML in 
cell cycle regulation. The expression of PML alters through the cell cycle with entry 
into the cell cycle disrupting the normal NB structure238. This is in keeping with the 
evidence that PML is important in activating p53-mediated cell senescence and 
permanent exit from the cell cycle239. This is achieved by recruiting E2F 
transcription factors into the PML NB and blocking their proliferative role. This 
action was dependent on also recruiting retinoblastoma proteins to the NBs239.  
In this study there was a reduction in the expression of PML at the messenger 
RNA level, however there appeared to be an increase in the interaction of JAK2 
with PML in JAK2 V617F mutation positive PV monocytes compared to normal. 
There is also an alteration in the JAK2 and PML interaction with manipulation of 
JAK2 in JAK2 V617F positive cell lines, with an increase in association following 
treatment with IFN-γ, which was mirrored by an increase in the association of 
JAK2 and SUMO 2/3, and following treatment with ruxolitinib, which was not seen 
in cells assessed for JAK2 and SUMO 2/3 interaction. Interestingly, there was a 
reduction in the association of JAK2 and SUMO 2/3 following treatment with 
TG101209. It would be interesting to further assess this in patient samples and 
investigate if this has a positive of negative effect on apoptosis and cell signalling. 
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5 Delineating the potential mechanisms 
underlying chronic inflammation in 
polycythaemia vera 
5.1 Introduction 
In response to trauma or infection the body has an effective response designed to 
remove and repair damaged or infected tissue. A major component of this is 
inflammation which in normal circumstances will trigger and effect the required 
response needed and contain it within the affected area240. However many 
conditions are associated with an abnormal inflammatory response either locally or 
systemically including cancer241, rheumatological disease153 and atherosclerotic 
disease231. The MPNs have previously been shown to be associated with elevated 
levels of inflammatory cytokines and inflammatory markers, which is worst in 
advanced disease150. This leads to a significant symptomatic burden which is 
poorly managed in clinic at present. The introduction of JAK2 inhibitors to clinical 
practice has changed this for some patients, with significant improvements in 
symptom scores for patients with PV and MF on ruxolitinib132,133.  
The role of inflammatory cytokines in maintaining MPN is a topic of interest with 
evidence that PV HSCs behave differently in response to inflammatory signalling. 
When exposed to TNF-α, which is increased in MPN, normal HSCs will not 
proliferate, while PV HSCs are resistant to TNF- inhibitory effect151. Additionally 
PV cells in the BM alter the behaviour of the normal BM stoma cells to produce 
cytokines to further enhance their survival151. This alteration leads to chronic 
inflammation in the BM, which in turn can drive an increase in fibrous tissue 
deposition and transformation to MF242. This increase in inflammation is also 
thought to contribute to the increased risk of leukaemic transformation, with cells 
tending to be JAK2 V617F mutation negative on transformation136, suggesting that 
it arises from cells independent of the MPN clone, that have been exposed to the 
chronic inflammatory milieu of the BM.  
The molecular aspects of the deregulation of inflammation in MPN are of interest 
as it represents a complex interaction of different pathways and processes, which 
have been altered to support the abnormal clone. The recent discovery that JAK2 
enters the nucleus to directly affect epigenetic regulators of myeloid cell growth80 
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opens a new area to investigate the alterations JAK2 V617F makes to cells. With 
respect to the inflammatory response in PV it is known there is an increase in the 
level of IFN-γ in patients with PV and ET150. IFN-γ has a well-recognised effect on 
mobilising HSCs out of quiescence and promoting myelopoiesis243. In addition 
IFN-can affect the activity of PML NBs where multiple signals for cell growth, 
apoptosis and DNA repair converge. The normal mechanism for the increase in 
PML expression following exposure to IFN-γ is through JAK1/JAK2/STAT1 
signalling leading to an increase in the activity of interferon response elements 
which act on the expression of PML158,163.  
This study looked at the role mature myeloid cells, in particular monocytes, play in 
the inflammatory phenotype seen in PV. Serum samples were processed from 
normal aged matched donors and PV patients and analysed to determine whether 
PV patients showed any alterations in serum cytokines associated with 
inflammation. In addition, the monocyte subsets were measured in normal age 
matched donors and PV patients to ascertain whether these were altered in PV. 
Following separation, monocytes were differentiated towards M1 and M2 
macrophage phenotypes and cultured in the presence of 20% serum taken either 
from normal controls or PV patients to see what effect the serum had on these 
mature cells and if it differs depending on cell source. We also assessed these 
differentiated macrophages for their level of PML and JAK2  
5.2 Results 
5.2.1 Alteration of monocyte subsets in the peripheral blood of 
JAK2 V617F positive PV patients 
Monocytes are a group of cells in the peripheral blood which are identified 
morphologically as large cells with abundant grey-blue cytoplasm, fine cytoplasmic 
granulation and large irregularly contoured nuclei. Functionally there are 3 distinct 
groups of monocytes; classical monocytes, which make up 85-90% of monocytes, 
non-classical monocytes which make up 5% of monocytes, and intermediate 
monocytes which comprise the remaining 5%34,244. Classical monocytes are 
typically phagocytic and produce some inflammatory cytokines including G-CSF, 
CCL2, CCL5 and IL-6245. Non-classical monocytes are anti-inflammatory with 
constitutive production of IL1-RA, while the intermediate monocytes are pro-
inflammatory producing TNFα in response to stimulation245. Interest in the 
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intermediate monocytes has increased recently due to  the finding that higher 
levels of these in the peripheral blood is associated with an increased risk of 
cardiovascular disease37. Peripheral blood monocytes can be placed in subsets 
based on the surface expression of CD14 and CD1634. Samples taken from 
patients with PV and normal controls were analysed for expression of CD14 and 
CD16, with classical monocytes being CD14Hi, CD16Low, intermediate monocytes 
CD14Hi, CD16Hi and non-classical monocytes CD14Low, CD16Hi. 
Figure 5.1 Monocyte subsets in PV 
 
Mononuclear cells were obtained from peripheral blood of PV patients (n=10) and 
normal controls (n=8) following Ficol gradient separation. 1x106 cells were 
incubated with fluorescent labelled CD14 and CD16 antibodies before analysing 
monocytes. Gates were placed based on relative expression of these proteins to 
identify classical, non-classical and intermediate monocytes. Each result has the 
mean indicated by a line. Results were compared using the Students t-test (* 
p≤0.05, ** p≤0.01). 
 
The majority of monocytes are of the classical subset with about 10% comprising 
non-classical and intermediate monocytes. Ten normal samples and 11 PV 
samples were assessed using flow cytometry and showed that PV samples had an 
increase in the pro-inflammatory intermediate subset with a reduction in classical 
monocytes. Non-classical monocytes were not significantly different between the 
two groups. Interestingly, higher than normal intermediate monocyte numbers 
have recently been identified as a positive predictor of cardiovascular events, 
where they play a significant role in vascular inflammation through secretion of 
TNFα and IL-1β37.  Intermediate monocytes also express CCR2 and CCR5, which 
are critical for monocyte homing and trans-endothelial migration into 
atherosclerotic plaques244. Platelet activation and blood coagulation are also 
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initiated at the site of injury by monocyte/macrophage secreted exosomes and 
microvesicles which contain tissue factor and P-selectin glycoprotein ligand-1 on 
their surface246. It is therefore not unreasonable to postulate that the increased risk 
of cardiovascular complications observed in PV patients could, in part, be linked to 
these elevated intermediate monocyte levels. 
5.2.2 Co-localisation of JAK2 with PML and SUMO 2/3 is 
increased by the presence of the JAK2 V617F mutation in 
peripheral blood monocytes 
Based on the alteration of JAK2 co-localising with PML and SUMO 2/3 in cell lines 
following JAK2 manipulation, we looked at the effect of the JAK2 V617F mutation 
in peripheral blood monocytes using the Duolink® immunofluorescent co-
localisation assay. Peripheral blood monocytes were suspended in Promocell 
monocyte adhesion media before incubating them on microscope slides. The non-
adherent cells were washed off and the remaining attached monocytes were 
processed as before. By using ImageJ analysis of corrected total cell fluorescence 
we showed there was an increase in the degree of localisation of JAK2 with both 
PML and SUMO 2/3 in monocytes derived from PV patients compared to normal 
controls (Figure 5.2).  
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Figure 5.2 Duolink co-localisation assay in normal and PV monocytes 
a) Duolink co-localisation images 
 
a) Corrected total cell fluorescence graphs 
 
Peripheral blood mononuclear cells were incubated in monocyte attachment media 
on microscope slides. After the non-adherent cells were washed off those 
remaining were prepared for Duolink immunofluorescent co-localisation assay as 
described previously. At least 90 cells were counted for each sample with 4 normal 
samples and 5 PV samples being assessed. The corrected total cell fluorescence 
was calculated and statistical significance was assessed using Students t-test and 
annotated as * p≤0.05, ** p≤0.01, *** p≤0.001, **** p≤0.0001. The images (3a) are 
representative of the experiments while the graphs (3b) show the average of the 
corrected total cell fluorescence for all samples +/- SEM.  
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5.2.3 Alteration of serum cytokine profiles in PV 
Some studies have previously been carried out looking at cytokine profiles in 
MPN. A study by Pourcelot et al looked at plasma cytokines in ET and PV, 
comparing levels between disease phenotypes and between JAK2 V617F positive 
and negative states, with comparisons also being made to previously reported 
normal ranges rather than to normal samples tested at the same time. This study 
looked at 13 cytokines and growth factors and found that both PV and ET had 
elevated concentrations of all cytokines when compared to normal physiological 
ranges. Additionally there was an increased concentration of 8 factors including IL-
4, IL-8, IFN-γ and VEGF in ET compared to PV150.  
Serum was collected from 10 PV patients and 8 normal controls to assess the 
concentration of 29 inflammation-associated cytokines and chemokines using a 
multiplex array and analysed using Luminex technology. Many of those tested 
were pro-inflammatory cytokines or associated with proliferation and maintenance 
of cells of the immune system, but some were anti-inflammatory (IL-1 RA, IL-10) or 
immunomodulatory (IL-7, IL-2). Of the 29 cytokines and chemokines tested, 19 
were significantly increased in PV samples compared to normal, 5 were not 
significantly changed and 5 had too many results below the limit of detection for 
significance to be assessed. Those that were significantly altered included 
predominantly the pro-inflammatory cytokines and growth factors (IFNγ, G-CSF 
Figure 5.3 and Figure 5.4), but 3 of the 4 anti-inflammatory (IL-1 RA, IL-4, IL-10 
and 1 of the 2 immunomodulatory cytokines (IL-7) (Figure 5.5) were also 
increased in PV compared to normal. This shows that there is a complex and wide 
ranging alteration of inflammatory and immune responses in these patients 
potentially impacting on a wide range of cellular processes and interactions. 
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IFN-γ and TNF-α are both well recognised pro-inflammatory cytokines which play 
an important role in both the local and systemic response to microbial pathogens, 
and are significantly elevated in PV patients compared to normal (Figure 5.3). IFN-
γ tends to cause a more global anti-viral response through up-regulation of 
inflammatory macrophages systemically, leading to increased levels of both IFN-γ 
and TNF-. TNF– drives pyrexia and, when extremely high levels are present, 
can cause shock and death247. HSCs from PV patients have been shown to be 
resistant to the apoptotic effects of TNF-α through a combination of reduced 
proliferation and inducing quiescence in normal HSCs, giving a survival advantage 
to the abnormal clone151.  
Figure 5.3 Pro-inflammatory cytokines in PV 
 
Serum cytokines were measured by Luminex technology on samples taken from 8 
normal and 10 PV patients. Each result has the mean indicated by a line. Statistical 
significance was determined using unpaired t-test with Welch’s correction for 
unequal standard deviation (* p≤0.05, ** p≤0.01, *** p≤0.001, **** p≤0.0001). 
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The role of G-CSF in haematopoiesis as a regulator of granulocyte differentiation 
is well described. The G-CSF receptor exists on myeloid precursors, and 
stimulation leads to proliferation of these cells and differentiation to mature 
neutrophils. In PV, the JAK2 V617F mutation results in activation of the G-CSF 
receptor, rendering the need for activation unnecessary, however there is still an 
increase in the circulating levels of this cytokine which will augment the increase in 
signalling (Figure 5.4). VEGF has previously been shown to be elevated in PV, 
which is confirmed by our data (Figure 5.4), and is thought to contribute to 
angiogenesis248. 
Figure 5.4 Growth factors in PV 
 
Serum cytokines were measured by Luminex technology on samples taken from 8 
normal and 10 PV patients. Each result has the mean indicated by a line. Statistical 
significance was determined using unpaired t-test with Welch’s correction for 
unequal standard deviation (* p≤0.05, ** p≤0.01, *** p≤0.001, **** p≤0.0001). 
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The pro-inflammatory chemokines are important in attracting and activating 
different cells of the immune system to areas of inflammation. CCL3 and CCL4 are 
important attractant and activating signals for macrophages, monocytes and NK 
cells, with CCL3 being produced by monocytes and CCL4 by CD8 positive T cells. 
CXCL10 is produced by monocytes and endothelial cells in response to 
stimulation by IFN-γ and is therefore directly related to the increased levels of IFN-
γ seen in PV (Figure 5.4).  
Figure 5.5 Chemokines in PV 
 
Serum cytokines were measured by Luminex technology on samples taken from 8 
normal and 10 PV patients. Each result has the mean indicated by a line. Statistical 
significance was determined using unpaired t-test with Welch’s correction for 
unequal standard deviation (* p≤0.05, ** p≤0.01, *** p≤0.001, **** p≤0.0001). 
IL-6 has been shown to be significantly increased in PV in many studies however 
in this case the difference was found to be non-significant, but the number of 
samples in which a detectable level was present in the normal controls is small 
making comparison difficult. Of interest is that there are more detectable levels in 
the PV samples than in the normal samples which would suggest that the known 
increase is present and would become apparent either using more sensitive 
testing or by increasing the number of samples tested.  
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Table 5.1 Serum cytokines from normal and PV patients 
Cytokine 
Normal 
median 
(pg/ml) 
St dev 
PV median 
(pg/ml) 
St dev p value 
Pro-inflammatory cytokines 
IL1-β 0.9 0.4 5.1 3.6 0.0072 
IL-5 28.2 4.5 127.2 33.3 <0.0001 
IL-6 0.6 0.3 3.5 4.9 0.0648 
IL-8 1.9 0.7 11.7 9.2 <0.0001 
IL-9 26.1 6.7 74.7 29.1 0.0004 
IL12 (p70) 4.4 2.9 74.9 85.9 0.0049 
IL-17 32.2 9.5 99.6 53.7 0.0028 
CCL11 80.7 51.9 310.8 155.1 0.0021 
G-CSF 10.7 2.7 37.0 13.4 0.001 
IFNγ 82.6 17.6 323.9 157.1 0.0005 
CXCL10 672.4 187.0 3550.3 1501.1 0.0002 
PDGF-BB 3697.2 1898.1 7276.0 8520.9 0.0587 
CCL2 0.6 0.2 1.6 7.9 0.3241 
CCL3 0.4 0.4 1.8 1.1 0.0006 
CCL4 25.8 5.3 139.4 73.6 0.0008 
CCL5 3771.0 1331.8 13047.1 4377.6 0.0002 
TNF-α 19.6 6.8 71.6 31.3 0.0006 
VEGF 7.1 6.8 139.1 146.5 0.0099 
Anti-inflammatory cytokines 
IL-1RA 16.6 9.4 52.1 73.1 0.0049 
IL-4 7.2 2.0 24.4 10.1 0.0005 
IL-10 1.0 1.0 11.8 9.8 0.0061 
IL-13 0.8 7.4 12.6 7.6 0.0631 
Immunomodulatory cytokines 
IL-2 1.12 0.6 3.34 4.3 0.965 
IL-7 15.29 26.8 170.7 131.5 0.0046 
Luminex technology was used to analyse 29 cytokines in the serum of 8 normal and 
10 PV samples. Of these 29, 5 cytokines (IL-15, FGF-basic, GM-CSF, CXCL1, IFN-α) 
failed to produce usable results. Significance was determined using an unpaired t-
test with Welch’s correction for unequal standard deviation, and defined as p ≤0.05. 
Significant results are highlighted in bold. 
Several of the pro-inflammatory cytokines signal through JAK2 alone (IL-6, G-
CSF) or in combination with another JAK protein (IFN-γ, IL-5), meaning the 
presence of the JAK2 mutation will either render the pathway either constitutively 
active or more reactive/sustained than normal48. Given that many of these 
cytokines are increased above basal levels in PV, this will potentiate these 
signalling pathways even further leading to a cycle of chronic inflammation. The 
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anti-inflammatory cytokines may be increased as a homeostatic measure to try 
and control this abnormal cytokine profile.  
5.2.4 Assessment of efficacy of macrophage differentiation 
Macrophages are involved in a wide range of actions within the body. The main 
role they play is in pathogen removal and inflammation, where different types of 
macrophages play differing roles. In addition to this, they play a critical role in red 
cell development, by providing the environment needed for red cells to obtain iron 
for haemoglobin and to remove the nucleus, a step required for the final stages of 
erythropoiesis. In mouse models of PV, where there has been pharmacological 
ablation of BM macrophages, the PV phenotype does not develop249. It also leads 
to a less severe phenotype in β-thalassaemia models and leads to impaired red 
cell recovery following induced anaemia, suggesting that macrophages play a key 
role in stress erythropoiesis249.  
The classical inflammatory macrophages develop at the site of inflammation to 
help remove infecting organisms, damaged cells and play a key role in tissue 
remodelling. Given that these mature cells develop from circulating monocytes, we 
looked at the effect the alteration in monocyte subsets had on PV monocytes to 
differentiate towards M1 and M2 macrophage subsets. Using the Promocell® 
macrophage differentiation protocol (Section 2.3.1.8) monocytes from peripheral 
blood samples were cultured in the presence of cytokines to drive differentiation to 
M1 or M2 primed macrophages. To assess the efficacy, of this primed 
macrophages were assessed for the presence of M1 (CD80 and CD86) and M2 
(CD163 and CD206) surface markers (Figure 5.6). This shows that both M1 and 
M2 macrophages expressed markers consistent with effective differentiation in 
both the normal and PV samples.  
 
 
 
 
 
 
208 
 
Figure 5.6 Assessment of the efficacy of macrophage differentiation by 
FACS 
 
Following differentiation, macrophages were removed from culture plates using the 
Promocell® macrophage detachment solution. Cells were incubated with 
fluorescent labelled CD80, CD86, CD163 and CD206 antibodies. CD80 and CD86 
were used to assess the M1 macrophages, while CD163 and CD206 were used to 
assess M2 macrophages by flow cytometry using FACSCanto, with representative 
dot plots shown.  
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5.2.5 Co-localisation of JAK2 and PML in the nucleus of 
macrophages 
As above, monocytes were isolated using monocyte attachment media 
differentiated into M1 or M2 macrophages in chambered slides. Five normal 
samples and 6 PV samples were prepared in this way. Following completion of the 
culture as described previously (Section 2.4.1.8) cells were fixed using 
paraformaldehyde and prepared as described (Section 2.3.5.1). 
These images show the appearance of M1 and M2 macrophages under different 
culture conditions. M1 macrophages tend to be circular with a central nucleus 
often described as a “fried egg” appearance, while M2 macrophages tended to be 
more elongated. When cultured in normal serum with no stimulation the normal M1 
macrophages had some variability in the appearance, with some elongated forms 
present among the classical M1 phenotype, while the PV M1 macrophages all had 
the classical fried egg appearance regardless of their culture conditions (Figure 
5.7). The M2 macrophages generated from normal monocytes showed a classical 
elongated appearance when cultured in normal serum both with no stimulation and 
stimulation with IL-4, while in the presence of PV serum, regardless of the 
stimulation, there tended to be a more M1 phenotype. The M2 macrophages 
generated from PV monocytes had an M2 phenotype in normal serum with IL-4 
stimulation, but all other culture conditions resulted in an M1 phenotype (Figure 
5.7).    
The immunofluorescent images show clear localisation of JAK2 to the cytoplasm 
and nuclear co-localisation with PML. The number of PML NBs does not appear to 
change when comparing macrophages derived from PV or normal monocytes, or 
when comparing those cultured with PV or normal serum. The M1 macrophages 
which have been stimulated with IFN-γ appear to have larger NBs than those 
which have not been stimulated, and this appears to be the same for both normal 
and PV samples. The difference in the M2 macrophages does not appear to be as 
marked, and this may be due to the known effect of IFN-γ stimulation on PML NBs 
(Figure 5.8). 
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Figure 5.7 M1 macrophages 
a) M1 macrophages from normal monocytes 
 
b) M1 macrophages from PV monocytes 
 
Representative immunofluorescent images of M1 macrophages generated from 
normal (a) and PV (b) monocytes. Monocytes were cultured in the presence of 
macrophage generation media + 20% normal or PV serum with or without 
stimulation with LPS and IFN-γ. Experiments were carried out on 5 normal and 6 PV 
samples.  
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Figure 5.8 M2 macrophages 
a) M2 macrophages from normal monocytes 
 
b) M2 macrophages from PV monocytes 
 
Representative immunofluorescent images of M2 macrophages generated from 
normal (a) and PV (b) monocytes. Monocytes were cultured in the presence of 
macrophage generation media + 20% normal or PV serum with or without 
stimulation with IL-4. Experiments were carried out on 5 normal and 6 PV samples.  
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5.2.6 Effects of the JAK2 V617F mutation on macrophage 
cytokine production 
Macrophages are cells that reside in tissues and develop from peripheral blood 
monocytes39. Under pressures from specific cytokines these macrophages can 
develop into either M1 macrophages or M2 macrophages250. M1 macrophages 
develop in response to exposure to LPS produced from bacterial membranes or in 
response to stimulation from IFN-γ and GM-CSF251. M2 macrophages have a 
more immunomodulatory role and develop in response to signalling from Th2 T 
lymphocytes through IL-4 or IL-13252. As a result M1 macrophages are involved in 
killing of intracellular pathogens, tumour destruction and tissue damage while M2 
macrophages are involved in clearance of parasites, tissue remodelling and 
immune regulation39. The role macrophages play in the inflammation seen in PV 
has not previously been investigated, and given the important role the cells play in 
the immune system we have created a model to investigate this further by 
generating M1 and M2 macrophages from peripheral blood monocytes as 
described above (Section 2.4.1.8). For this we investigated 5 normal samples and 
6 PV samples in total. Per experiment monocytes were isolated from one normal 
sample and one/two PV samples, differentiated into macrophages and then 
stimulated as outlined using either normal or PV serum (Figure 5.9).   
Figure 5.9 Experimental conditions compared to base media 
 
Culture conditions for generation of macrophages from peripheral blood 
monocytes. M1 polarisation media was the Promocell® macrophage differentiation 
base media supplemented with GM-CSF 5ng/ml, with stimulation media using the 
same base media supplemented with LPS 100ng/ml and IFNγ 20ng/ml. M2 
polarisation media was the Promocell® macrophage differentiation base media 
supplemented with M-CSF 50ng/ml, with stimulation media using the same base 
media supplemented with M-CSF 10ng/ml and IL-4 20ng/ml.   
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The effect the presence of the JAK2 mutation has on macrophage function has not 
previously been investigated. This is of interest as it is likely that a significant 
proportion of macrophages will develop with the JAK2 V617F mutation present, 
and this could potentially alter the responses of these macrophages to stimulation. 
In turn this may lead to a change in the cytokines subsequently produced by these 
cells. 
5.2.6.1 M1 Macrophages 
M1 macrophages produce a range of pro-inflammatory cytokines including IL-1β, 
IL-6, IL-8, IFN-γ and TNF-α in response to stimulation253. We tested these 
cytokines, and others, to see if there was any alteration in the levels produced 
when macrophages were exposed to serum collected from PV patients or normal 
controls, if they differed between macrophages derived from PV monocytes or 
normal monocytes, or if they behaved differently when stimulated with LPS and 
IFN-γ.  
The effect on cytokine production of culturing monocyte-derived M1 macrophages 
in the different culture conditions was assessed as previously described (Section 
2.3.1.8). As expected there was an alteration in the concentration of IFN-γ in the 
stimulated conditions, with an increase of more than ten-fold above the 
unstimulated cells. The level of IFN-γ in the unstimulated culture conditions was 
higher than would be expected as a result of the serum being added (Figure 5.10), 
which supports the data showing successful differentiation into M1 macrophages 
(Figure 5.6). Unexpectedly the levels of CXCL10, usually produced as a direct 
result of IFN-γ stimulation, were higher in the base media conditions of both 
sample groups than in the unstimulated conditions, and the normal samples had 
slightly higher, concentrations than the PV samples cultured the same way.  
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Figure 5.10 Interferon-γ and CXCL10 production from M1 macrophages 
Cytokines produced by M1 macrophages generated from patient monocytes were 
measured by Luminex technology using media following culture in the previously 
described culture conditions. 5 normal and 5 PV samples were used. Each result 
has the mean indicated by a line. Samples with undetectable levels are shown as 
0pg/ml and statistical significance was determined using Students t-test (* p≤0.05, 
** p≤0.01). 
M1 macrophages release a range of cytokines and growth factors. CCL11 is a 
chemokine which attracts myeloid cells, particularly eosinophils, to the site of 
inflammation254. Following culture, M1 macrophages increased their production of 
CCL11 compared to base media. The differences are more than would be 
expected just from adding serum and were more marked in the normal samples 
compared to the PV samples (Figure 5.11). Similarly PDGF-BB was increased in 
all culture conditions compared to base media, but with a less marked increase in 
samples cultured with PV serum compared to normal serum and with fewer 
significant alterations in PV samples compared to normal samples (Figure 5.11).  
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Figure 5.11 Inflammatory cytokines produced by M1 macrophages 
Cytokines produced by M1 macrophages generated from patient monocytes were 
measured by Luminex technology using media following culture in the previously 
described culture conditions. Each result has the mean indicated by a line. 5 
normal and 5 PV samples were used. Samples with undetectable levels are shown 
as 0pg/ml and statistical significance was determined using Students t-test (* 
p≤0.05, ** p≤0.01). 
When comparing normal M1 macrophage cytokine production with PV M1 
macrophage production there is a surprising trend. Looking at the cells cultured in 
their own serum with no stimulation, there appears to be a blunting of production 
of CCL11, PDGF-BB and IL-7, with an increased production of CCL5 (Figure 
5.12). Interestingly, following stimulation there is only a significant alteration in 
CCL11, with PV samples having lower levels than normal samples as seen in the 
unstimulated samples. The presence of the JAK2 V617F mutation and chronic 
activation of JAK2 dependent signalling pathways could lead to compensatory 
mechanisms within the cell. This chronic activation of signalling would lead to 
reduced responsiveness within the cells and alter the cytokine production. The 
differences seen may also relate to other cytokines being produced within the 
culture. The cells were cultured for 24 hours in the different treatment arms, which 
would be enough time for cytokines produced to have an autocrine effect on the 
behaviour of the cells in culture.  
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Figure 5.12 M1 macrophage cytokines  
 
Cytokines produced by M1 macrophages generated from patient monocytes were 
measured by Luminex technology using media following culture in the previously 
described culture conditions. Each result has the mean indicated by a line. 5 
normal and 5 PV samples were used. Samples with undetectable levels are shown 
as 0pg/ml and statistical significance was determined using Students t-test (* 
p≤0.05, ** p≤0.01). 
The complete list of cytokines produced by M1 macrophages in this model is 
summarised in Appendix 1. 
5.2.6.2 M2 macrophages 
M2 macrophages are viewed as having a more immunomodulatory role with the 
ability to help with tissue repair following inflammation, producing IL-1RA, IL-4, IL-
10, VEGF and FGF basic252. Alterations in these cytokines were seen following 
culture, although the only significant alteration was in normal M2 macrophages 
cultured in PV serum following stimulation with IL-4. It was not possible to assess 
the effect of stimulation on IL-4 production as this was masked by the presence of 
IL-4 in the culture, but when samples stimulated with serum alone were assessed 
there was a slight, but non-significant, increase in the amount of IL-4 produced, 
suggesting the serum produced a direct stimulatory effect (Figure 5.13). 
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Figure 5.13 Immunomodulatory cytokines in M2 macrophages 
 
Cytokines produced by M2 macrophages generated from patient monocytes were 
measured by Luminex technology using media following culture in the previously 
described culture conditions. 5 normal and 5 PV samples were used. Each result 
has the mean indicated by a line. Samples with undetectable levels are shown as 
0pg/ml and statistical significance was determined using Students t-test (* p≤0.05, 
** p≤0.01). 
Several cytokines were altered in unexpected ways in these samples including an 
increase in TNF-α and PDGF-BB following culture in serum as M2 macrophages 
would not be expected to produce these. The TNF-α results show significant 
increases in both normal and PV samples compared to base media, which 
appears to increase further in the normal samples following stimulation with IL-4 
(Figure 5.13).  While the high levels of PDGF-BB present following serum 
stimulated may be partially explained by the high levels present in the PV serum, 
the similar results elicited by the normal serum which have much lower levels 
(Table 5.1), suggest it was a direct effect of serum stimulating the M2 cells to 
produce PDGF-BB. 
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Figure 5.14 Inflammatory cytokines in M2 macrophages 
 
Cytokines produced by M2 macrophages generated from patient monocytes were 
measured by Luminex technology using media following culture in the previously 
described culture conditions. 5 normal and 5 PV samples were used. Each result 
has the mean indicated by a line. Samples with undetectable levels are shown as 
0pg/ml and statistical significance was determined using Students t-test (* p≤0.05, 
** p≤0.01). 
CXCL1 is a chemo-attractant chemokine that is produced by M1 macrophages to 
attract neutrophils to a site of inflammation255. In macrophages primed to develop 
into M2 macrophages following culture in M-CSF only CXCL1 was detected, which 
then reduced following the introduction of serum and stimulation with IL-4. This 
may be an indication that the macrophages underwent further 
differentiation/maturation following the introduction of stimulation and serum to the 
culture. IL-7 is an immunomodulatory cytokine that acts predominantly on 
lymphocytes to mediate proliferation of all lymphoid lineages256. There is also 
more recent evidence that elevated levels of IL-7 are seen in mice with advanced 
atherosclerosis and the levels dropped following cholesterol lowering 
interventions. In this model, it was seen that IL-7 induced recruitment of 
monocytes which then differentiated to macrophages in the vascular 
endothelium257.  We see an increase in IL-7 levels produced by normal samples 
cultured in serum, which was more marked following stimulation with IL-4. 
Interestingly, this was not seen in the PV cells. However the level of IL-7 in the 
serum is already increased in PV patients compared to normal (Figure 5.15).  
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Figure 5.15 Cytokines and chemokines in M2 macrophages 
  
Cytokines produced by M2 macrophages generated from patient monocytes were 
measured by Luminex technology using media following culture in the previously 
described culture conditions. 5 normal and 5 PV samples were used. Each result 
has the mean indicated by a line. Samples with undetectable levels are shown as 
0pg/ml and statistical significance was determined using Students t-test (* p≤0.05, 
** p≤0.01). 
The complete list of cytokines produced by M2 macrophages in this model is 
summarised in Appendix 2. Overall our results suggest that M1 and M2 derived 
macrophages from PV patients and normal donors express similar levels of 
chemokines/cytokines, but PV patient-derived macrophages are less responsive to 
stimulation compared to their normal counterpart. This may be due to the V617F 
JAK2 mutation causing up-regulation of negative regulators of signalling, leading 
to a damping down of the pro-stimulatory effects mediated by LPS, IFN- and IL-4.  
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5.2.7 Effect of the JAK2 V617F mutation on neutrophil cytokine 
production 
Given the alterations in chemokine and cytokine profiles observed in PV patient-
derived macrophages, next we investigated whether mature neutrophils from PV 
patients also displayed altered responses. We compared cells separated from PV 
patients to normal individuals. Neutrophils were cultured for 24 hours in the 
presence or absence of PV or normal serum, with or without stimulation by LPS. 
The media was then collected for cytokine analysis and tested using multiplex 
bead technology for 29 cytokines and chemokines as previously described, with 
each sample being tested in duplicate and compared to standards to determine 
the final concentration. Statistical significance was assessed using Students two-
tailed t-test and determined as p≤0.05.  
The addition of serum led to an alteration of cytokine production by neutrophils. 
Vascular endothelial growth factor (VEGF) reduces in the presence of serum, with 
other growth factors GM-CSF and FGF-basic both being present in neutrophils 
cultured in the absence of serum but being undetectable in those cultured in the 
presence of serum (Figure 5.16). G-CSF behaved in exactly the opposite way 
being almost or completely undetectable in samples cultured in base media and 
increased when serum was added. This is not accounted for by the G-CSF in the 
serum samples added as the levels seen in serum (Table 5.1) was less than would 
be seen in these culture conditions suggesting the neutrophils were producing G-
CSF directly. 
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Figure 5.16 Growth factors in normal and PV neutrophil culture 
 
 
Neutrophil cytokines were measured by Luminex technology using media following 
24 hours of culture in the previously described culture conditions. 5 normal and 5 
PV samples were used. Each result has the mean indicated by a line. Samples with 
undetectable levels are shown as 0pg/ml and statistical significance was 
determined using Students t-test (* p≤0.05, ** p≤0.01).  
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Pro-inflammatory cytokines, such as CCL11 and PDGF-BB, also increased in both 
normal and PV neutrophil cultures under the different culture conditions with 
concentrations much higher than those measured in the serum alone (Figure 
5.17). Although not significant, the PV neutrophils secreted higher levels of CCL11 
than normal neutrophils following stimulation. IL-9 also increased following 
stimulation with either normal or PV serum, but only when LPS was added to 
stimulate the neutrophils, again PV neutrophils showed a bias towards higher 
levels. 
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Figure 5.17 Pro-inflammatory cytokines in normal and PV neutrophils 
 
 
Neutrophil cytokines were measured by Luminex technology using media following 
24 hours of culture in the previously described culture conditions. 5 normal and 5 
PV samples were used. Each result has the mean indicated by a line. Samples with 
undetectable levels are shown as 0pg/ml and statistical significance was 
determined using Students t-test (* p≤0.05, ** p≤0.01).  
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Some cytokines, such as CCL5 and CXCL10, were increased from baseline at a 
level which would be explained by the dilution of the serum when added to culture 
alone, suggesting there is no real increase when compared to neutrophils cultured 
in media alone (Figure 5.18). Alteration in the levels of these would also be 
unexpected as neither are produced by neutrophils normally. The cytokine results 
for all samples are presented in Appendix 3.  
Figure 5.18 Unchanged cytokines in normal and PV neutrophils 
 
Neutrophil cytokines were measured by Luminex technology using media following 
24 hours of culture in the previously described culture conditions. 5 normal and 5 
PV samples were used. Each result has the mean indicated by a line. Samples with 
undetectable levels are shown as 0pg/ml and statistical significance was 
determined using paired Students t-test (* p≤0.05, ** p≤0.01). 
 
 
 
 
  
225 
 
5.3 Discussion 
Inflammation is one of the major features of myeloproliferative disease, with 
evidence that this confers a survival benefit to the abnormal clone151, as well as 
driving many of the symptoms and contributing to the complications of the 
conditions230. Recently, there has been increasing evidence that MPN cells have 
abnormal functions in addition to being present in increased numbers149,205,4. 
Previous studies have identified several clear abnormalities of MPN cell function 
with basal neutrophil reactive oxygen species production increased in MPN 
patients with the JAK2 V617F mutation when compared to normal neutrophils and 
to JAK2 V617F negative MPN149. There is also evidence to show that abnormal 
cytokine levels are associated with alterations in the peripheral blood counts such 
as an increase in IL-1β, IL-2 and IL-7 in patients with leucocytosis258. There is no 
data directly correlating JAK2 V617F allele burden to cytokine expression profiles. 
However there is data showing different cytokine profiles associated with ET, PV 
and myelofibrosis which would suggest that allele burden has an effect on cytokine 
production150,258.  
The JAK2 inhibitor ruxolitinib is known to have a relatively specific effect on JAK2. 
However in the initial studies assessing this compound it is clear that it has an 
equally important effect on JAK1194. The combination of JAK1 and JAK2 is an 
important one as these two JAKs are often associated with inflammatory cytokine 
receptors together (IL-5 and IFN-γ) or separately (IL-15 and IFN-α). This dual 
inhibitory effect of ruxolitinib is likely to be part of the reason it is so effective in 
reducing clinically significant inflammatory symptoms in patients133,204 where there 
is significantly abnormal cytokine activity. However given that the predominant 
abnormality here is the JAK2 V617F mutation causing chronic activation of 
signalling it is likely that most of the effect seen is due to inhibition of JAK2. This is 
supported by the fact that both fedratinib and pacritinib achieved improvements in 
both symptoms and spleen size despite having no JAK1 activity259,260. 
In this study we have shown neutrophil cytokine responses are also abnormal, 
although many of the abnormalities are not significant, there are clear trends 
towards an increased production of inflammatory cytokines by PV neutrophils 
compared to normal. We have also shown that monocytes from PV patients have 
an abnormal distribution with an increase in the pro-inflammatory intermediate 
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monocytes at the expense of classical monocytes. This has implications not only 
in the serum cytokine levels but in aspects of arterial thrombosis, where monocyte 
infiltration of vascular endothelium and differentiation into tissue macrophages is 
an important initiating step in atherosclerosis37. It appears that IL-7, which is 
elevated in PV, is a key regulator of the expression of adhesion molecules on the 
vascular endothelium which act to increase monocyte adhesion257. This is an 
important step in the initiation of atherosclerosis with accumulation of 
macrophages in the vascular endothelium. Given that we have shown that 
macrophages derived from peripheral blood monocytes behave abnormally this 
could explain the alterations in endothelial function and partly explain the increase 
in arterial vascular events seen in these patients.  
Macrophages are known to be important for red cell maturation, particularly 
provision of iron for haemoglobin production and in aiding the expulsion of the 
nucleus in maturing red cells249. Despite this key role in erythropoiesis, the role of 
macrophages in the support of erythropoiesis in PV has not been investigated. 
Here we show that PV macrophages have an abnormal response, both as M1 and 
M2 macrophages, in response to culturing in serum and to stimulation. These cells 
exist throughout the body and have a wide range of roles, from tissue specific 
roles such as macrophages seen in the bone marrow, liver and lungs261, to 
responding to infection or inflammation through egress and differentiation of blood 
monocytes into the affected tissues253. Tissue resident macrophages tend to be 
self-maintaining in the steady state with support from monocyte derived 
macrophages in the context of acute inflammation262. As a result tissue resident 
macrophages are less likely to harbour the JAK2 V617F mutation at the time of 
diagnosis. However given the chronic inflammation seen there may be an 
increased trafficking of monocytes from the blood into the tissues. It would be 
interesting to evaluate if these is an accumulation of tissue resident macrophages 
harbouring the JAK2 V617F mutation occurred with time, and whether this was 
associated with increased inflammatory symptoms.  
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6 Summary of findings 
6.1 JAK2 dependent gene expression 
Signalling through JAK2 and STAT5 is a key pathway in haematopoiesis 
especially myelopoiesis, with multiple cytokine receptors relying on this signalling 
pathway to activate intracellular effects138. It is also a frequently overactive in 
haematological malignancy, both myeloid and lymphoid263, either as a result of a 
mutation activating the pathway111,114,142,264 , or due to overactivity of the normal 
pathway mediated through other oncogenic mutations265. In this study we looked 
at two models of overactivity; the JAK2 V617F mutation causing constitutive 
activation of the pathway, and overactive wild-type JAK2 through activation of the 
pathway by the novel oncoprotein BCR-ABL. The JAK2 V617F mutation leads to 
ligand independence of receptors associated with JAK2 on both intracellular 
arms266,267, while those where JAK2 associates with another JAK protein this is 
thought to be via a prolongation of the response following activation of the receptor 
by ligand47,268. The data presented here shows that there is extensive gene 
expression abnormalities seen in both CML and PV with similar genes being 
altered in each condition. These included important genes involved in cell cycle 
progression (CCND2, CCNF), cytokine signalling (STAT1, PI3K), apoptosis 
(BCL2L1, MCL1) transcriptional regulation (TAF1, EGR2) and inflammation (IRF6, 
PML, SUMO3). Many of the changes have been seen before, but it was interesting 
to see that although similar genes were altered, often they were not changed in 
the same way between CML and PV; decreased expression of EGR2 in CML and 
increased expression in PV, increased expression of PML in CML with decreased 
expression in PV, and increased expression of TAF1 in CML while this was 
decreased in PV. There were also some new changes identified such as 
alterations in SUMO expression. The importance of SUMO in CML has not 
previously been explored, but given the increasingly diverse cellular processes 
altered by SUMOylation269 this could be an interesting area to look in to further.  
6.2 JAK2 interactions in the nucleus 
The role of JAK2 in the nucleus is a recent finding that has changed the way we 
think about JAK2 signalling78,79. While the classical model of JAK-STAT signalling 
has a wide role to play in many aspects of cellular function, the direct role JAK2 
plays in the epigenetic regulation of target gene expression opens an entire new 
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area of research. While it has been shown that following phosphorylation JAK2 
acquires the ability to enter the nucleus through post-translational modification with 
SUMO proteins, the regulation of JAK2 signalling and how it mediates its actions 
within the nucleus is less clear. Here we show that following entry into the nucleus 
JAK2 associates with the PML NB and this interaction can be modified following 
treatment with a known PML inducer, IFN-γ, or JAK2 inhibition. In addition to this 
there is a clear increase in the degree of association between JAK2 and PML in 
PV peripheral blood monocytes compared to normal indicating that this interaction 
results from activation of the JAK2 protein. PML NBs have long been known to act 
as a hub where proteins are brought into association with targets to effect 
changes237,270. In addition to this PML NBs associate with transcriptionally active 
sites, where effector proteins can interact with histones271. Finally PML NBs have 
been shown to be involved in the degradation of proteins272–274 through facilitating 
ubiquitination and proteosomal degradation. Exactly which of these actions is 
achieved by the interaction of JAK2 and PML is not yet clear however the increase 
in apoptosis seen following treatment of cells with ruxolitinib and arsenic trioxide 
would suggest that the interaction enhances the effects of JAK2s activity within the 
nucleus. The normal role of PML has typically been associated with enhancing 
apoptosis270,275 and control of cellular proliferation through downregulation of PI3K 
signalling at the level of Akt276 and reduction of c-Myc and c-Myc target genes277, 
so it may be that the interaction in PV may result in JAK2 exerting an inhibitory 
effect on normal PML functions thereby promoting cellular proliferation and 
differentiation.  
6.3 JAK2 in inflammation 
The cardiovascular risk associated with PV improves dramatically following 
aggressive normalisation of haematocrit and platelet count278, but does not return 
to the expected risk associated with age matched controls279. There is evidence to 
show that an abnormal intermediate monocyte subset is associated with an 
increase in the risk of acute cardiovascular events37. Over the last decade it has 
become clear that arterial thrombotic events are increased in conditions with 
chronic inflammation153, with elevated intermediate monocyte subsets increasing 
the risk of cardiovascular events in rheumatoid arthritis280. In addition to this, 
patients with an elevated intermediate monocyte subset at the time of myocardial 
infarction had a higher risk of death and poor myocardial recovery281. The PV 
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patients in this study were mostly on effective treatment at the time of sampling, 
but still had elevated intermediate monocytes and reduced classical monocytes. It 
is unclear if this alteration in monocyte subsets is due to the underlying PV or 
occurs as a result of treatment with hydroxycarbamide, but the abnormality may in 
part explain why patients do not have a complete correction of their cardiovascular 
risk following correction of the peripheral blood counts. In addition to this there is 
an ongoing low level of inflammation which has been shown in several 
studies150,230,282. In this study the serum cytokine levels remain abnormal despite 
ongoing therapy indicating that the ongoing inflammation is independent of the 
correction of counts. This ongoing inflammation will continue to support the 
malignant clone as the diseased stem cells are resistant to the apoptotic effects of 
inflammatory cytokines such as TNF-α151.  
6.4 Conclusions 
In this study we have shown patients with CML and PV have significant alterations 
to many cellular processes that support the survival of the abnormal clone and that 
JAK2 is a central regulator of many of these changes. We have also confirmed 
recent evidence that JAK2 enters the nucleus and furthered the understanding of 
its role by demonstrating an interaction with PML NBs which can be modulated by 
inhibition of JAK2 or stimulation with IFN-γ. This interaction is not limited to cell 
lines only, but is demonstrated in both normal and PV patient monocytes and 
macrophages. The presence of the JAK2 V617F mutation in patient monocytes 
leads to an increase in the localisation of JAK2 and PML indicating that activation 
of JAK2 is required for these proteins to come together. To further highlight that 
this is a functionally relevant interaction, treating JAK2 V617F containing cell lines 
with the JAK2 inhibitor ruxolitinib and arsenic trioxide, which degrades PML, in 
combination led to a significant increase in apoptosis when compared to either 
compound alone. Currently we don’t know exactly what the nature of this 
interaction is, but this would be an interesting area to investigate further.  
We have also shown that in PV, cells of the innate immune system behave 
differently from normal samples. Based on findings in other conditions, the 
increase of inflammatory intermediate monocytes seen in PV would in part explain 
the ongoing cardiovascular risk seen in these patients and it will be interesting to 
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see if, in time, the use of JAK2 inhibitors will lead to a normalisation of monocyte 
subsets and a reduction in cardiovascular risk.  
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7 Future Work 
The work presented in this thesis shows that the role JAK2 plays in cellular 
signalling networks is complex and that the presence of JAK2 V617F activating 
mutation has profound effects on cellular function. However the full story has not 
been elucidated here and there are several interesting findings that could be 
investigated further either as individual projects or in collaboration with other 
research teams.  
The interaction of JAK2 and PML identified here is a novel interaction which is 
likely to be of importance to the functioning of haematopoietic cells. Both JAK2 
and PML play key roles in many cellular functions including cell cycle, apoptosis, 
cellular growth and the inflammatory response. Here we show that combining 
pharmacological inhibition of JAK2 and PML using ruxolitinib and arsenic trioxide 
leads to an increase in apoptosis in cell lines harbouring the JAK2 V617F 
mutation. It would be of interest to see if this combination is synergistic or merely 
additive. This would need formal synergy experiments to be carried out wither 
using flow cytometry or trypan blue exclusion counts as a method of assessing cell 
viability. In addition to this the co-localisation of JAK2 and PML raises many 
avenues for further evaluation. The functional consequences of this interaction 
were not elucidated here making it difficult to ascertain for certain the reason for 
the interaction. It may be that JAK2 enters the PML NBs to be marked for 
degradation following completion of its activity within the nucleus, or it may be that 
entering the PML NB brings JAK2 into proximity with histones and proteins to 
allow JAK2 to directly alter their activity and increase transcription of target genes. 
Finally the interaction may allow JAK2 to directly alter the functioning of PML itself 
which is associated with cellular senescence and potentiation of apoptotic signals. 
Another interesting finding in this thesis is the increase in intermediate monocytes 
seen in PV compared to normal. These monocytes display a more inflammatory 
phenotype and have been shown to play an important role in the development of 
cardiovascular disease in patients without the JAK2 V617F mutation. Patients with 
PV are known to have a persistent increase in the risk of cardiovascular disease 
despite normalisation of peripheral counts. The underlying cause of this has been 
previously attributed to a chronic inflammatory response as part of the disease and 
an alteration of platelet responsiveness driven by the presence of the JAK2 V617F 
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mutation. However the finding that intermediate monocytes are increased in 
patients with PV raises the possibility that the underlying mechanisms of 
cardiovascular disease are more complex than previously thought. It would be of 
significant interest to investigate the interaction of PV monocytes with vascular 
endothelium and whether this plays a role in the development of cardiovascular 
disease. This would probably best be achieved through collaboration between a 
cardiovascular research team who would be able to provide models of 
cardiovascular disease and a haematology research team who would provide 
patient samples.  
The final area of particular interest raised in this work is the abnormal function of 
macrophages derived from PV patient monocytes. The macrophages generated in 
this project showed abnormal function with blunting of some cytokine responses 
and heightening of others. However there was marked heterogeneity in the 
concentration of cytokines released with these samples and it would be interesting 
to obtain further samples and try to obtain more meaningful results in the first 
instance. It would also be of interest to look at the effect of the JAK2 V617F 
mutation on other functional aspects of the macrophages such as tissue 
remodelling and response to pathogens. The other area of macrophage biology 
which could be investigated is whether the JAK2 V617F mutation enters the tissue 
resident macrophage pool. The currently available evidence suggests that tissue 
resident macrophages maintain themselves with monocyte derived macrophages 
only developing in response to inflammatory stimuli262. However bone marrow 
macrophages, that are essential for the development of red cells, would be of 
particular interest to investigate further as they may be more susceptible to the 
introduction of the JAK2 V617F mutation into the pool, which would be likely to 
lead to alterations in their function. Given the role that macrophages play in tissue 
remodelling the presence of the JAK2 mutation within these cells may have a role 
to play in disease progression to myelofibrosis. 
 
 
 
233 
 
8 Appendix 
Appendix 1a. Cytokine levels of M1 macrophages generated from normal 
monocytes 
 
Cytokine 
Normal Samples (pg/ml) 
Base 
Media 
St dev 
N 
Serum 
Unstim 
St dev 
N 
Serum 
Stim 
St dev 
PV 
Serum 
Unstim 
St dev 
PV 
Serum 
Stim 
St dev 
Pro-inflammatory 
IL-1β 284 203 168 47 444 234 161 45 230 56 
IL-5 26 7 62 15 69 18 47 13 48 12 
IL-6  766 426 453 243 5469 1948 317 144 2872 882 
IL-8 22829 12401 25418 16842 73427 56598 21549 8965 45046 25841 
IL-9 93 36 180 66 210 79 164 61 178 71 
IL-
12(p70) 
11 5 30 21 30 21 13 8 17 14 
IL-15 44 40 106 97 195 175 103 100 173 162 
IL-17 85 35 104 19 133 28 85 12 102 22 
CCL11 37 13 144 28 146 16 109 23 127 25 
FGF 
basic 
31 13 33 19 47 20 NA NA 45 31 
G-CSF 54 33 140 67 313 204 95 38 258 155 
GM-CSF 4932 1528 1874 885 NA NA 1427 728 681 326 
IFN-γ 224 140 1003 498 41267 18561 602 208 38056 14898 
CXCL10 14066 10465 1804 1135 108961 32402 2143 910 131124 36265 
CCL2 313 159 918 470 1473 515 704 495 1242 435 
CCL3 6648 4056 4594 2188 10373 4291 48264 44650 23373 12142 
PDGF-bb 90 21 2103 313 2389 346 907 236 1213 398 
CCL4 7459 4397 1855 512 4930 3405 2582 1129 4653 2663 
CCL5 3677 3037 185 41 1295 778 289 118 1089 426 
TNF-α 32 14 110 27 4056 2437 77 22 3577 1901 
VEGF 30 13 39 26 64 33 30 22 60 39 
CXCL1 1925 1308 225 86 2127 934 135 43 1702 703 
IFN-α 7.0 3.7 81.9 40.0 195.0 103.1 44.8 16.0 210.9 142.9 
Anti-inflammatory 
IL-1RA 379 130 773 245 770 270 713 175 977 309 
IL-4 24 10 90 63 81 55 79 60 72 52 
IL-10 13 8 35 23 31 20 31 24 29 22 
IL-13 146 140 24 11 57 44 15 10 15 11 
Immunomodulatory 
IL-2 45 29 62 38 76 42 50 38 65 45 
IL-7 73 34 274 62 203 73 158 42 106 25 
Media taken from the culture of M1 macrophages generated from normal 
monocytes, was analysed using BioRad Bio-Plex cytokine assays. The table shows 
the median result of 5 normal samples with standard deviation for each culture 
condition in pg/ml. 
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Appendix 1b. Cytokine levels of M1 macrophages generated from PV 
monocytes 
 
Cytokine 
PV Samples (pg/ml) 
Base 
Media 
St dev 
N 
Serum 
Unstim 
St dev 
N 
Serum 
Stim 
St dev 
PV 
Serum 
Unstim 
St dev 
PV 
Serum 
Stim 
St dev 
Pro-inflammatory 
IL-1β 183 54 529 235 604 209 461 176 627 204 
IL-5 25 7 54 15 49 17 46 15 50 16 
IL-6  918 496 568 258 1667 773 508 305 1764 695 
IL-8 21934 12980 136836 115015 9165 1154 14538 7512 17942 7013 
IL-9 99 28 169 39 167 24 134 27 164 20 
IL-
12(p70) 
18 4 NA NA 22 6 16 5 14 5 
IL-15 44 25 89 53 129 59 58 28 90 39 
IL-17 83 31 107 22 107 18 83 19 107 15 
CCL11 43 15 92 23 79 21 56 16 71 17 
FGF 
basic 
40 8 44 17 41 11 NA NA 34 9 
G-CSF 65 27 136 54 132 47 89 37 134 45 
GM-CSF 5788 2507 2260 856 341 217 1542 772 386 257 
IFN-γ 291 161 682 360 13797 3625 401 233 13440 3619 
CXCL10 3449 2993 329 85 37190 16579 375 93 35365 15388 
CCL2 396 282 672 410 1353 394 563 404 1519 352 
CCL3 4471 2634 9852 3161 11194 3034 7998 2815 10066 2535 
PDGF-bb 98 34 1645 310 1384 274 1021 368 1274 478 
CCL4 5755 2003 5461 2493 8148 2677 6279 3151 7942 2984 
CCL5 901 308 1050 293 2660 1298 1247 401 2519 1248 
TNF-α 45 13 121 32 1128 384 101 63 1166 745 
VEGF 33 5 25 12 44 16 24 6 34 8 
CXCL1 1745 1009 326 139 1328 524 217 132 1340 592 
IFN-α 15.2 0.1 70.7 24.9 130.9 42.4 35.0 20.3 85.9 31.2 
Anti-inflammatory 
IL-1RA 361 161 451 126 364 138 372 168 429 171 
IL-4 30 11 82 33 56 15 48 12 47 10 
IL-10 11 4 21 7 21 7 15 4 15 5 
IL-13 10 3 25 7 21 2 16 4 14 4 
Immunomodulatory 
IL-2 29 7 55 17 42 13 31 6 40 7 
IL-7 27 9 120 32 63 16 76 28 61 23 
Media taken from the culture of M1 macrophages generated from PV monocytes, 
was analysed using BioRad Bio-Plex cytokine assays. The table shows the median 
result of 6 PV samples with standard deviation for each culture condition in pg/ml. 
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Appendix 2a. Cytokine levels of M2 macrophages generated from normal 
monocytes 
 
Cytokine 
Normal Samples (pg/ml) 
Base 
Media 
St dev 
N 
Serum 
Unstim 
St dev 
N 
Serum 
Stim 
St dev 
PV 
Serum 
Unstim 
St dev 
PV 
Serum 
Stim 
St dev 
Pro-inflammatory 
IL-1β 224 160 42 27 189 86 101 54 246 108 
IL-5 15 5 41 10 96 36 28 5 106 67 
IL-6  1608 1025 377 256 375 194 250 112 566 314 
IL-8 17163 4208 4465 1664 14460 6720 22559 13105 12939 5162 
IL-9 77 32 110 39 293 152 113 34 353 225 
IL-
12(p70) 
13 7 18 11 47 35 9 6 47 32 
IL-15 60 52 81 71 167 155 132 97 273 266 
IL-17 70 27 59 8 129 31 57 11 132 45 
CCL11 31 10 97 19 202 53 78 17 230 105 
FGF 
basic 
22 13 34 14 52 31 NA NA 100 82 
G-CSF 46 26 95 48 208 96 71 29 209 102 
GM-CSF 315 307 NA NA 95 75 NA NA 111 101 
IFN-γ 151 93 666 338 1316 653 455 155 1075 246 
CXCL10 658 360 543 84 516 74 1911 817 1216 269 
CCL2 1208 582 1335 474 895 493 964 595 1057 566 
CCL3 3822 2641 174 155 3094 2610 1067 907 15936 8106 
PDGF-bb 114 17 2079 320 2177 248 834 228 1240 395 
CCL4 5780 4219 863 316 2996 1575 954 309 3063 1800 
CCL5 2916 2628 69 11 253 116 72 19 260 135 
TNF-α 21 8 61 14 118 25 51 18 102 20 
VEGF 34 14 22 15 71 48 21 11 112 93 
CXCL1 4933 1603 331 113 156 47 194 63 246 98 
IFN-α 7 4 82 40 195 103 45 16 211 143 
Anti-inflammatory 
IL-1RA 357 116 595 223 1038 311 725 199 1249 245 
IL-4 14 9 46 30 16162 550 37 24 15794 1736 
IL-10 17 11 28 18 66 46 35 28 92 77 
IL-13 6 4 14 7 40 21 12 6 53 41 
Immunomodulatory 
IL-2 18 10 28 19 108 72 27 20 194 172 
IL-7 30 8 212 46 361 59 126 42 304 73 
Media taken from the culture of M2 macrophages generated from normal 
monocytes, was analysed using BioRad Bio-Plex cytokine assays. The table shows 
the median result of 5 normal samples with standard deviation for each culture 
condition in pg/ml. 
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Appendix 2b. Cytokine levels of M2 macrophages generated from PV 
monocytes 
Cytokine 
PV Samples (pg/ml) 
Base 
Media 
St dev 
N 
Serum 
Unstim 
St dev 
N 
Serum 
Stim 
St dev 
PV 
Serum 
Unstim 
St dev 
PV 
Serum 
Stim 
St dev 
Pro-inflammatory 
IL-1β 200 109 438 162 490 165 374 153 506 180 
IL-5 11 1 40 12 53 18 40 13 55 16 
IL-6  808 330 471 176 425 213 397 208 552 260 
IL-8 10932 945 19313 10159 6959 1837 10562 3245 10312 4685 
IL-9 80 20 158 35 181 34 130 28 170 31 
IL-
12(p70) 
23 6 23 8 34 4 17 5 16 6 
IL-15 65 29 105 49 102 46 57 26 69 29 
IL-17 58 16 92 19 107 20 83 22 102 17 
CCL11 18 4 76 22 101 30 52 16 78 22 
FGF 
basic 
33 8 46 15 44 16 35 4 38 8 
G-CSF 40 15 112 49 162 70 78 35 125 54 
GM-CSF 116 50 60 9 174 69 43 6 191 68 
IFN-γ 29 10 529 331 821 457 346 227 562 307 
CXCL10 85 32 262 71 277 86 360 91 417 130 
CCL2 903 280 1226 396 514 235 640 296 585 224 
CCL3 1966 1223 6964 2658 20707 11023 5282 2315 8926 2578 
PDGF-bb 61 15 1608 349 1591 337 998 343 1275 485 
CCL4 6262 2934 4866 1767 6128 2026 5497 2712 6314 2452 
CCL5 833 448 703 147 873 214 965 329 1348 372 
TNF-α 24 8 68 19 70 16 43 12 54 9 
VEGF 41 11 33 12 31 10 25 6 23 8 
CXCL1 2868 1180 398 164 164 109 282 186 242 149 
IFN-α 15 0 71 25 131 42 35 20 86 31 
Anti-inflammatory 
IL-1RA 140 59 344 132 441 181 320 155 462 217 
IL-4 34 17 56 18 14626 2407 36 8 13928 2306 
IL-10 14 4 26 7 29 6 16 5 17 5 
IL-13 12 3 21 5 39 10 21 7 23 6 
Immunomodulatory 
IL-2 24 5 48 14 62 14 28 6 45 11 
IL-7 22 2 104 31 120 39 71 26 67 29 
Media taken from the culture of M2 macrophages generated from PV monocytes, 
was analysed using BioRad Bio-Plex cytokine assays. The table shows the median 
result of 6 PV samples with standard deviation for each culture condition in pg/ml. 
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Appendix 3a. Cytokine levels of normal neutrophils 
 
Cytokine 
Normal Samples (pg/ml) 
Base 
Media 
St dev 
N 
Serum 
Unstim 
St dev 
N 
Serum 
Stim 
St dev 
PV 
Serum 
Unstim 
St dev 
PV 
Serum 
Stim 
St dev 
Pro-inflammatory 
IL-1β NA NA 4 1 41 13 4 1 33 11 
IL-5 NA NA 94 17 99 18 109 11 99 22 
IL-6  NA NA  NA NA  329 122 52 25 308 96 
IL-8 982 389 368 119 3632 1449 310 77 2640 921 
IL-9 16 3 28 6 68 15 31 5 71 11 
IL-
12(p70) 
24 7 NA  NA 5 2 4 1 10 4 
IL-15 2 0 3 1 4 2 2 1 2 1 
IL-17 15 2 NA 4 50 9 NA  NA 37 11 
CCL11 17 4 69 6 59 5 57 9 42 7 
FGF 
basic 
31 4 NA  NA NA   NA  NA NA   
G-CSF NA  NA 52 12 134 37 33 11 102 23 
GM-CSF 16 4 NA  NA NA   NA NA  NA   
IFN-γ NA  NA 223 64 327 90 251 68 361 71 
CXCL10 NA  NA 280 60 255 52 385 70 369 67 
PDGF-BB 13 3 985 142 1162 204 727 284 863 403 
CCL2 NA NA 28 19 34 22 70 45 51 37 
CCL3 8 7 1 0 77 27 2 1 50 25 
CCL4 165 113 95 40 718 177 146 59 638 153 
CCL5 16 4 413 70 591 153 508 80 617 124 
TNF-α 7 2 26 3 37 9 13 3 24 5 
VEGF 146 22 11 4 41 6 29 8 61 17 
Anti-inflammatory 
IL-1RA 18 3 109 26 166 40 153 80 229 93 
IL-4 3 1 17 2 19 3 15 4 15 4 
IL-10 4 1 2 1 4 1 2 1 5 2 
Media taken from the culture of normal neutrophils, was analysed using BioRad 
Bio-Plex cytokine assays. The table shows the median result of 5 normal samples 
with standard deviation for each culture condition in pg/ml. 
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Appendix 3b. Cytokine levels of PV neutrophils 
 
Cytokine 
PV Samples (pg/ml) 
Base 
Media 
St dev 
N 
Serum 
Unstim 
St dev 
N 
Serum 
Stim 
St dev 
PV 
Serum 
Unstim 
St dev 
PV 
Serum 
Stim 
St dev 
Pro-inflammatory 
IL-1β NA NA  5 1 82 45 6 1 121 73 
IL-5 NA  NA 96 18 102 18 117 14 121 13 
IL-6  NA  NA 59 36 1139 921 63 22 1781 1305 
IL-8 2161 1368 271 118 4820 2673 305 166 5680 4324 
IL-9 30 13 31 3 96 22 36 7 101 28 
IL-
12(p70) 
29 5 NA  NA 7 3 5 3 10 3 
IL-15 NA NA 6 1 6 1 2 1 2 1 
IL-17 26 9 NA  NA 71 13 16 1 67 18 
CCL11 22 4 64 8 79 11 54 12 72 11 
FGF 
basic 
39 5 NA  NA NA  NA NA  NA NA NA 
G-CSF NA  NA 55 18 180 71 54 5 257 135 
GM-CSF 19 5 NA NA  NA  NA NA NA  NA  NA 
IFN-γ NA  NA 251 41 564 139 250 61 579 206 
CXCL10 NA  NA 245 34 264 24 367 66 365 59 
PDGF-BB 15 3 978 172 1310 282 753 286 892 333 
CCL2 3 1 123 100 93 87 71 43 69 41 
CCL3 106 84 4 3 424 355 5 3 1263 1119 
CCL4 654 456 105 22 979 271 163 52 909 315 
CCL5 22 9 444 77 621 146 458 76 560 86 
TNF-α 22 10 25 4 54 19 18 3 63 28 
VEGF 179 38 12 7 37 11 26 10 51 15 
Anti-inflammatory 
IL-1RA 66 41 106 19 231 43 174 95 314 91 
IL-4 4 1 17 2 21 2 15 3 20 2 
IL-10 6 1 2 1 6 1 2 1 5 1 
Media taken from the culture of PV neutrophils, was analysed using BioRad Bio-
Plex cytokine assays. The table shows the median result of 6 PV samples with 
standard deviation for each culture condition in pg/ml. 
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